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HEADACHE DISORDERS are called ‘primary’ when no causal underlying struc-tural lesion is present. The diagnostic criteria of the International Headache Society 
(IHS) define four groups of primary headaches, that is (1) migraine, (2) tension-type 
headache, (3) cluster headache and other trigeminal autonomic cephalalgias, and (4) 
other primary headaches, examples of which are hemicrania continua and hypnic head-
ache.1 These main categories of primary headaches are thought to consist of multifacto-
rial diseases, meaning that they are likely caused by a combination of multiple environ-
mental and genetic factors. Whereas not much is known about genetic factors in cluster 
headache and tension-type headache, there is growing body of knowledge on the genetics 
of migraine and its variants. In this section, first genetic knowledge on migraine and 
cluster headache will be summarized, followed by a description of our research strategies 
and populations.
Migraine
Clinical aspects of migraine 
Migraine is a paroxysmal neurovascular disorder that is characterized by recurrent attacks 
of throbbing, unilateral headache of moderate to severe intensity. Attacks are aggravated 
by physical exercise and last 4-72 hours and are often accompanied by nausea, vomiting, 
photophobia, and/or phonophobia. One-year migraine prevalence in the general popu-
lation is 11%, with a clear female preponderance (males 6-8% and females 15-18%).2-5 
Due to the lack of objective reliable biomarkers, such as measurements of specific 
compounds in blood, migraine diagnoses are currently based on questionnaires and/or 
interviews using consensus criteria of the International Classification of Headache Disor-
ders (ICHD-3beta) from the International Headache Society (IHS)  (table 1).1 Approx-
imately one-third of migraine patients experience transient focal neurological symptoms, 
known as migraine auras, which can precede attacks of headache. Auras develop gradually 
and have duration of 5 to 60 minutes and include (in decreasing order of prevalence) 
visual, sensory, speech and/or motor symptoms.6 Based on the presence or absence of the 
aura phase two main migraine subtypes are distinguished, migraine with aura and migraine 
without aura, which can co-occur in the same patient.5,7 
Migraine pathophysiology
The prevailing view is that migraine is a neurovascular disorder.8 The migraine aura is 
caused by cortical spreading depression (CSD), a wave of neuronal and glial depolariza-
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Table 1 - International headache criteria for migraine without and migraine with aura (ICHD-3beta).
Migraine without aura
A. At least five attacks fulfilling criteria B-D
B. Headache attacks lasting 4 to 72 hours (untreated or unsuccessfully treated)
C. Headache has at least two of the following four characteristics:
1. Unilateral location
2. Pulsating quality
3. Moderate or severe pain intensity
4. Aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing 
stairs)
D. During headache at least one of the following;
1. Nausea and/or vomiting
2. Photophobia and phonophobia
E. Not better accounted for by another ICHD-3 diagnoses
Migraine with aura
A. At least two attacks fulfilling criteria B-C
B. One or more of the following fully reversible aura symptoms:
1. Visual
2. Sensory




C. At least two of the following characteristics:
1. At least one aura symptom spreads gradually over ≥5 minutes, and/or two or more symptoms 
occur in succesion
2. Each individual aura symptom lasts 5-60 minutes
3. At least one aura symptom is unilateral
4. The auro is accompanied, or followed within 60 minutes, by headache
D. Not better accounted for by another ICHD-3 diagnoses, and transient ischemic attack has been 
excluded
tion that moves slowly over the cortex.9 Using functional MRI to study the aura in patients 
with migraine with aura, Hadjikhani and colleagues10 were able to detect local increases 
in blood oxygen level-dependent signal that spread through the visual cortex at a rate of 
approximately 3 mm/min, a speed similar to what is seen when a CSD is evoked in an 
experimental animal. The headache itself is caused by activation of the trigeminovascular 
system which consists of the meningeal and superficial cortical blood vessels that are 
innervated by the trigeminal nerve and that project to the trigeminal nucleus caudalis in 
the brainstem, which in turn projects to higher-order pain centers (thalamus and cortex) 
leading to pain.11 
Migraine is a genetic disorder
Migraine shows strong familial aggregation and is a multifactorial complex genetic 
disorder.12-14 Such complex disorders are likely caused by a combination of environmental 
factors and multiple genetic factors, each with a small effect size meaning that the indi-
vidual genetic factors increase disease risk only slightly. Population-based family studies 
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revealed that the relative risk of migraine for a first-degree relative of the index patient is 
1.5 to 4 times higher compared to the general population. The risk is highest for patients 
with migraine with aura, an early age of onset, and high attack severity and disease 
disability.12 Twin studies also revealed a higher genetic load in migraine with than migraine 
without aura.15,16 A large study of approximately 30,000 twins from six different countries 
showed that genetic and environmental factors play an almost equal role in migraine 
susceptibility.17 Heritability, which is defined as the contribution of genetic factors to 
susceptibility for a disease, was estimated to range from 34 to 57% in that study. Shared 
environmental factors seemed to play a minor role, as migraine prevalence was similar 
in twins raised together and twins raised apart.18,19 
 There is debate whether migraine with and migraine without aura are two separate 
disease entities or merely different expressions of the same disease. The first view is 
supported by observations that there is no increased co-occurrence of both types of 
migraine in Danish twins20 and the general Danish population.6,12 In contrast, a study 
of 210 Finnish migraine families suggested the existence of a migraine continuum with 
pure migraine with aura and pure migraine without aura on both ends of the spectrum 
and a combination of both types of attacks in between.21 The idea that migraine indeed 
is a continuum is supported by other studies22,23 as well as by clinical observations that 
headache characteristics are identical in both migraine with and without aura and that a 
large number of patients experience both types of attacks.24 
Approaches to Discover Migraine Genes
Hemiplegic migraine as a monogenic model for common 
migraine
Identifying genes and biological pathways of a monogenic subtype of a disease is likely 
to provide useful insight into the pathophysiology of the complex disease form. Gene 
mutations underlying monogenic disease have a large effect size and are expected to have 
clear consequences on either the level or the amino acid sequence of the affected protein, 
which can be investigated in cellular and animal disease model systems. With respect to 
genetic migraine research, Familial Hemiplegic Migraine (FHM) is a rare monogenic 
subtype of migraine with aura and insight into its pathophysiology may therefore serve 
to help unraveling part of the pathophysiology of common forms of migraine as well. 
 FHM is characterized by a transient hemiparesis during the aura phase, which may 
last several days. Diagnostic criteria for FHM were determined by the IHS1 (table 2). 
Hemiplegic migraine occurring in isolated cases is called Sporadic Hemiplegic Migraine 
(SHM) and apart from the absence of an affected first-degree relative, diagnostic criteria 
are identical to those in FHM. Because of its clinical presentation, a significant number 
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Table 2 - International headache criteria for familial hemiplegic migraine (IHS 2013).
Hemiplegic migraine
A. At least two attacks fulfilling criteria B and C
B. Aura consisting of both of the following:
1. Fully reversible motor weakness
2. Fully reversible visual, sensory and/or speech/language symptoms
C. At least two of the following four characteristics:
1. At least one aura symptoms develops gradually over ≥ 5 minutes, and/or different aura 
symptoms occur in succession 
2. Each individual non-motor aura symptom lasts 5–60 minutes, and motor symptoms last <72 
hours
3. At least one aura symptom is unilateral
4. The aura is accompanied, or followed within 60 minutes, by headache
D. Not better accounted for by another ICHD-3 diagnosis, and transient ischaemic attack and stroke have 
been excluded.
of patients with hemiplegic migraine initially are diagnosed with stroke or epilepsy. Except 
for the hemiparesis, the visual and sensory aura symptoms are identical to those seen in 
migraine with aura, although duration of the aura often is significantly longer than in 
migraine with aura patients.25 The headache characteristics in hemiplegic migraine patients 
and patients with the common forms of migraine are identical. Moreover, the majority 
of hemiplegic migraine patients experience attacks of common migraine in addition to 
their hemiplegic attacks.26 Thus, from a clinical perspective hemiplegic migraine seems 
to be a valid model to study the common forms of migraine.7 
Hemiplegic migraine genes
Genetic studies in FHM resulted in the discovery of three genes.27 As several FHM fami-
lies do not have a gene mutation in one of the known genes, likely more FHM genes 
exist. CACNA1A, the first FHM gene (FHM type 1; FHM1) is located on chromosome 
19p13 and encodes the α1 pore-forming subunit of CaV2.1 calcium channels.28 Some 
FHM1 mutations lead to pure hemiplegic migraine, whereas other mutations are asso-
ciated with additional clinical symptoms such as cerebellar ataxia or epilepsy and have 
been shown to cause gain-of-function of CaV2.1 channel activity.27,29 FHM1 is allelic 
with two other monogenic disorders: episodic ataxia type-2 (EA2)28, and spinocerebellar 
ataxia type-6 (SCA6).30 EA2 is a paroxysmal disorder that is characterized by vertigo, 
ataxia and nausea and approximately half of the patients suffer from migraine headaches 
and attacks can be accompanied by hemiplegia. EA2 mutations cause loss-of-function 
of CaV2.1 channel activity. SCA6 is a late-onset cerebellar ataxia disorder caused by 
moderate polyglutamine repeat expansion in the carboxyl-terminal part of the α1 pore-
forming subunit.30 It is still unclear how expansion of the glutamine stretch causes SCA6 
and to what extent the pathoanatomical consequences of the different types of CACNA1A 
mutations overlap. 
 The second FHM gene (FHM2), ATP1A2, is located on chromosome 1q23 and encodes 
the α2 subunit of sodium-potassium pumps.31 In contrast to FHM1 mutations, hardly 
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any recurrent mutations were reported for ATP1A2.32,33 Another striking difference with 
FHM1 mutations is that almost all ATP1A2 mutations are associated with pure hemi-
plegic migraine, that is without any additional clinical symptoms,31,34-37 although some 
mutations are associated with epileptic seizures,35,38 benign familial childhood convul-
sions,39 febrile seizures40 and mental retardation.35 FHM2 mutations cause loss-of-func-
tion of the Na+,K+ ATPase.27,29
 The third FHM gene (FHM3), SCN1A, is located on chromosome 2q24 and encodes 
the α1 subunit of neuronal NaV1.1 sodium channels.41 SCN1A mutations seem to account 
for only a small proportion of FHM families. Interestingly, the SCN1A gene is a well-
known epilepsy gene with many mutations causing monogenic forms of childhood 
epilepsy, i.e. Dravet syndrome (also known as severe myoclonic epilepsy of infancy (SMEI)) 
or generalized epilepsy with febrile seizures (GEFS+).42 At the start of the research described 
in this thesis, only five FHM3 mutations had been reported,41,43-46 although from the 
clinical description in patients it is far from certain that one of them, mutation T1174S, 
is an FHM3 mutation as patients with the mutation may not have hemiplegic migraine.45 
Mutations L1649Q and Q1489K are associated with pure familial hemiplegic migraine,43 
whereas mutations Q1489H, and L263V have been associated with childhood epilepsy 
and generalized tonic-clonic seizures41,44,46 in addition to FHM, at least in some of the 
mutation carriers. Some patients with FHM3 mutations Q1489H and F1499L were also 
reported to suffer from ‘elicited repetitive daily blindness’ (ERDB), which occurred apart 
from their hemiplegic migraine attacks.46,47 FHM3 mutations seem to cause either gain 
or loss of function of NaV1.1 channel activity.27 
 The first screens of FHM genes in hemiplegic migraine patients without a positive 
family history of other patients with hemiplegic migraine (so-called sporadic hemiplegic 
migraine = SHM) revealed mutations, predominantly in ATP1A2, in only a small propor-
tion of patients.48-50 Riant and coworkers, however, recently identified mutations in 
CACNA1A and ATP1A2 in 23 out of 25 SHM patients with an age-of-onset before 16 
years, of which most had additional symptoms such as epilepsy, learning difficulties, 
cerebellar ataxia and/or coma.33 Three-quarter of the mutations had occurred de novo and 
mutation carriers thus represent the first patients of new FHM families. The question 
remains what is causing SHM in the patients that do not have an FHM gene mutation, 
which is a rather large proportion of patients in most studies.48-50 Possibilities are that 
either other FHM genes may cause hemiplegic migraine in those patients or that SHM 
(especially when the phenotype is not severe) is due to a combination of multiple low-risk 
genetic variants, similar to what is predicted to occur in common forms of migraine. 
Support for the latter hypothesis comes from the observation that migraine with aura is 
frequent in families of SHM patients.24 Also it would fit a view of migraine being a spec-
trum of disorders. 
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Investigating Monogenic Disorders in which Migraine is a Part of 
the Phenotype
Migraine can also be part of non-FHM monogenic disorders, which may be a useful 
source for identifying genes that may shed light on the pathophysiological mechanisms 
involved in migraine. In fact, the number of examples that are relevant to migraine is 
increasing (table 3). 
Migraine as part of the phenotype of monogenic vasculopathies
Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoenceph-
alopathy (CADASIL) is a monogenic syndrome characterized by recurrent stroke, cogni-
tive deterioration, and psychiatric disease.51 CADASIL is caused by mutations in the 
NOTCH3 gene,52 which encodes a cell surface receptor that is expressed in vascular 
smooth muscle cells. About one-third of CADASIL patients also suffer from migraine, 
predominantly migraine with aura, often with migraine as the presenting clinical symptom.53 
Whether there is a genetic link between migraine and Notch3 is still under debate, also 
because genetic association studies investigating NOTCH3 polymorphisms gave conflicting 
results.54,55
 Retinal Vasculopathy with Cerebral Leukodystrophy (soon to be renamed to Cerebral 
Hereditary Angiopathy with Vascular Retinopathy and Impaired Organ Function caused 
by TREX1 Mutations (abbreviated as CHARIOT)) is a monogenic vascular syndrome 
caused by mutations in the TREX1 gene56 that encodes the major 3’-5’-mammalian 
exonuclease, an enzyme thought to be involved in clearing cytosolic DNA.57 RVCL 
patients suffer from a number of features that can include pronounced retinopathy, kidney 
and liver dysfunction, Raynaud phenomenon and various neurological features such as 
cognitive disturbances, depression and migraine.58 In advanced stages of the disease, brain 
imaging shows characteristic contrast-enhancing white matter lesions.58 A small genetic 
family-based study seemed to suggest a potential role for the RVCL gene as a suscepti-
bility gene in migraine and Raynaud phenomenon.59 
 An increased prevalence of migraine with aura was reported in a rare angiopathy that 
can be described as Heriditary Infantile Hemiparesis, Retinal Arteriolar Tortuosity, and 
Leucoencephalopathy (or its acronym HIHRATL) with clinical symptoms of porencephaly 
and cerebral and retinal microangiopathy, hemiparesis, and stroke.60 The causal gene is 
COL4A1, which encodes type IV collagen, an integral component of the vascular base-
ment membrane.61 The association adds to growing evidence for a link between migraine 
and early-onset cerebral angiopathies that is remarkable, but the mechanisms underlying 
this association are still poorly understood.62 An additional piece of information that 
links affected blood vessels with migraine comes from a genetic study in a large pedigree 
in which patients suffer from familial aortic dissection and several other blood vessel 
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abnormalities.63 Ten out of 14 carriers of the R460H mutation in the transforming growth 
factor factor-β receptor 2 (TGFBR2) gene also suffer from migraine.
 In particular it needs to be further investigated whether endothelial dysfunction, which 
was also observed for migraine in several studies,64-67 may underlie the extensive vascu-
lopathy seen with CADASIL and RVCL. Given the high occurrence of migraine with 
aura in CADASIL patients, increased susceptibility for CSD may well explain the link 
with migraine. For RVCL this explanation seems unlikely, since the disease seems to be 
linked with both migraine without and with aura. Interestingly, prevalence of cardiovas-
cular disease is increased in common forms of migraine, especially in migraine with aura 
patients. The basis for the comorbidity of migraine and cardiovascular disease is yet 
unknown, but these findings support the notion that shared pathophysiological processes 
could be involved.68,69
Other monogenic disorders in which migraine is part of the phenotype 
There are several other monogenic disorders in which migraine can be prominent (table 
3). First of all, in Familial Advanced Sleep Phase Syndrome (FASPS) there is a severe 
disruption of the sleep-wake cycle and other circadian rhythms. The disease is caused by 
missense mutations in the CSNK1D gene encoding Casein Kinase 1d (CK1δ), which is 
involved in the phosphorylation of the circadian clock protein Per2.70 In two independent 
families a pathogenic CSNK1D mutation co-segregated with both FASPS and migraine 
with aura. Second, a complex monogenic phenotype of episodic ataxia, hemiplegic 
migraine, and seizures was reported for a 10-year-old boy with a P290R mutation in 
SLC1A3 that encodes the excitatory amino acid transporter 1 (EAAT1), which removes 
glutamate from the synaptic cleft.71 The missense mutation causes a dramatic loss in 
glutamate uptake in a cellular assay. Third, Suzuki and co-workers72 reported various 
homozygous mutations in the Na+ -HCO3– co-transporter NBCe1 in patients with 
proximal renal tubular acidosis and ocular anomalies and, in addition, various clinical 
presentations of migraine, that is migraine without or with aura, hemiplegic migraine, 
and even episodic ataxia. Although the mutations themselves clearly are pathogenic in 
the sense that they are the cause of the renal and ocular problems, it is less obvious why 
they would cause the migraine and hemiplegia phenotypes that are very common and 
sometimes hard to diagnose. 
 A fourth monogenic syndrome that is associated with migraine is MELAS (Mitochon-
drial Encephalomyopathy, Lactic Acidosis, and Stroke-like syndrome) which is caused 
by a mitochondrial DNA (mtDNA) 3243 A>G tRNALeu point mutation.73 Fifth, many 
carriers of mutations in the POLG gene, which encodes the nuclear polymerase-γ that is 
essential for the maintenance of mitochondrial DNA, suffer from migraine as well.74-76 
Lastly, Alternating Hemiplegia of Childhood (AHC) can be considered a monogenic 
model that has relevance to migraine. AHC is a rare syndrome characterised by recurrent 
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hemiplegic attacks, movement disorders, seizures, and developmental delay starting before 
the age of 18 months.1 Due to the considerable clinical overlap in severely affected hemi-
plegic migraine patients and AHC patients, it is sometimes impossible to establish the 
correct diagnosis.77 The clinical overlap prompted investigating the FHM genes CACNA1A 
and ATP1A2 in AHC patients. A CACNA1A mutation was found in monozygous twins 
with overlapping clinical features of both disorders78 and an ATP1A2 mutation was iden-
tified in a Greek atypical AHC family.79,80 No CACNA1A or ATP1A2 mutations were 
found in any of the patients meeting all diagnostic criteria.81,82 Due to the overlapping 
clinical and genetic features, advances in genetic research of AHC may also provide 
important information about the genetics of monogenic and complex forms of migraine.
Genetic Studies in Common Forms of Migraine
Identifying genes involved in complex disorders has proven difficult, especially before 
the era of genome-wide association studies (GWAS) (see below). Two main hypotheses 
are used to explain the genetic origin of complex diseases.83 One hypothesis proposes that 
common disease is caused by common variants (CD-CV), which means that relatively 
frequent genetic variants cause disease, each with a small effect size cause disease but none 
of them is sufficient. In contrast, the common disease - rare variant (CD-RV) hypothesis 
assumes that multiple, relatively rare variants with a larger effect size may explain suscep-
tibility to disease. To date, most findings in complex diseases test the first hypothesis only 
although a few rare variants with a moderate effect have been detected, such as Factor V 
Leiden in deep venous thrombosis.84 
Linkage and candidate gene association studies in migraine
Until a few years ago, the main approach used in genetic studies of common migraine 
was family-based linkage analysis, which led to the identification of many chromosomal 
susceptibility regions, but did not result in the discovery of migraine genes. A second 
popular approach consisted of candidate gene association studies that search for signifi-
cant differences in allele frequencies between migraine cases and controls in genes that 
had emerged from other knowledge of migraine pathophysiology. These association studies 
tested only one or at best a few DNA polymorphisms in such a gene. Candidate gene-
based association studies in theory are a powerful tool, if carefully designed to overcome 
methodological issues regarding sample size, selection of cases and controls, selection of 
variants, correction for multiple testing, and replication of findings in independent popu-
lations. Unfortunately, the great majority of candidate gene association studies performed 
in migraine suffered from one or more methodological weakness and led to the conclu-
sion that most results must be false positives.85 Among the selected candidate genes that 
were most often tested are genes in the dopaminergic and serotonergic systems, hormone 
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receptors, and inflammatory pathways (for review see De Vries et al, 200927). The best 
replicated finding is the association with the C677T polymorphism in the 5’,10’-meth-
ylenetetrahydrofolate reductase (MTHFR) gene that increases the risk of migraine in 
carriers of the T-allele,86-91 although other large and well-designed studies could not find 
such association.92,93 Two meta-analyses showed an association of this polymorphism with 
migraine with aura, but not with migraine without aura.94,95 MTHFR codes for an enzyme 
with an important role in homocysteine and folate metabolism.96 Carriers of the T-allele 
have increased homocysteine concentrations, which is a well-known risk factor for cardio-
vascular disease. It is hypothesized that high homocysteine levels may induce vascular 
endothelial dysfunction and thereby increase migraine risk. 
Genome-wide association studies in migraines
Over the last few years, genome-wide association studies (GWAS) have become the most 
used approach to identify genes that confer susceptibility to complex disorders. In a 
GWAS, hundreds of thousands of SNPs that are distributed over the genome are tested 
in a hypothesis-free manner for association with a disease trait. For each SNP, the allele 
frequencies are compared between cases and controls. Significant differences in allele 
frequency either pinpoint the SNP itself as a genetic susceptibility factor or provide 
statistical evidence that a causal gene variant is in close vicinity, i.e. is the causal variant 
is in linkage disequilibrium. Several major migraine GWA studies have been performed 
investigating so-called end-diagnoses migraine with aura97 or migraine without aura98 in 
two well-defined clinic-based studies, migraine in a population-based cohort99, and, most 
recently, a systematic migraine meta-analysis.97 Over a dozen migraine susceptibility gene 
variants have been identified that point to genes that cluster into five main different 
pathways related to (i) glutamatergic neurotransmission; (ii) synapse development and 
plasticity; (iii) pain sensing; (iv) metalloproteinases; and (v) vasculature & metabolism. 
The pathophysiological and clinical implications of these variants, however, still have to 
be determined. 
Reduction of clinical heterogeneity for genetic studies of common migraine 
Apart from genetic heterogeneity, the gene hunt in common migraine is also complicated 
by extensive clinical heterogeneity regarding for instance presenting symptoms or age-of-
onset in addition to the lack of reliable biomarkers to establish a migraine diagnosis. 
Clearly, diagnostic criteria of the IHS that are useful to diagnose attacks in the clinic are 
less suited for genetic research, because multiple combinations of symptoms lead to the 
same end-diagnosis, not necessarily through the same pathophysiological mechanism. 
Two types of strategies can be applied to reduce clinical heterogeneity among participants 
of genetic studies in migraine. The first approach takes advantage of the well-known 
comorbidity of migraine with various disorders.100 Although the observation can be 
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spurious due to selection bias or reflect a unidirectional causal relationship, that is migraine 
causes (or is caused by) the co-morbid disorder, it may also be that shared genetic and/
or environmental factors underlie both migraine and the co-morbid disorder.101 Migraine 
patients are at increased risk of epilepsy, ischemic stroke, myocardial infarction, major 
depressive disorder, anxiety disorders, bipolar disorder, asthma, and chronic pain disor-
ders102,103 and genetic heterogeneity might be reduced by selecting those migraine patients 
that also suffer from the co-morbid disorder. The second type of approach uses other 
classification than the ICHD-2 criteria1 as a trait in genetic analysis. Two examples of 
this latter strategy are trait component analysis104,105 (TCA; using individual symptoms 
instead of ICHD-2 diagnosis as traits in the analysis)) and latent class analysis106-108 (LCA, 
using different classes of patients based on clustering of symptoms), which led to the 
discovery of various chromosomal regions potentially harboring migraine susceptibility 
genes. Until now, no susceptibility genes have been found using TCA or LCA. 
 An attractive alternative could be the use of a (set of ) migraine biomarker(s) as a trait 
in genetic studies to search for novel migraine susceptibility genes. Past research on 
migraine biomarkers was hypothesis-driven and tested a small number of metabolites in 
small study populations66,109-117 and failed to identify a clinically useful migraine biomarker. 
Current high-throughput proton nuclear magnetic resonance (1H NMR) spectroscopy 
enables generating a profile of tens to hundreds low-molecular-weight metabolites from 
a blood sample in a single measurement.118,119 Interestingly, GWAS using metabolite 
concentrations have led to the identification of genetic variants with much larger effect 
sizes than commonly encountered in GWAS using ‘just’ clinical diagnoses.120 Combining 
the existing knowledge on genetics of metabolites with yet unidentified migraine biomarkers 
could be an attractive approach to identify novel migraine susceptibility genes.
Studying the genetics of cluster headache
Cluster headache is a rare, disabling, primary headache disorder.1 Clinical characteristics 
and treatment options partly overlap with migraine and involvement of the trigemino-
vascular system may be a key feature of both disorders.11,121,122 Cluster headache is much 
rarer than migraine and has a lifetime prevalence of only 0.12%.123 In contrast to migraine, 
there is a striking male preponderance with a male-to-female ratio of 3:1.123,124 Cluster 
headache is characterised by attacks of unilateral severe (supra)orbital and/or temporal 
pain accompanied by restlessness and/or ipsilateral autonomic symptoms, that is eyelid 
oedema, conjunctival injection, miosis, ptosis, lacrimation, nasal congestion, rhinorrhoea, 
forehead and facial sweating. Attacks have duration from 15 to 180 minutes and occur 
up to eight times a day.1 Approximately 90% of patients have the episodic form of the 
disease. Patients with episodic cluster headache experience bouts of frequent attacks 
lasting weeks to months, followed by remission lasting several months to years. The 
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remaining 10% has chronic cluster headache, characterised by short (less than one month) 
or absent periods of remission.
 Cluster headache is considered a complex genetic disorder, although an autosomal 
dominant pattern of transmission has been suggested in some cases.124 The relative risk 
for family members of cluster headache patients is estimated to be 5-18 for first-degree 
relatives and 1-3 for second-degree relatives. Due to the low prevalence of the disorder, 
no large cohorts of patients are available for large-scale genetic studies such as GWAS. 
Therefore, genetic research in cluster headache has been limited mainly to candidate gene 
studies. Multiple small-scale studies have been performed, but many of them lack a repli-
cation sample, thereby precluding a final conclusion regarding the association of the 
reported genes with cluster headache. To date, only one genetic factor (i.e. a missense 
variant in the hypocretin type 2 receptor gene HCRTR2) was found to be associated with 
cluster headache in two of the three small conducted studies and in a meta-analysis of 
these studies.125-128
Study populations 
Leiden University Migraine Neuro-Analysis (LUMINA) 
population
The Leiden University Migraine Neuro-Analysis LUMINA program was initiated in 
March 2008 and inclusion is still ongoing. The aim of the program is to enroll a large 
number of self-reported migraine patients for genetic and epidemiological studies through 
the project’s website (www.lumc.nl/hoofdpijn). Self-reported migraine patients from the 
Dutch population were invited to complete a validated screening questionnaire. Screen-pos-
itives were subsequently asked to complete a newly developed extended web-based ques-
tionnaire aiming to diagnose migraine based on the ICHD-2 criteria. Many previously 
developed questionnaires are good at assessing headache characteristics, but fail to make 
reliable aura diagnoses. Discriminating between migraine with and without aura is of 
particular interest in genetic studies and such migraine type information can be reliably 
obtained using questionnaire-based aura diagnoses with our LUMINA questionnaire. 
Five years after the start of the project, approximately 5,000 migraine patients have been 
collected and have contributed to the identification of susceptibility genes for common 
forms of migraine in various GWAS.97,98,129
Leiden University Cluster headache Analysis (LUCA) population
The Leiden University Cluster headache Analysis (LUCA) program is the cluster headache 
counterpart of the LUMINA study and started in April 2010. Genetic studies in cluster 
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headache are greatly hampered by the combination of low prevalence and putative complex 
genetic background of the disorder. The LUCA study aimed to collect a large group of 
self-reported cluster headache patients for genetic and epidemiological studies. Self-re-
ported cluster headache patients were invited to complete a screening questionnaire. 
Screen-positive participants were asked to complete the newly developed web-based 
extended questionnaire to enable diagnosing cluster headache for genetic and epidemi-
ological studies. Three years after the start of the project, 917 patients cluster headache 
patients were enrolled in the program, of which 560 provided a DNA sample, resulting 
in the largest single sample set of cluster headache patients to date. 
Erasmus Rucphen Family (ERF) Study
The ERF population originates from a genetically isolated region in the southwest of the 
Netherlands.130 The study population consists of the 3,465 living descendants of 22 
founder couples that had at least six children baptized in the community church between 
1850 and 1900. The pedigree of this large family is characterized by multiple consan-
guinity and increased inbreeding. The occurrence of disease in isolated populations is 
influenced by a less heterogeneous genetic and environmental background than the 
occurrence of disease in the general outbred population. Identification of susceptibility 
genes in isolated populations is therefore considered easier because genetic drift (that is 
rare variants tend to disappear or become overrepresented), facilitates investigating rare 
variants underlying common disease, while isolated populations are equally well suited 
to detect common variants associated with disease, as these variants in general have similar 
allele frequencies in genetic isolates and the general outbred population.131 
Scope and outline of the thesis
The studies presented in this thesis aim to advance genetic knowledge of primary head-
ache disorders with a focus on migraine and cluster headache. 
In Chapter 2 the identification is reported of two novel mutations in the SCN1A gene 
in Spanish families with familial hemiplegic migraine. The identification of such muta-
tions is important as the overwhelming majority of mutations in this gene cause epilepsy 
and it is still unclear why certain SCN1A mutations cause FHM instead. Chapter 3 
describes a mutation in the SLC2A1 gene in a patient that links hemiplegic migraine 
with alternating hemiplegia of childhood, which may be of use to understand how one 
mutation causes features of both monogenic disorders and may be of relevance in dissecting 
mechanisms of migraine pathophysiology. Also attempts were made to investigate the 
possible role of the SLC2A1 and ATP1A3 genes in familial and sporadic hemiplegic 
migraine. 
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Chapters 4 and 5 are dedicated to the validation of extended web-based questionnaires 
that were developed to enrol self-reported headache patients for large-scale genetic studies. 
Chapter 4 focuses on the LUMINA program that aims to recruit migraine patients and 
addresses the difficulties in obtaining reliable aura diagnoses using questionnaire data. In 
Chapter 5 a similar approach was applied to recruit patients with cluster headache for 
the LUCA (Leiden University Cluster headache Analysis) program. One aim was to select 
which questions are best predictors for cluster headache diagnosis in the Dutch cluster 
headache population, generating a shorter questionnaire suitable for case-finding in large 
population-based studies. 
Chapter 6 contains the results of a candidate gene study and subsequent meta-analysis 
investigating the role of a missense variant in the HCRTR2 gene in cluster headache 
susceptibility. That variant had been associated with cluster headache in several small-
scale association studies and HCRTR2 is considered the only replicated cluster headache 
susceptibility gene. Using patients recruited in the LUCA program this association was 
re-investigated, now including the LUCA population as the largest single sample set of 
patients with cluster headache to date. 
Chapter 7 contains the results of a genetic epidemiology investigation using the geneti-
cally isolated population of the Erasmus Rucphen Family study that aimed to investigate 
whether atherosclerosis is the cause of the previously observed increased rate of cardio-
vascular disease in migraine patients. The study also addresses, to certain extent, the 
question how useful it can be to select migraine patients that have a comorbid disease, 
in this case cardiovascular disease. In Chapter 8 the same ERF cohort was used for meta-
bolic profiling in serum using nuclear magnetic resonance (NMR) spectroscopy in a first 
attempt to identify molecular biomarkers for migraine. This study aims to identify a set 
of metabolites that may predict disease status.
Finally, Chapter 9 provides a general discussion of the main findings presented in this 
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Background – Familial hemiplegic migraine (FHM) is a rare monogenic 
subtype of migraine with aura, characterized by motor auras. FHM 
is known to be caused by mutations in the CACNA1A, ATP1A2 and 
SCN1A genes (FHM1, FHM2 and FHM3, respectively). Sofar, less 
than 5% of FHM cases are explained by mutations in the SCN1A 
gene. Two Spanish FHM families without mutations in CACNA1A 
and ATP1A2 were screened for mutations in the SCN1A gene.
Methods – We assessed the clinical features of both FHM families and 
performed direct sequencing of all coding exons (and adjacent 
sequences) of the SCN1A gene. 
Results – FHM patients in both families had pure hemiplegic migraine 
with highly variable severity and frequency of attacks. We identified 
a novel SCN1A missense mutation p.Ile1498Met in all three tested 
hemiplegic migraine patients of one family. In the other family, novel 
SCN1A missense mutation p.Phe1661Leu was identified in six out 
of eight tested hemiplegic migraine patients. The mutation 
p∙Ile1498Met affects a part of the protein that is responsible for 
adequate occlusion of the ion pore of the Nav1.1 channel. 
Conclusions – We identified two mutations causing pure FHM, thereby 
increasing the number of FHM3 mutations to seven. SCN1A 
mutations are an infrequent cause of FHM.
Key Words:  migraine ■ ion channel defects ■ familial hemiplegic 




FAMILIAL HEMIPLEGIC MIGRAINE (FHM) is a rare monogenic subtype of migraine with aura (MA) that is characterized by transient hemiparesis during the 
aura phase. Headache and aura characteristics are identical in FHM and MA patients, 
apart from the motor auras and possible longer duration of auras in FHM.1 Mutations 
in three neuronal or glial ion transporter genes (CACNA1A, ATP1A2, SCN1A) are known 
to cause FHM.2 Thus far, over 70 mutations in the CACNA1A (FHM1)3 and ATP1A2 
(FHM2)4 genes have been identified and mutations in these genes seem to account for 
the majority of cases with FHM 5. Only five mutations were reported for the third FHM 
(FHM3) gene SCN1A5,6 encoding the α1 subunit of neuronal voltage-gated NaV1.1 
sodium channels that are primarily expressed on inhibitory neurons.7,8 Of these, SCN1A 
mutations p.Leu1649Gln and p.Gln1489Lys cause pure FHM.6,9 The other FHM3 
mutations either cause FHM and seizures occurring separately from the hemiplegic 
migraine attacks (p.Gln1489His10 and p.Leu263Val11) or FHM and ‘elicited repetitive 
daily blindness’ (p.Gln1489His and p.Phe1499Leu mutations)10). Functional analyses 
of pure FHM3 mutations predict a loss-of-function effect on inhibitory neurons, thereby 
leading to overall neuronal hyperexcitability12, although this is debated by others13. 
Notably, SCN1A is a well-known epilepsy gene with several hundred mutations causing 
various forms of childhood epilepsy: Dravet syndrome (also known as severe myoclonic 
epilepsy of infancy (SMEI)) and the milder generalized epilepsy with febrile seizures 
(GEFS+).14 Here we report the identification of two novel FHM3 mutations in two 




This four-generation Spanish family includes four hemiplegic migraine patients (see 
Figure 1, Family 1 and Table 1). The family members were interviewed and neurologi-
cally examined (ODF). Diagnoses were established according to the International Clas-
sification of Headache Disorders, 2nd edition (ICHD-2).1 The diagnosis of the proband’s 
deceased father was based on information provided by the proband. 
 The proband (II-4) had her first migraine attack at age 11 and continued to have on 
average two attacks per month until the age of 73. These hemiplegic attacks were usually 
preceded by flashing lights or scotoma, speech problems and/or unilateral sensory symp-
toms. Auras developed gradually during 5 to 15 minutes, but on several occasions hemi-
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plegia occurred instantaneously, causing her to fall. In general, hemiplegia lasted 30 to 
60 minutes and then diminished gradually. After these auras, she suffered from a typical 
migraine headache, i.e. unilateral pulsatile headache that increased with movement and 
was best relieved by sleep, accompanied by photophobia and phonophobia. At the age 
of 69 years, she experienced an episode of benign paroxysmal positional vertigo that lasted 
for fifteen days and then resolved gradually over the course of two weeks. At age 70, she 
presented with prolonged hemiplegia for ten days, which completely recovered during 
the subsequent three weeks. Cerebral MRI (see Figure 2) and SPECT (data not shown) 
during the hemiplegic phase showed vasogenic edema and cortical hypoperfusion in the 
right hemisphere. Further extensive diagnostic workup for cerebrovascular disease and 
epilepsy, including electroencephalography, cerebrospinal fluid analysis, echography of 
the heart and carotid arteries, laboratory analysis of coagulation factors and autoimmune 
titers, and skin biopsy for excluding CADASIL (Cerebral Autosomal Dominant Arte-
riopathy with Subcortical Infarcts and Leukoencephalopathy) showed no abnormalities. 
Figure 1 - Pedigrees of FHM families 1 and 2. The arrow indicates the proband. Symbols: black lower-half: 
hemiplegic migraine; right upper square: migraine with aura (MA); left upper square: migraine without 

























































































































































































































































































































































































































































































































































































































































MA= migraine with aura; MO= migraine without aura; WT: wild-type allele; p.Ile1498Met and p.Phe1661Leu: 
heterozygous carrier of the respective SCN1A mutations. The symbol ‘?‘ indicates this information was unavailable.
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From age 72, she showed progressive cognitive deterioration and was diagnosed with 
Alzheimer’s disease. She died at the age of 79 years of urinary sepsis. Post-mortem exam-
ination of the brain showed multiple senile plaques and confirmed the diagnosis of 
Alzheimer’s disease. No ischemic lesions were found.  
 The proband’s father (I-1) had similar FHM attacks. He suffered from dementia from 
age 70 and died at age 80. Patient III-5, now 58 years old, suffered from MA and FHM 
with an attack frequency of two per year until he was 44. No hemiplegic attacks have 
occurred over the last 13 years. Patient IV-10, currently 33 years old, has experienced 
four hemiplegic migraine attacks from age 15 to 31. His attacks started with hypesthesia 
and hemiparesis during 20 minutes, followed by migraine headache. An MRI scan 
performed during one of these attacks showed no abnormalities. He also suffers from 
migraine with visual aura, with an attack frequency of one per three months.
Family 2
This three-generation family is also of Spanish origin. Eight family members were diag-
nosed with FHM (see Figure 1, Family 2 and Table 1). Their diagnoses were established 
according to the ICHD-2 criteria1, and confirmed by a neurologist specialized in headache 
(JP). After the passing of the proband’s grandmother, additional information was provided 
by her children.  
 The proband (III-12) had been suffering from approximately three migraine attacks 
per month since she was nine years old, with visual, sensory, and speech auras. At the age 
of 16 she presented at the emergency department with right-sided hemiparesis, accom-
A B C
Figure 2 - Cerebral MRI of the proband of family 1 during prolonged aura (A+B) and after full recovery 
(C). A+B: MR FLAIR T2-weighted image in axial plane and gadolineum-enhanced T1-weighted image 
showing a subcortical area of white matter in the perirolandic region on the right is hyperintense on image 
A and relatively hypointense on image B, with blurring of the cortical sulci adjacent to the convexity. C: 
T1-weighted MR image showing the resolution of the radiological abnormalities, in agreement with the 
patient’s clinical recovery.  
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Novel SCN1A mutations
panied by scotoma, photopsia, right-sided hypesthesia, contralateral headache and vomiting 
lasting for three hours. She was diagnosed with hemiplegic migraine. 
 The proband’s mother (II-4) had three to four FHM attacks per year from age 14 to 
30, later decreasing to one attack per several years. All attacks include visual, sensory, 
motor and speech symptoms lasting 30-60 minutes. The five affected siblings of the 
proband’s mother experience multiple aura types, in varying combinations during sepa-
rate attacks, followed by typical migraine headaches (for summary see Table 1). 
 The proband’s grandmother (I-2) had suffered migraine attacks since the age of 13. 
She always experienced visual, sensory and dysphasic auras. Hemiparesis occurred on 
most occasions. At age 85 she was diagnosed with dementia. She died one year later after 
a stroke.
Genetic analysis
Genomic DNA was isolated from peripheral leukocytes according to standard procedures 
15. All 26 exons and flanking intronic sequences of the SCN1A gene were amplified by 
PCR and analyzed for mutations by direct sequencing. Detailed information is available 
from the authors upon request.
Results
In Family 1, a novel heterozygous point mutation in exon 24 (c.4460G>C; p.Ile1498Met) 
of the SCN1A gene was identified. The mutation co-segregated with FHM in this family 
(Figure 1, Family 1) and was absent in 161 healthy controls. The p.Ile1498Met mutation 
is located in the intracellular loop between transmembrane domains III and IV (Figure 
3A) and affects the “IFMT motif ”. This motif encodes the hydrophobic latch that is 
responsible for adequate occlusion of the ion pore, which leads to inactivation of the 
Nav1.1 channel, thereby regulating the generation and propagation of action potentials.7,8 
The IFMT motif is named after the four amino acids encoding it, i.e. isoleucine (I), 
phenylalanine (F), methionine (M), and threonine (T). Mutation p.Ile1498Met leads to 
the substitution of isoleucine for a methionine residue at the first position of the IFMT 
motif. Both are hydrophobic nonpolar amino acids with similar molecular weight. 
However, isoleucine is aliphatic while methionine is a sulfur-containing amino acid and 
is important for the function of the SCN1A-encoding protein. Analysis of this amino 
acid in homologous and orthologous sodium channel α1 subunits shows high conserva-
tion of isoleucine1498 (Figure 3B).10   
 Mutation scanning in Family 2 revealed a novel heterozygous point mutation in exon 
26 (c.4981C>T; p.Phe1661Leu) of the SCN1A gene. This mutation partially co-segregated 
with FHM in this family as two of the eight tested clinically affected individuals (II-5 
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and II-7) did not have the mutation and are thus diagnosed as phenocopies (Figure 1, 
Family 2). The p.Phe1661Leu mutation was not found in the probands unaffected aunt 
nor in 161 healthy control subjects. Phenylalanine1661 is located in domain IV, in the 
intracellular loop between the voltage-sensing S4 segment and part of the transmembrane 
pore (S5) (Figure 3A).14 It is highly conserved within all orthologues and homologues 
except for the SCN7A gene, which, notably, has a leucine at the equivalent position 
(Figure 3B). Although both amino acids are hydrophobic, phenylalanine is a large aromatic 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1. L263V   Castro et al. 
2. Q1489K   Vahedi et al. 
3. Q1489H   Dichgans et al. 
4. F1499L   Vahedi et al.





















I II  III  IV  
N
C
Figure 3 -   A: Topology of the SCN1A gene product. Arrows indicate the location of the novel p.Ile1498Met 
(I1498M) and p.Phe1661Leu (F1661L) FHM3 SCN1A mutations. Previously identified FHM3 mutations 
are indicated by numbers 1- 5. Figure adapted from De Vries et al4. B: Conservation of the I1498 and F1661 
amino acid residues. Alignment of the amino acid sequence of alpha1 subunits of sodium channels from 
various species, indicating the conservation of the amino acids that are affected by FHM3 mutations. 
Isoleucine1498 (I1498) is completely conserved across homologues and orthologues of the human SCN1A 




We report two Spanish families with pure hemiplegic migraine (i.e. without other parox-
ysmal or permanent neurological symptoms such as epilepsy or ataxia) and two novel 
SCN1A mutations (p.Ile1498Met and p.Phe1661Leu). Attacks in both families started 
at a young age, ranging from age 9 to 20 years. Attack frequency was highly variable, 
ranging from one attack per week to one attack per several years. Prolonged duration of 
auras, varying from three hours to three weeks, and co-occurrence of FHM attacks with 
attacks of migraine with and without aura were observed in both families, as has been 
reported for other FHM families.16 
 Ictal MRI abnormalities (Figure 2), as observed in the proband of Family 1, have not 
been reported in FHM3 patients, but are similar to observations made in FHM1 and 
FHM2.16 Post-mortem examination revealed that the dementia in patient II-4 of Family 
1 was due to Alzheimer’s disease. Dementia in patient I-2 of Family 2 is also unlikely 
related to the SCN1A mutation, given the age at onset after 80. 
 Although functional testing of the mutations has not been performed, we are confident 
that mutations p.Ile1498Met and p.Phe1661Leu are pathogenic. First of all, p.Ile1498Met 
is present only in the three family members with hemiplegic migraine and absent from 
a panel of 161 control subjects. Second, isoleucine1498 is a highly conserved amino acid 
in α1 subunits of vertebrate sodium channels. Third, the mutation is located in the same 
intracellular loop as three of the five previously described FHM3 mutations (p.Gln1489Lys, 
p.Gln1489His, p.Phe1499Leu) (Figure 3A).6,10 Of these, the p.Phe1499Leu mutation is 
also located in the IFMT motif, which encodes the hydrophobic latch, and is essential 
for the function of the neuronal voltage-gated NaV1.1 sodium channel.7,8 Interestingly, 
none of the more than 600 mutations causing Dravet syndrome or GEFS+ affect the 
IFMT motif.14,17 It is hypothesized that a defective hydrophobic latch will lead to delayed 
sodium channel inactivation with concomitant decreased neuronal inhibition. 
 Several lines of evidence indicate that the p.Phe1661Leu mutation in Family 2 also is 
pathogenic. The mutated phenylalanine1661 is a highly conserved amino acid across homo-
logues and orthologues except for SCN7A, a gene that shares only 52% overall sequence 
similarity with the SCN1A gene. The p.Phe1661Leu mutation is absent from our panel 
of healthy control subjects and co-segregates in six of eight hemiplegic migraine patients. 
The remaining two hemiplegic migraine patients should be considered phenocopies. 
Phenocopies have been described before in FHM families.18-20 
 The p.Phe1661Leu FHM3 mutation is the first mutation to co-localize with a known 
Dravet mutation, i.e. p.Phe1661Ser. In the Dravet patient, phenylalanine1661 is mutated 
into a much smaller, nucleophilic serine residue.21 Substitution of the phenylalanine for 
a leucine apparently has a less detrimental effect on protein function, which is in agree-
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ment with the much milder phenotype in our FHM family. The importance of phenyl-
alanine1661 for sodium channel function is further illustrated by the fact that mutating 
the corresponding residue in SCN4A, causing paramyotonia congenita, showed alterations 
of the kinetic properties of the channel. 22 
 In conclusion, we identified two novel SCN1A mutations causing pure FHM with 
large intra-familial variation in severity and frequency of the attacks. Our findings increase 
the number of FHM-causing SCN1A mutations to seven. Although this still needs to be 
proven by functional studies, the p.Ile1498Met mutation most likely disrupts the fast 
inactivation of the NaV1.1 channels and decreased neuronal inhibition. If true, this would 
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Background – Hemiplegic migraine (HM) and alternating hemiplegia 
of childhood (AHC) are rare episodic neurological brain disorders with 
partial clinical and genetic overlap. Recently, ATP1A3 mutations were 
shown to account for the majority of AHC patients. In addition, a 
mutation in the SLC2A1 gene was reported in a patient with atypical 
AHC. We therefore investigated whether mutations in these genes may 
also be involved in HM. Furthermore, we studied the role of SLC2A1 
mutations in a small set of AHC patients without ATP1A3 mutations.
Methods – We screened 42 HM patients (21 familial and 21 sporadic 
patients) for ATP1A3 and SLC2A1 mutations. In addition, four typical 
AHC patients and one atypical patient with overlapping symptoms of 
both disorders were screened for SLC2A1 mutations.
Results – A pathogenic de novo SLC2A1 mutation (p.Gly18Arg) was 
found in the atypical patient with overlapping symp- toms of AHC and 
hemiplegic migraine. No mutations were found in the HM and the 
other AHC patients.
Conclusion – Screening for a mutation in the SLC2A1 gene should be 
considered in patients with a complex phenotype with overlapping 
symptoms of hemiplegic migraine and AHC.
Key Words:  Hemiplegic migraine (HM) ■ alternating hemiplegia 
of childhood (AHC) ■ SLC2A1 gene, exercise-induced 
dystonia ■ GLUT1 deficiency syndrome 
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A novel SLC2A1 mutation linking HM with AHC
Introduction
HEMIPLEGIC MIGRAINE (HM) and alternating hemiplegia of childhood (AHC) are two rare episodic neurological brain disorders in which hemiplegia is a prom-
inent symptom. Hemiplegic migraine is a subtype of migraine with aura that is charac-
terized by transient hemiparesis during the aura phase.1 HM can present as a familial 
(familial hemiplegic migraine; FHM) or a sporadic (sporadic hemiplegic migraine; SHM) 
disease. HM can occur in a pure form or with additional symptoms such as cerebellar 
ataxia, intellectual disability, and seizures.2 Mutations in the CACNA1A, ATP1A2 and 
SCN1A genes are well known to cause HM. The CACNA1A gene codes for a subunit of 
voltage-gated neuronal CaV2.1 calcium channels, the ATP1A2 gene for a subunit of Na+/
K+ ATPases, and the SCN1A gene codes for a subunit of neuronal NaV1.1 sodium chan-
nels.3–5 Functional studies of HM gene mutations suggest a net increase in neurotrans-
mitter levels (that is glutamate in the cortex) in the synaptic cleft as a key mechanism in 
HM,6 either due to an increased CaV 2.1 function or reduced NaV 1.1 channel function 
in excitatory and inhibitory neurons, respectively, or due to reduced functionality of glial 
Na+/K+ ATPases. Recently, truncating mutations in the PRRT2  gene have been reported 
in HM patients, of whom the majority also have phenotypes that are frequently associated 
with such PRRT2  mutations (i.e. paroxysmal kinesigenic dyskinesia, benign familial 
infantile seizures, and infantile convulsion choreoathetosis syndrome).7–13 Based on this 
association, PRRT2  has been suggested as the fourth FHM gene.
 AHC is characterized by intellectual disability and by recurrent attacks of hemiplegia, 
movement disorders, and seizures starting before the age of 18 months.14 The ATP1A3 
gene was recently shown to be the major cause of AHC with mutations in more than 
70% of patients.15–17 ATP1A3 codes for another subunit of Na+/K+ ATPases and is expressed 
in neurons of basal ganglia, cerebellum, and hippocampus. Na+/K+ ATPases are involved 
in the regulation of sodium and potassium gradients across glial (in the case of ATP1A2) 
or neuronal (in the case of ATP1A3) plasma membranes, thereby affecting sodium-cou-
pled ion transport, neuronal excitability, and/or osmoregulation. In the respective cell 
types, FHM ATP1A2  and AHC ATP1A3  mutations result in a reduction of sodium-po-
tassium pump activity.15–17
 In addition to typical AHC and HM patients there are also atypical patients who either 
do not fulfill all criteria of AHC or present with clinical symptoms of both AHC and 
HM. The atypical presentation makes it difficult, if not impossible, to determine the 
correct clinical diagnosis.18 Identification of gene mutations in atypical patients, therefore, 
may shed light on possible overlapping pathophysiological mechanisms between AHC 
and HM, and may confirm clinical diagnoses. Until now, an ATP1A2 mutation was 
identified in a Greek family with atypical AHC in which patients did not fulfill all diag-
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nostic criteria of AHC.19,20 In addition, a CACNA1A  mutation was identified in two 
German monozygous twins who displayed clinical features both of AHC and FHM,18 
and a mutation was identified in the glucose transporter 1 GLUT1 gene SLC2A1  in an 
atypical AHC patient.21 The GLUT1 protein is pivotal for glucose transport into the 
brain, and mutations in SLC2A1 are a well-known cause of GLUT1 deficiency syndrome22, 
which is characterized by developmental delay, medication-resistant epilepsy, and move-
Table 1 -  Diagnostic criteria for alternating hemiplegia of childhood and sporadic hemiplegic migraine.
Alternating Hemiplegia of Childhood 




migraine (International Classification of 
Headache Disorders, 2nd ed.)1
Our 
patient
A) Onset of symptoms before 18 months 
of age
No A) At least two attacks fulfilling criteria B 
and C
Yes
B) Repeated attacks of hemiplegia invol- 
ving either side of the body
Yes B) Aura consisting of fully reversible 
motor weakness and at least one of the 
fol- lowing:
1. Fully reversible visual symptoms 
including positive features (e.g. flickering 
lights, spots or lines) and/or negative 
features (i.e. loss of vision)
2. Fully reversible sensory symptoms 
including positive features (i.e. pins and 
needles) and/or negative features (i.e. 
numbness)





C) Other paroxysmal disturbances includ- 
ing tonic or dystonic spells, oculomotor 
abnormalities, and autonomic phenomena 
during bouts in isolation
Yes C) At least two of the following:
1. At least one aura symptom develops 
gradually over ≥ 5 minutes and/or different 
aura symptoms occur in succession over 
≥5 minutes
2. Each aura symptom lasts ≥5 minutes 
and <24 hours
3. Headache fulfilling criteria B–D for 
migraine without aura begins during the 
aura or follows onset of aura within 60 
minutes
Yes
D) Episodes of bilateral hemiplegia 
or quadriplegia as generalization of a 
hemiplegic episode, or bilateral from the 
beginning




E) Immediate disappearance of symptoms 
upon sleeping, which later may resume 
after waking
No E) Not attributed to another disorder No
F) Evidence of developmental delay 
and neurologic abnormalities including 
choreoathetosis, dystonia, or ataxia
Yes Other paroxysmal and permanent features 
described in SHM:
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ment disorders including ataxia and  dystonia. Because of the partially overlapping clin-
ical manifestations of AHC and HM, the CACNA1A and ATP1A2 genes earlier were 
screened in typical AHC fulfilling all diagnostic criteria as well, but no mutations have 
been identified.23,24
 Because of the clinical and genetic overlap of AHC and HM, we investigated (i) in 
our cohort of HM patients (who screened negative for mutations in known HM genes) 
whether mutations are found in the coding regions of SLC2A1 and in those exons of 
ATP1A3 in which previously AHC mutations had been identified; and (ii) whether 
SLC2A1 mutations are present in patients with AHC who screened negative for ATP1A3 
mutations. Our results revealed no mutations in ATP1A3 or SLC2A1 in our cohort of 
HM patients. However, we did identify a p.Gly18Arg mutation in SLC2A1 in a patient 
with a complex phenotype consisting of clinical features of AHC and HM (Table 1). In 
our study we did not provide evidence that AHC genes ATP1A3 and SLC2A1 play a role 
in FHM or SHM. We suggest considering screening for mutations in SLC2A1 in atyp-
ical patients with overlapping symptoms of HM and AHC.
Methods
Patients
For mutation screening of the SLC2A1 and ATP1A3 genes we selected 42 patients with 
HM (21 FHM and 21 SHM) for whom mutations in FHM genes (CACNA1A, ATP1A2, 
and SCN1A) had been excluded prior to the study by direct sequencing of all exons and 
flanking intronic regions. HM diagnoses were established according to the International 
Classification of Headache Disorders, 2nd ed. (ICHD-2; see Table 1 for SHM criteria).1 
We also included five ATP1A3-negative patients referred to us with a suspected AHC 
diagnosis in our screen of SLC2A1 mutations. Four of these patients fulfilled all diagnostic 
criteria for AHC, as outlined by Sweney et al. (see Table 1).14. The fifth patient was atyp-
ical and met diagnostic criteria for SHM, but presented with a particularly severe pheno-
type of intellectual disability, seizures, and exercise-induced dystonia in addition to 
hemiplegic attacks, and thus symptoms fulfilled three of the six diagnostic criteria for 
AHC (see Table 1).
 Three of the five AHC patients were sequenced for the CACNA1A and ATP1A2 genes, 
including the atypical patient. This was performed as part of a large mutation screen prior 
to the discovery of the ATP1A3 gene as a major gene for AHC. As these results were 
negative.23,24 we did not continue to screen for these genes in AHC patients. SCN1A 
screening was also performed in a group of AHC patients (data not published) and was 
negative as well. As SCN1A mutations have not been found in three large series of sporadic 
hemiplegic migraine patients with or without associated neurological symptoms,25–27 we 
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did not perform SCN1A  screening in the five AHC patients. PRRT2 was screened only 
in the atypical AHC patient, as screening in a large subset of our HM patient cohort 
showed no mutations (data not published). The local medical ethics committee approved 
the study and all patients or their parents provided written informed consent.
Mutation screening of ATP1A3 and SLC2A1
Ethylenediaminetetraacetic acid (EDTA) blood samples were collected from all patients 
and DNA was isolated using a standard salting out method.28 For the five AHC patients, 
genetic analysis of the ATP1A3 gene was performed by direct sequencing of all exons 
(and flanking intronic sequences) (ATP1A3 reference sequence: Genbank Accession 
Number NM_152296.4). For the 42 HM patients, ATP1A3 exons (and flanking intronic 
sequences) containing AHC-causing mutations (that is exons 5, 7–9, 13–16, 17, 18, 
20–22) were sequenced. Genetic analysis of the SLC2A1 gene was performed by direct 
sequencing of all 10 exons and flanking intronic sequences (SLC2A1 reference sequence: 
Genbank Accession Number NM_006516). Multiplex ligation-dependent probe ampli-
fication was performed for SLC2A1 to search for intragenic deletions, using the SALSA 
multiplex ligation-dependent probe amplification (MLPA) kit P138 (MRC Holland, 
Amsterdam, the Netherlands) according to the manufacturer’s instructions.
Results
We did not identify any causal mutations in the ATP1A3 or SLC2A1 gene in the 42 HM 
patients and four typical AHC patients. In contrast, in the atypical patient with overlap-
ping features of AHC and SHM, we identified a novel heterozygous p.Gly18Arg muta-
tion (c.52G>C) in exon 2 of the SLC2A1 gene. This mutation was not found in 150 
healthy controls nor in single-nucleotide polymorphism (SNP) databases (dbSNP, 1000G, 
Ensemble, ESP5400 and GoNL). It was also absent in the unaffected parents, and thus 
had occurred de novo. This patient showed a unique combination of symptoms, which 
were published 15 years ago without a genetic diagnosis.29 At the age of 20 years, she 
presented with progressive cerebellar ataxia and exercise-induced dystonia responding to 
oral corticosteroid treatment, and moderate intellectual disability. No ocular abnormal-
ities were observed. From the age of 11 years, she had experienced episodes of hemiplegia, 
which did not resolve upon falling asleep. Hemiplegic attacks were always accompanied 
by inability to speak and confused speech. Flashing lights and ipsilateral numbness were 
present in some of the attacks. Hemiplegia, visual, and sensory symptoms were followed 
by contralateral headache and vomiting. Furthermore, she suffered from simple and 
complex partial seizures. Interictal electroencephalograms (EEGs) showed epileptiform 
activity, predominantly located right parietal. Brain magnetic resonance imaging scans 
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(MRIs) were normal apart from a small non-specific white matter abnormality. Interictal 
cerebrospinal fluid (CSF) showed normal cell count, low glucose concentration of 2.4 
mmol/l (reference: 2.5–3.7 mmol/l) and low lactate concentration of 1.2 mmol/l (refer-
ence: 1.3–1.9 mmol/l) (30). Blood glucose was not simultaneously measured.
 Clinical follow-up at the age of 32 years revealed that no hemiplegic attacks had 
occurred during the last 10 years. Limb paresthesiae and hemianopsia lasting for several 
minutes without headache continued to occur and were classified as migraine with aura. 
Exercise-induced dystonia led to daily falls during walking. Ataxia had remained stable 
and seizures were never completely responsive to treatment with lamotrigine, sodium 
valproate, carbamazepine or clobazam. In retrospect, the CSF glucose and lactate concen-
trations were recognized as borderline low. The patient currently is considering starting 
a ketogenic diet.
Discussion
In this study we identified a novel pathogenic heterozygous SLC2A1 p.Gly18Arg muta-
tion in an atypical sporadic patient with overlapping symptoms of both AHC and HM. 
In 2009, Rotstein et al.21 found a p.Arg93Trp SLC2A1 mutation in a patient with atyp-
ical AHC features with intellectual disability, hemiplegic attacks (but otherwise not typical 
for HM either), episodes of ataxia, microcephaly and hypoglycorrhagia. Characteristically, 
mutations in SLC2A1 cause autosomal dominant glucose transporter type 1 (GLUT1) 
deficiency syndrome.31 The classical phenotype of GLUT1 deficiency syndrome consists 
of developmental delay, medication-resistant epilepsy, and movement disorders including 
ataxia and dystonia. A diagnosis of GLUT1 deficiency syndrome is suspected when 
hypoglycorrhachia (i.e. a low CSF glucose in a normoglycemic patient) is present. Symp-
toms improve with a ketogenic diet. Over the last few years it has become apparent that 
the clinical spectrum of the GLUT1 deficiency syndrome is broader.31,32
 Our patient expands the clinical phenotype of SLC2A1 mutations with episodes of 
HM and migraine with aura (without hemiplegia). The episodes of hemiplegia in our 
and Rotstein’s21 patient differ from classic AHC because in contrast to classical AHC 
patients (i) the age of onset in these two patients was after 18 months; (ii) sleep had no 
beneficial effect on the attacks; (iii) dysconjugated eye movements were absent; and (iv) 
quadriplegic attacks were absent. Therefore, these patients do not meet the diagnostic 
criteria for AHC (Table 1).1 Moreover, the hemiplegia in our patient meets the ICHD-2 
diagnostic criteria for SHM (Table 1),1 but no mutations in CACNA1A  and ATP1A2 
were found, so far the only two genes with strong evidence for implication in the sporadic 
form of HM. The phenotype of our patient combines symptoms from GLUT1 deficiency 
syndrome and some of the severest presentations of SHM, both of which can present 
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with intellectual disability, seizures and ataxia. The exercise-induced dystonia that is 
prominently present in our patient is not described in patients with SHM.2
 Different lines of evidence indicate that the p.Gly18Arg SLC2A1 mutation is the 
disease-causing mutation in our patient. The mutation had occurred de novo and was 
not found in healthy controls. Moreover, glycine at position 18 is a conserved amino acid 
in the first transmembrane segment of the GLUT1 protein. This segment is part of the 
central aqueous channel of the protein.33 Since the nonpolar glycine residue is replaced 
by a positively charged arginine residue, the mutation most likely interferes with normal 
GLUT1 function by disrupting glucose transport across the aqueous central channel. 
Finally, CSF glucose was low in combination with a low normal CSF lactate, which is 
within the range observed in SLC2A1 mutation carriers.30 The exercise-induced dystonia 
improved with oral corticosteroid treatment, possibly due to corticosteroid-induced 
hyperglycemia leading to increased GLUT1-mediated glucose transport in the brain, as 
has been shown by experiments in rats.34
 The absence of SLC2A1 mutations in the four classical AHC patients is in line with a 
previous mutation screening in 23 classical AHC patients35 that was conducted before 
the identification of ATP1A3 as the causal gene in typical AHC patients15,16 We did not 
identify causal mutations in ATP1A3 exons implicated in AHC in our HM patients. In 
conclusion, we propose that mutation screening of SLC2A1 should be considered in 
patients with a complex phenotype with overlapping symptoms of AHC and HM, espe-
cially if hypoglycorrhachia is detected in CSF. Diagnosing patients with a similar complex 
phenotype and SLC2A1 mutations may be of importance also because symptoms may 
ameliorate upon treatment with a ketogenic diet.
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Abstract
Objective – To assess validity and reliability of a self-administered 
web-based migraine-questionnaire in diagnosing migraine aura for the 
use of epidemiological and genetic studies.
Methods – Self-reported migraineurs enrolled via the LUMINA-website 
and completed a web-based questionnaire on headache and aura 
symptoms, after fulfilling screening criteria. Diagnoses were calculated 
using an algorithm based on the International Classification of Headache 
Disorders (ICHD-2), and semi-structured telephone-interviews were 
performed for final diagnoses. Logistic regression generated a prediction 
rule for aura. Algorithm-diagnoses and predicted diagnoses were 
subsequently compared to the interview-derived diagnoses.
Results –  In one year, we recruited 2,397 migraineurs, of which 1,067 
were included in the validation. A seven-question subset provided higher 
sensitivity (86%vs.45%), slightly lower specificity (75%vs.95%) and 
similar positive predictive value (86%vs.88%) in assessing aura when 
comparing with the ICHD-2 based algorithm. 
Conclusions – This questionnaire is accurate and reliable in diagnosing 
migraine aura among self-reported migraineurs, and enables detection 
of more aura cases with low false-positive rate. 
Key Words:  migraine ■ headache ■ questionnaire validation ■ co-
hort study ■ screening in epidemiology 
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Introduction
MIGRAINE is a common brain disorder characterized by recurrent, disabling attacks of headache, autonomic features (migraine without aura; MO), and, in one third 
of patients, transient neurological aura symptoms (migraine with aura; MA). In western 
countries, the overall migraine prevalence in the general population is at least 12 percent, 
two-thirds of which concerns females1-4. Since no biomarker for migraine exists, diagnosis 
according to the headache classification of the International Headache Society (IHS)5 
relies exclusively on the headache history. A careful history taken by a headache specialist 
is the gold standard for making a valid migraine and aura diagnosis. 
 Large-scale studies with several thousands of participants are important to obtain 
information for epidemiological and genetic migraine research and may yield important 
insights in migraine pathophysiology. Migraine is a complex genetic disorder, i.e. multiple 
genetic and environmental factors contribute to migraine susceptibility.
 Twin and population-based family studies showed that genetic factors play an impor-
tant role in migraine susceptibility, especially in the MA subtype6-12. However, genetic 
linkage studies using migraine subtypes as an end diagnosis did not yield gene variants 
thus far. Clinical heterogeneity in migraine and aura diagnosis may have hampered the 
identification of such variants. Recently, in a large genome wide association analysis 
(GWA) with a large set of clinic-based migraineurs, a first-ever genetic risk factor was 
identified associated with common types of migraine, in patients that were largely recruited 
from specialist headache clinics with a clinic-based migraine diagnosis13. However, popu-
lation-based large-scale studies exclude the possibility of a face-to-face examination, and, 
therefore, a less time-consuming and less costly diagnostic strategy has to be chosen. A 
web-based questionnaire represents an attractive and inexpensive alternative for a clinic 
interview. Several groups have reported on the use of internet to recruit headache and 
other patients for clinical research14-18. However, reliably diagnosing aura remains an issue. 
 The availability of a validated, aura-specific questionnaire is important when large 
numbers of cases are needed, especially in studies with self-reported migraineurs from 
the general population19,20.  We developed the LUMINA (Leiden University MIgraine 
Neuro-Analysis) website and designed and validated a self-reporting, web-based question-
naire to reliably diagnose migraine headache and aura symptoms, using only a limited 
number of questions. In this paper, we will present the validation of this web-based 





Participants were Dutch adults aged 18 to 74 years with migraine (MA and MO), who 
were informed via the lay press nationwide to enrol via the especially designed LUMINA 
website. Additionally, patients from our outpatient headache clinic were invited by a 
letter. In this clinic-based study, all participants were self-reporting migraineurs, of which 







































































Figure 1 - Flowchart of (semi-)automated study flow. Screening = screening questionnaire; questionnaire = 
extended questionnaire; Alg.= ICHD-2 based algorithm diagnosis; Int.= interview diagnosis; MA = migraine 
with aura; MO = migraine without aura; *In the total MA group, 91.6% (447/488) reported visual aura symptoms.
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Study flow
Study flow is depicted in Figure 1. Patients who visited the website were informed about 
the study and could enrol directly. The first step was to fulfil the screening criteria, using 
a simple screening questionnaire that was validated previously in the population-based 
GEM-study3.  This screening questionnaire included five questions asking whether the 
patient i) had severe headaches in the past 12 months; ii) what the headache severity was; 
iii) had suffered from headaches which were preceded by visual disturbances; iv) had been 
diagnosed with migraine by a physician; and v) had ever used anti-migraine medication. 
After fulfilling these criteria, cases received a unique user ID-code via e-mail to log on to 
the study website, where they could participate in an extended, web-based questionnaire 
study. Having completed the extended questionnaire, a number of randomly selected 
participants were contacted by telephone by WPJvO, CMW, and AHS, who are experi-
enced in diagnosing migraine. This semi-structured telephone interview detailed questions 
on headache and aura characteristics including ICHD-2 migraine and aura criteria5 with 
special attention for visual, sensory, motor and speech aurasymptoms, was used as the 
gold standard. Median interview duration was 10-15 minutes, ranging up to 30 minutes 
if necessary. Afterwards, a final diagnosis was made: in case of ambiguity, a headache 
specialist (GMT) was consulted. Patients were excluded from the analysis if they could 
not be reached by telephone after five failed telephone contact attempts. The study was 
approved by the local medical ethics committee. All participants provided written informed 
consent.
Construction of questionnaire
The extended questionnaire (accessible via www.lumc.nl/hoofdpijn) was based on the 
ICHD-2 criteria5 and incorporated 127 items on migraine headache and aura character-
istics, premonitory symptoms, trigger factors, allodynia, and medication use and was 
presented to participants as a digital web-form. The questions were to be answered by 
choosing from categorical alternatives. On the web-form multicolour exemplary illustra-
tions were shown with the most characteristic visual aura features (hemianopsia, scotoma, 
fortification spectra, visual blurring) and sensory aura features (anatomical distribution). 
ICHD-2 based algorithm
After completion of the extended questionnaire, an algorithm based on ICHD-2 criteria5 
migraine criteria was run and individual diagnosis was determined. The algorithm had 
the following possible outcomes: ‘no migraine’; ‘migraine without aura’; and ‘migraine 
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Figure 2 - Structure of ICHD-II based algorithm used in LUMINA study. MO = migraine without aura; MA 
= migraine with aura; 
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Statistical analysis 
Descriptive statistics
Descriptive statistics were performed on demographic and clinical variables, on the algo-
rithm based diagnoses and on the interview-derived diagnoses. Results are reported as 
mean ± SD or as percentage. Differences in between-groups means were analyzed with 
independent sample t-tests and ANOVAs. Proportions were compared using Chi-square 
tests. All items from the extended questionnaire that concerned ICHD-2 migraine criteria 
were evaluated separately. Likelihood ratios were calculated using standard formulas for 
positive likelihood ratio (LR+, sensitivity/[1 – specificity]) and negative likelihood ratio 
(LR-, [1 – sensitivity]/ specificity). 
Questionnaire validation process
The questionnaire validation process was divided into two phases and was aimed at iden-
tifying a combination of items that were better predictors for diagnosing migraine aura 
than the ICHD-2 based algorithm, with the interview-derived diagnosis as the gold 
standard. In phase I, a sample of 838 self-reported migraineurs (approximately 80% of 
total group) was randomly selected and used as a training sample (see Figure 1) to derive 
a predictive model. These patients fulfilled set screening criteria from the five-item LUMINA 
screener before they could enter the extended questionnaire. Logistic regression (see 
below) was used to develop the predictive model that included questionnaire items most 
contributing to predict subcategories ‘aura’ and ‘no aura’. Subsequently, we compared 
both the ICHD-2 based algorithm diagnoses and the diagnoses predicted by the logistic 
model, to the gold standard. In phase II, we validated this derived predictive model in 
an independent validation sample, consisting of 200 patients, approximately 20% of our 
sample (see Figure 1). 
Phase I: Development of prediction rule
In phase I, a prediction rule for the aura subcategories ‘aura’ vs. ‘no aura’ was developed 
using a multivariate logistic regression analysis. Relevant, individual, dichotomized items 
(n=33) were selected from the extended questionnaire and were used as predictor variables 
for aura in the model. Selection of items was made by the authors (WPJvO; CMW; 
GMT) and was based on clinical relevance to migraine aura, and sensitivity, specificity, 
PPV, NPV en likelihood ratios of individual items. Inter-item correlation was assessed 
for relevant items using Spearman’s rank coefficients and when items correlated with 
coefficients >0.9, one of these items was excluded from the analysis. A forward selection 
strategy using the likelihood ratio test was performed to identify items that were signif-
icant (p<0.05) predictors for the outcome of aura. For each subject in this sample (n=838), 
a prediction score was calculated using these items. Subsequently, a receiver operator 
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characteristics (ROC) curve was generated to assess the optimum cut off point for this 
prediction score. Using the method proposed by Halpern et al.21, an optimum cut-off 
(highest sensitivity and specificity) was determined from the ROC curve. Therefore, the 
logistic model resulted in a selection of the 33 items with significant (p<0.05) contribu-
tion in the aura prediction. 
Phase II: Validation of prediction rule 
The derived predictive rule was subsequently validated in the second sample (validation 
sample; n=200; see Figure 1). Validity of this predictive model was assessed by checking 
whether the selected items contributed significantly (p<0.05) for the prediction in the 
second sample too. Subsequently, the sensitivity and specificity from the ROC optimum 
in the training sample were compared with these parameters in the validation sample, 
using the same cut-off value.  
Overall outcome measures
Sensitivity, specificity, positive and negative predictive values were calculated to compare 
the fit of the three different models with the interview-derived aura diagnosis as the gold 
standard. These models were: 1) ICHD-2 based algorithm; 2) predictive model from 
phase I; and 3) validation of predictive rule in phase II. 
 All data analyses were performed using SPSS 16.0.2 (SPSS inc., IBM, USA). P values 
less than 0.05 were considered significant. When appropriate, categorical items were 
dichotomized into binary variables for the analysis in an attempt to simplify the instru-
ment. 
Table 1 -  Baseline characteristics of total study population and separate study samples.















Age, years 42.8±11.9 41.6±12.0 44.3±11.6 43.9±11.1 44.4±11.6 44.6±1.7 43.3±11.5
Female 84.8 83.9 85.8 89.7 85.6 85.0 88.5
Ever M 
diagnosis
88.9 87.8 90.2 100 89.9 90.2 89.0
Anti-M 
drug use
82.8 80.3 85.8 93.1 85.6 85.2 87.5
Algorithm 
diagnosis M
87.1 97.3* 71.4* 79.3 72.4 72.1 73.5
Values are mean ± SD or %. * p<0.001 (χ2-test). M = migraine.
65
Validation of the web-based LUMINA questionnaire for recruiting migraineurs
Receiver Operator Characteristics (ROC) curve
From the data in the training sample, we generated an ROC curve by plotting the sensi-
tivity of the questionnaire against one minus the specificity. As a graphical representation 
of the trade-off between false negative and false positive rates for every possible cut-off 
point, the ROC curve reflects the trade-offs between sensitivity and specificity, and plots 
the false positive rate on the X axis and the true positive rate on the Y-axis. The area under 
the curve is a measure of correlation between the prediction of the questionnaire and the 
gold standard diagnosis. The closer the area under the curve (AUC) is to 1, the better the 
test is. To validate the derived logistic model, we compared the ROC from the prediction 
sample (n=838) to the ROC of the validation sample (n=200). 
Results
General results
Over a 1-year period, from April 2008 until April 2009, 2,397 subjects fulfilled the set 
screening criteria and completed the extended questionnaire (Figure 1). During this time 
period, a total of 1,067 subjects (44.5%) were randomly selected for the semi-structured 
telephone interview, of which 1,038 (97.3%) were reached and could be used in the 
analysis. A total of 29 subjects (2.7%) were not included in the analysis because they 
could not be reached by telephone, after having tried at least five times. From these 1,038 
subjects, 838 (79.4%) were randomly selected and used for the prediction model and 
the remaining sample of 200 subjects (18.9%) was used for validation (Figure 1). 
Table 2 -  Sensitivity, specificity, and positive and negative predictive values as well as the correspond-
ing likelihood ratios for diagnosis of migraine aura based on the IHCD-II-based algorithm (in both the 
total group and training sample) and the derived seven-item prediction model (in both the training 
sample and in the validation sample)
ICHD-2 based algorithm Model
Characteristic Total sample 
(n=1038)
 Predictive sample 
(n=838)




Sensitivity, % 45 44 83 86
Specificity, % 95 95 74 75
PPV MA, % 88 89 74 74
PPV MO (=NPV MA), % 70 64 83 86
Positive likelihood ratio 8.2 8.7 3.1 3.5
Negative likelihood ratio 0.6 0.6 0.2 0.2




Baseline characteristics of the total study population and separate prediction and valida-
tion samples are depicted in Table 1. Almost 90% of self-reported migraineurs had previ-
ously been diagnosed with migraine by a physician. Age, gender, prevalence of previous 
migraine diagnosis and use of anti-migraine medication did not differ significantly between 
selected subjects and non-selected subjects, nor between subjects that were reached 
compared to those that could not be reached for telephone interview (see Table 1). In 
the selected subjects (n=1,067; with special attention to patients which fulfilled ICHD-2 
migraine criteria except for attack duration), the algorithm diagnosis of ‘no-migraine’ 
was more prevalent (28.6% [305/1,067] vs. 2.7% [36/1,330]; p<0.001) compared to 
non-selected subjects (n=1,330). 
Screening questionnaire
In total, 94.6 percent of subjects (982/1,038) fulfilling the screening criteria, fulfilled 
ICHD-2 migraine criteria in the telephone interview. We considered everyone fulfilling 
the screening criteria to be migraineur. We used a logistic model to predict individual 
aura vs. no aura status. 
Algorithm diagnosis
From the total sample of 1.038 subjects, the ICHD-2 based algorithm classified 488 
subjects as MO patients, 251 as having MA, and 299 subjects as non-migraineurs (Figure 
1). Of these, 243 were misclassified as non-migraineurs due to reporting of longer than 
actual attack duration. Table 2 summarizes the sensitivity, specificity, positive and nega-
tive predictive values as well as the corresponding likelihood ratios for the ICHD-2 based 
Table 3 -  Sensitivity, specificity, predictive values and likelihood ratios of individual questionnaire 
headache items vs. the interview diagnosis of migraine headache. 
Question
Yes No
Variable M. No M. M. No M. Sens. Spec. PPV NPV LR+ LR-
Duration 4-72 hrs 721 19 249 49 0.74 0.72 0.97 0.16 2.64 0.36
Throbbing 670 232 40 96 0.94 0.29 0.74 0.71 1.32 0.21
Unilateral 863 57 46 72 0.95 0.56 0.94 0.61 2.16 0.89
Increase by activity 878 57 63 40 0.93 0.41 0.94 0.39 1.58 0.17
Severe 516 11 455 56 0.53 0.84 0.98 0.11 3.31 0.56
Nausea 867 63 36 72 0.96 0.53 0.93 0.67 2.04 0.08
Vomiting 627 87 64 260 0.91 0.75 0.88 0.80 3.64 0.12
Photophobia 859 91 25 63 0.97 0.41 0.90 0.72 1.64 0.07
Phonophobia 809 128 30 71 0.96 0.36 0.86 0.70 1.50 0.11
M = migraine; Sens. = sensitivity; Spec. = specificity; PPV = positive predictive value; NPV = negative 
predictive value; LR+ = positive likelihood ratio; LR- = negative likelihood ratio.
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Table 4 -  Sensitivity, specificity, predictive values and likelihood ratios of individual questionnaire aura 
items vs. the interview diagnosis of migraine aura.
Question
Yes No
Variable M. No M. M. No M. Sens. Spec. PPV NPV LR+ LR-
Visual aura symptoms
Suffer from visual 
disturbances? 
436 235 42 278 0.91 0.54 0.65 0.87 1.98 0.17
Shitters 335 117 143 396 0.70 0.77 0.74 0.74 3.04 0.39
Stars 201 71 277 442 0.42 0.86 0.74 0.62 3.00 0.67
Flashes 178 42 300 471 0.37 0.92 0.81 0.61 4.63 0.68
Scintillating lines 223 25 255 488 0.47 0.95 0.90 0.66 9.40 0.56
Figures 111 29 367 484 0.23 0.94 0.79 0.57 3.83 0.82
Coloured spots 153 70 325 443 0.32 0.86 0.69 0.58 2.29 0.79
Trembling air  
sensations
488 412 25 66 0.14 0.95 0.73 0.54 2.80 0.91
Wet window glass 118 71 360 442 0.25 0.86 0.62 0.55 1.79 0.87
Loss of vision 283 62 195 451 0.59 0.88 0.82 0.70 4.92 0.47
Diplopia 146 72 332 441 0.31 0.86 0.67 0.57 2.21 0.80
Other specific visual 
disturbances




114 268 13 623 0.90 0.70 0.30 0.98 3.00 0.14
Unilateral 111 236 16 655 0.87 0.73 0.32 0.98 3.22 0.18
5-60 min 49 50 78 841 0.39 0.94 0.50 0.92 6.50 0.65
Start before headache 94 154 33 737 0.74 0.83 0.38 0.96 4.35 0.31
Motor aura symptoms
Muscle weakness 20 203 6 802 0.77 0.80 0.09 0.99 3.85 0.29
Unilaterality 14 59 12 946 0.54 0.94 0.19 0.99 9.00 0.49
Duration 5-60 minutes 6 47 20 958 0.23 0.95 0.11 0.98 4.60 0.81
Starts prior to 
headache
14 128 12 877 0.54 0.87 0.10 0.99 4.15 0.53
Pinching 13 117 13 888 0.50 0.88 0.10 0.99 4.17 0.57
Arm lifting problem 10 62 16 943 0.39 0.94 0.14 0.98 6.50 0.65
Crippled walking 9 51 17 954 0.35 0.95 0.15 0.98 7.00 0.68
Facial asymmetry 8 26 18 979 0.31 0.97 0.24 0.98 10.33 0.71
Speech disturbances
Speech problems 132 366 8 489 0.94 0.57 0.27 0.98 2.19 0.11
Stiff mouth/ tongue 66 103 74 752 0.47 0.88 0.39 0.91 3.92 0.60
Wrong words 80 96 60 759 0.57 0.89 0.46 0.93 5.18 0.48
Expressive aphasia 119 311 21 544 0.85 0.64 0.28 0.96 2.36 0.23
Dysarthria 73 98 67 757 0.52 0.89 0.43 0.92 4.73 0.54
Prior to headache 102 154 38 701 0.73 0.82 0.40 0.95 4.06 0.33
Abbreviations as in Table 3.
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algorithm diagnosis of migraine aura in the total sample (n=1,038). Similar values for 
this classification in the training sample (n=838) suggest this sample is a good represen-
tation of the whole group. In both the total group and the training sample, sensitivity 
for aura was approximately 0.45, specificity 0.95, positive predictive value (PPV) 0.88 
and negative predictive value (NPV) 0.70 (Table 2). Additionally, we calculated charac-
teristics of all individual questionnaire items that reflect migraine headache and migraine 
aura criteria and summarized those in Table 3 and 4. The results show individual sensi-
tivity ranging up to 0.97 (photophobia; nausea) and PPV up to 0.98 (headache severity; 
headache duration). 
Phase I: Derivation of predictive model
Using logistic regression, 7 questions (from the 33 included; none showed Spearman 
rank correlation >0.9) showed a significant impact on the likelihood of having a migraine 
aura in accordance to the gold standard derived from the telephone interview. These 
questions are summarized in Table 5, which also shows significance levels and regression 
coefficients derived from the logistic model. The questions show partial overlap with the 
questions used in the ICHD-2 based algorithm. This model explained between 35.4% 
(Cox and Snell R Square) and 47.3% (Nagelkerke adjusted R Squared) of variance, and 
correctly classified 651/838 (77.8%) of subjects.
Table 5 -  Significantly correlated questions (n = 7) with regression coefficients, odds ratios and sig-
nificance levels derived from the logistic regression model (training sample; n = 838).
B OR (95% CI) p-value
Did you have visual disturbances before headache in the past 12 
months?
0.729 2.07 (132-3.26) 0.002
Did the visual disturbances last 5-60 minutes? 1.658 5.25 (3.08-8.96) <0.001
Have you had scintillating lines before or during your headache in 
the past 12 months?
1.210 3.35(2.06-5.45) <0.001
Have you had loss of vision before or during your headache in the 
past 12 months?
0.913 2.49(1.63-3.80) <0.001
Did you suffer from numbness or a tingling feeling in your face/ 
unilateral arm/ leg that started prior to headache in the past 12 
months?
0.631 1.88(1.07-3.29) 0.027
Did you use nonsense words prior or during your headache in the 
past 12 months?
0.680 1.97(1.22-3.19) 0.005
Did you use a triptan in the past 12 months? -0.561 0.57 (0.39-0.83) 0.003
B = regression coefficient; CI = confidence interval; OR = odds ratio..
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ROC curve
From the data in the predictive cohort, we generated an ROC curve by plotting the 
sensitivity of the questionnaire against one minus the specificity (Figure 3A). This anal-
ysis resulted in an optimal cut off point for the used logistic model at 0.35 with AUC of 
0.85 (95% C.I. 0.83-0.88), yielding a 7 item questionnaire with a sensitivity of 0.83 and 
a specificity of 0.74. Compared to the ICHD-2 based algorithm outcome, this approach 
therefore resulted in a vast increment in sensitivity, with only small decrement of speci-
ficity (Table 2).
Phase II: Validation of derived prediction rule
Using the predictive model and cut-off point (0.35) derived from the training sample 
(n=838), we validated this model in a second, independent sample (n=200) of subjects 
who also fulfilled the set screening criteria. This analysis showed the model to have 
approximately similar sensitivity and specificity in this validation sample (Table 2). In 
the validation cohort, the ROC curve yielded an AUC of 0.87 (95% C.I. 0.82-0.92), 
which is comparable to the output from the training cohort (Figure 3B). When using 
this cut off from the training cohort, migraine aura diagnosis was predicted correctly in 
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Figure 3 - Receiver operator characteristics (ROC) curves for (A) the derived prediction rule in the initial 
training sample (n=838) and (B) in the validation sample (n=200). The area under the ROC-curve (C-statistic) 





For a random selection of 44 patients who completed the extended questionnaire a second 
time, with a mean test-retest interval of 155 days (median 89 days, range 1-422 days), 
test-retest reliability was found to be good with a test-retest kappa for algorithm diagnostic 
group of 0.59 (95% CI 0.38-0.80). Test-retest interval did not influence agreement (linear 
regression, p=0.852). 
Discussion
Our study has been the first one to validate a web-based questionnaire for purposes of 
diagnosing aura cases using a large sample of self-reported migraineurs. Few previous 
studies on migraine screeners and questionnaires have focussed on migraine aura, and 
the numbers of MA cases used to validate the questionnaire instruments in these studies 
were limited to n=8-18617,19,22-24 respectively, in comparison to the large number of 488 
aura cases in our study. Physicians frequently rely on aura as a cardinal symptom of 
migraine, as suggested by the 1.9 fold higher rate of medical diagnosis in interview settings 
when comparing MA cases to cases of MO25. Our study shows that, in self-reported 
migraineurs, a distinction between MA and MO can be made via a self-administered 
web-based questionnaire, with a focus on visual aura symptoms. The difficulty in diag-
nosing other aura types might be explained by the lack of perceptions and recognition 
of verbal and other non-visual auras by patients26. For diagnosing patients with these 
specific aura symptoms a clinical interview is needed. However, since the vast majority 
of the self-reported aura cases suffer from visual auras and only a small minority suffers 
from non-visual auras27, we believe this number is neglectable when recruiting aura cases 
from a population of self-reported migraineurs. Perhaps the most helpful item identifying 
aura cases is the duration of the aura phenomena, since this question enables to distin-
guish visual aura symptoms from non-specific visual disturbances. Additionally, our data 
show aura patients are less likely to use triptans for rescue medication, which might be 
an indicator of lower headache severity. 
 We show that the question addressing the duration of the headache may hamper correct 
identification of migraine cases in a web-based questionnaire setting because some 
migraineurs overestimate the duration of an attack.  Conversely, a question addressing 
headache severity should be included because this is helpful in distinguishing aura cases 
with migraineous headache from patients with non-specific headache. 
 The strength of our study includes the large samples of both the training (n=838) and 
validation sample (n=200), which are representative for the population studied. Both 
outclinic patients and other patients (most of whom are treated by their own GP or 
neurologist elsewhere) were included via the same web-based flow. We found no clinical 
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or demographic differences between these populations that could have affected the predic-
tive model. Secondly, the use of a telephone interview as a gold standard by well-trained 
physicians with consultation of a headache specialist assured precise categorisation of 
migraineurs.  Although we did not  had a face-to-face interview as gold standard, we feel 
that our thorough semi-structured telephone interview safeguarded a very reliable migraine 
and aura diagnosis. Thirdly, the use of a validated screening instrument prior to our new 
questionnaire resulted in a group of self-reported migraineurs in which 95% could in 
fact be diagnosed with migraine. Fourth, we used a web-based questionnaire that was 
easy to fill out and send in for participants. With this approach, we successfully recruited 
large samples of migraineurs and contributed to the identification of the first genetic risk 
factor for the common forms of migraine13. We included a selected population of self-
reported migraineurs, that had already been diagnosed with migraine by a physician, or 
otherwise thought they suffered from migraine, in which our questionnaire shows a high 
reliability in diagnosing aura. Our study did not aim to validate the questionnaire as a 
screening instrument for migraine in a naïve, general population. 
 The World Wide Web as a tool for recruiting patients and conducting research has 
several advantages. First, a large and diverse subject population can be reached at low 
cost16. Secondly, internet research imposes fewer burdens on participants, compared to 
non-internet research15. Thirdly, available software permits data entry and analysis in a 
secure Web database. Fourth, investigators may be able to increase patient awareness and 
participation on clinical research. However, there might be certain challenges too28. 
Internet users tend to be younger and better educated than the patient population as a 
whole; visually impaired and minority groups may be underrepresented; and the symp-
toms expressed by participants may be more severe then is typical. We feel, however, these 
potential biases haven’t pivotally influenced our data. Additionally, the so-called ‘virtual 
Munchhausen syndrome’, i.e. individuals referring themselves for studies for which they 
are not truly eligible, may compromise the validity of results29.  In our study, we have no 
evidence that data have been influenced by subjects masquerading electronically as patients. 
This is in accordance with previous migraine research15. Even with such biases, altogether, 
the internet represents an appropriate aid to conduct research aimed at collecting clinical 
headache data from large numbers of patients.
 We conclude that our web-based recruitment system in combination with an auto-
mated study flow is a very successful instrument to truly distinguish MA and MO in 
self-reported migraine patients. We propose to use our identified seven questions that 
have a higher accuracy in identifying aura cases from a population of self-reported 
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Background – Cluster headache (CH) is a primary headache disorder 
that is diagnosed based on the patient’s history. For large-scale epidemi-
ologic and genetic studies, a web-based, preferably short, questionnaire 
can be a feasible alternative to replace time-consuming clinical interviews.
Methods – Self-reported CH patients were enrolled via our research 
website. Participants meeting screening criteria were directed to the 
Leiden University Cluster headache Analysis program (LUCA) 
questionnaire. Individual diagnoses were calculated using an algorithm 
based on International Headache Society criteria. Subsequently, 
semi-structured telephone interviews were carried out to validate the 
LUCA questionnaire. The shorter Quick Ascertainment of Cluster 
Headache (QATCH) questionnaire for diagnosing CH was constructed 
by using logistic regression to select the most predictive questions.
Results – Via our website 437 self-reported CH patients were recruited. 
Of these, 291 patients were included in this cross-sectional study. The 
LUCA questionnaire was valid and accurate. Using logistic regression, 
three questions (QATCH) provided similar sensitivity (53.8% vs. 57.2%), 
specificity (88.9% vs. 87.5%), positive predictive value (95.5% vs. 
95.9%) and negative predictive value (30.8% vs. 28.8%) compared with 
the LUCA questionnaire.
Conclusion – The web-based LUCA questionnaire was accurate and 
reliable in diagnosing CH among self-reported patients. Males with 
headache attacks of short duration and long headache-free intervals 
(months to years) are very likely to have CH.
Key Words:  cluster headache ■ questionnaires ■ genetics ■  valida-
tion ■ LUCA 
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Introduction
CLUSTER HEADACHE (CH) is one of the so-called ‘trigeminal autonomic ceph-algias’ (TACs) that are characterized by severe, short-lasting headache attacks accom-
panied by ipsilateral facial autonomic symptoms1. CH consists of attacks of severe, strictly 
unilateral, orbital, supraorbital and/or temporal pain, lasting 15 to 180 minutes and 
occurring from once every other day to a maximum of eight times a day2. The attacks 
are associated with one or more of the following symptoms: restlessness or ipsilateral 
autonomic symptoms, i.e. conjunctival injection, lacrimation, nasal congestion, rhinorhea, 
forehead and facial sweating, miosis, ptosis, and eyelid edema. CH can be either episodic 
or chronic, with the vast majority of patients having episodic CH. Episodic CH is char-
acterized by periods of weeks to months with frequent attacks that alternate with symptom-
free periods of several months to years. About 10% of CH patients have chronic CH 
without attack-free periods or attack-free periods of less than one month. Recent epide-
miologic studies have documented that the life-time prevalence of CH ranges from 0.05 
to 0.4%3. CH is more prevalent in men (ratio male to female of 4.4:1) with a peak age 
of onset between the ages of 20 and 29 years3,4.
 CH is a complex genetic disorder; i.e. multiple genetic and environmental factors 
contribute to CH susceptibility3. Based on a prevalence of 0.2%, the relative risk for 
first-degree family members of CH patients varies between five and 18 and for second-
degree relatives between one and three3. Thus far one genetic factor, i.e. a variant in the 
hypocretin type 2 receptor gene HCRTR2, was found to be associated with CH, albeit 
inconsistently5.
 More research is necessary to elucidate the genetics of CH. Genome-wide association 
studies (GWAS) aim to identify genetic factors by testing hundreds to thousands of 
single-nucleotide polymorphisms of affected individuals for associations with complex 
genetic diseases or particular traits6. Recent GWAS have been successful for migraine7–9. 
However, at least several hundred but preferably thousands of patients are needed for this 
type of study. Direct diagnostic interviews of such a large number of subjects are time 
consuming and expensive; therefore, a short reliable questionnaire would be preferable. 
An important pitfall of using such self-administered questionnaires is the inclusion of 
false-positive cases. This is a major concern for genetic research for which it is of the 
utmost importance to obtain reliable diagnoses.
 Studies validating self-administered screening questionnaires for CH so far were small 
and included highly selected patients10–13. We aimed to develop web-based questionnaires 
for recruiting large numbers of patients with self-reported primary headache syndromes 
such as CH and migraine. Recently, we published the first results of our Leiden Univer-
sity Migraine Neuro Analysis (LUMINA) study in which we described a reliable web-
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based screening questionnaire for migraine14 that has been used in our GWAS for 
migraine7,9.
 In the present cross-sectional study, we developed and validated our Dutch, web-based 
CH questionnaire ‘Leiden University Cluster headache Analysis program’ (LUCA ques-
tionnaire) to diagnose CH patients. In addition, we assessed which questions from the 
LUCA questionnaire contribute most in assessing CH diagnosis to develop an ultra-short 
‘Quick Ascertainment of Cluster Headache’ (QATCH) questionnaire to select patients 
in a large cohort.
Materials and methods
Subjects
Male and female patients aged 18 years and older were recruited via our headache research 
website (www.lumc.nl/hoofdpijn), which was developed in 2008 for research of primary 











































Figure 1 - Flowchart study flow. Screening: screening questionnaire; Questionnaire: extended question-
naire (LUCA); CH: cluster headache; alg.: International Classification of Headache Disorders: 2nd edition 
(ICHD-2)-based algorithm diagnosis; hoofdpijn: Dutch for headache.
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our previous efforts to collect a population-based cohort in the Netherlands in the large 
population-based GEM-study15 led to identification of only a few CH patients (personal 
communication, GMT and MDF, 1996). CH patients who participated in previous 
studies by our group, in which patients were recruited via general practitioners and tertiary 
headache centers throughout the Netherlands, were invited by letter to complete the 
web-based questionnaire16. Announcements were made in local newspapers and on 
national medical TV programs. Self-reported CH patients were able to participate on 
their own initiative. Approval for this study was obtained by the local medical ethical 
committee. All participants provided written informed consent.
Study flow
The study flow is depicted in the Figure 1. Our study consisted of a three-step procedure. 
Phase 1 consisted of the actual enrollment of participants with a screening questionnaire, 
the LUCA questionnaire and a calculated diagnosis by algorithm based on the Interna-
tional Classification of Headache Disorders: 2nd edition (ICHD-2) (the LUCA ques-
tionnaire is available by request at www.lumc.nl/clusterheadache). In phase 2 we validated 
the accuracy of the extended questionnaire (LUCA) by performing a direct interview. In 
the last phase of the study we aimed to develop a shorter questionnaire (QATCH) for 
diagnosing CH with at least the same accuracy as the LUCA questionnaire.
Phase I: Enrollment of patients
First the subjects were informed about the study and were asked to complete a short 
screening questionnaire (Supplementary Figure 1) on the headache website. The purpose 
of this screening questionnaire, which was minimally adapted from previous question-
naires in migraine (questions on restlessness, autonomic symptoms and attack duration 
were added and questions on possible aura symptoms were removed)15, was to exclude 
participants who were very unlikely to suffer from CH. The screening questionnaire was 
validated previously in 31 CH patients, 29 migraine patients and four tension-type head-
ache patients at our outpatient clinic and was found to have a sensitivity of 100%, a 
specificity of 58%, a positive predictive value (PPV) of 69% and a negative predictive 
value (NPV) of 100% (unpublished data). Because we have an open-access website, we 
decided that if the screening conditions were not met, the data of the subjects were not 
to be stored in our database. This prevents storage of junk information of subjects from 
whom we could not obtain informed consent, and who could not be used for validation 
of the questionnaire. If the screening conditions were met, patients were registered in 
our system and received an email in which they were asked to complete the LUCA ques-
tionnaire.
 The LUCA questionnaire was based on the ICHD-2 criteria2 and consisted of 142 
items on CH and more specific and detailed questions concerning CH symptoms, demo-
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graphical information, co-existing headaches and treatments of CH. The answers consisted 
of categorical alternatives.
 Upon completion of the LUCA questionnaire, a second algorithm based on the ICHD-2 
criteria was run automatically to determine the individual diagnoses (not shown). The 
following criteria, all to be fulfilled for receiving CH diagnoses, were used for the algo-
rithm: severe pain, unilateral pain, temporal or orbital pain, presence of one or more 
autonomic symptoms or restlessness, occurrence of at least five CH attacks in the past, 
untreated attack duration between 15 minutes and three hours and a headache attack 
frequency of at least one on every other day to a maximum of eight times a day. The 
outcome categories of the algorithm were ‘‘cluster headache’’ (all items fulfilled) and ‘‘no 
cluster headache’’ (not all items fulfilled).
 We also used a more lenient algorithm; criterion ‘‘untreated attack duration between 
15 minutes and three hours’’ was changed to ‘‘treated or untreated attack duration between 
15 minutes and three hours.’’
Phase II: Validation of the LUCA questionnaire
Semi-structured telephone interview. Within two months after completion of the 
LUCA questionnaire, enrolled participants were approached for a semi-structured tele-
phone interview to diagnose CH according to the ICHD-2 criteria2. The interview diag-
nosis was used as the gold standard. Interviews were performed by a medical student 
(CC) trained in diagnosing CH under supervision of the study physicians (LAW and 
CMW). The interviewer and supervisors were blinded for the automatically calculated 
algorithm diagnosis. If participants were not reached after two attempts, they were 
excluded from the validation procedure. Final diagnoses were made directly after the 
interview by CC and LAW/CMW. In case of ambiguous symptoms or when the diagnoses 
determined by CC and one of the study physicians did not correspond, a headache 
specialist (JH), also blinded for the calculated diagnoses, was consulted, and a final diag-
nosis was made. 
Statistical analysis of the LUCA questionnaire. All data analyses were performed using 
SPSS 17 (SPSS, IBM, US). Baseline characteristics of participants who were successfully 
interviewed and participants who were not reached were compared using two-sided χ2 
tests for categorical data and Student’s t tests for continuous variables. Alpha was set to 
0.05. Algorithm and interview diagnoses were compared to assess the sensitivity, speci-
ficity, the (prevalence dependent) PPV and NPV, respectively, and the positive and nega-
tive likelihood ratios for the entire LUCA questionnaire.
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Phase III: Toward the short QATCH questionnaire
Development of a prediction rule. In this phase of the study, we aimed to identify a 
subset of questions from the extended LUCA questionnaire to construct a shorter ques-
tionnaire (named Quick Ascertainment of Cluster Headache, abbreviated as QATCH) 
that predicts the CH diagnoses in our participants equally well or even better. To select 
these questions, we assessed the contribution of the individual 142 LUCA items to the 
CH diagnoses by calculating sensitivity, specificity, PPV and NPV, and positive and nega-
tive likelihood ratios, and selected questions based on PPVs of more than 0.90 and/or a 
positive likelihood ratio of more than 1.5.
 To develop a prediction rule, the successfully interviewed study population was randomly 
divided into a training set (80% of participants) and a validation set (20% of participants) 
to construct and validate the generated regression model. The selected LUCA items were 
incorporated in a forward logistic regression model on the 80% sample to assess their 
contribution to discriminating CH patients from non-CH patients.
Validation of the prediction rule. The questions that contributed significantly to the 
CH diagnoses in the forward regression model were incorporated in the prediction rule. 
The regression coefficients of these items were used to assign weights to the questions 
and to calculate the predicted probabilities for a CH diagnosis based on this model. 
Subsequently, a receiver operating characteristics (ROC) curve was computed for deter-
mining the optimal cut-off value for a CH diagnosis based on our prediction rule in the 
80% group according to the method of Halpern et al17.
 The area under the curve (AUC) was assessed as a measure of correlation between the 
prediction of the short questionnaire and the gold standard (interview) diagnosis. Finally, 
interview diagnoses were compared with diagnoses obtained by our new model to detemine 
sensitivity and specificity of our newly generated short questionnaire. In addition, we 
assessed the performance of this test in our population by means of the PPV and NPV 
in the 20% validation sample.
Table 1 -  Baseline characteristics of total study population and separate study samples.
Characteristic Total  Telephone interview Not reached
Number of participants 437 291 146
Age in years: mean (SD) 46.4 (11.9) 47.3 (11.7)a 44.5 (12.0)a 
Gender (% male) 64.8% 65.9% 62.3% 
Physician CH diagnosis 93.6% 93.8% 93.1% 
Use of anti-CH drugs 
(prophylactic and/or acute) 
89.9% 90.7% 88.3% 
Algorithm diagnosis CH 49.2% 49.8% 47.9%
Duration of CH in years (SD) 17.1 (11.3) 18.0 (11.3)b 15.3 (11.2)b 
Years of education (SD) 




Phase I: Enrollment of patients
The recruitment of patients started in April 2010, and two months later a total of 437 
participants met the screening criteria and completed the LUCA questionnaire (Figure 
1). In this study, all participants were self-reported CH patients, of whom 94% also 
reported a physician diagnosis of CH (Table 1).
Phase II: Validation of LUCA questionnaire
Telephone interview. From these 437 participants, a total of 146 (33%) were excluded 
in the analysis because they could not be reached by telephone after at least two attempts. 
Thus 291 participants (67%) were interviewed. In total 83.5% of subjects (243/291) 
fulfilled ICHD-2 criteria in the telephone interview.
 Baseline characteristics of 291 included patients were compared to 146 excluded 
patients. Interviewed subjects were significantly older (p = 0.018), had longer duration 
of CH (p = 0.046) and fewer years of education (p = 0.0049) but absolute differences 
were small. There were no significant differences with respect to gender, proportions of 
patients using anti-CH medication (prophylactic and acute), the proportion of patients 
with a physician diagnosis of CH, or algorithm diagnosis (Table 1).
Statistical analysis of the LUCA questionnaire. We interviewed 291 participants of the 
LUCA study and established a CH diagnosis in 243 (83%) of them. Of these 243 subjects, 
139 were also diagnosed as having CH by our LUCA questionnaire. Using the interview 
as the gold standard, the algorithm of the LUCA questionnaire had a sensitivity of 57.2% 
Table 2 -  Sensitivity, specificity, positive and negative predictive values as well as the corresponding 
likelihood ratios for diagnosis of cluster headache based on: 1) the ICHD-2-based algorithm; 2) the ICHD-
2-based lenient algorithm, including patients with headache duration of 15–180 minutes upon treatment.
Characteristic ICHD-II based 
algorithm total 
sample (n = 291)
ICHD-II lenient 
algorithm total 
sample (n = 291)




Positive likelihood ratio 4.58 2.42
Negative likelihood ratio 0.49 0.41
ICHD-2: International Classification of Headache Disorders: 2nd edition; PPV; positive predictive value; 
NPV: negative predictive value; Gold standard: direct interview.
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and a specificity of 87.5%. The PPV was 95.9% and the NPV was 28.8% in this popu-
lation (Table 2). A total of 152 subjects (52.2%) stated that they had an attack duration 
of 15 minutes to three hours, despite using symptomatic medication. A total of 252 
subjects (86.6%) stated that their attacks lasted 15 minutes to three hours without or 
with attack medication (lenient algorithm) and 183 subjects (75.3%) stated that their 
attacks lasted 15 minutes to three hours without attack medication (strict algorithm).
 With the use of the more lenient algorithm, which also includes patients with headache 
duration between 15 to 180 minutes upon treatment, the sensitivity increased to 70.4%, 
and the NPV increased to 67.6% with only a slightly decrease of the PPV to 92.5% 
(Table 2).
Phase III: Toward a short CH questionnaire
Development of a prediction rule. Nine variables from our LUCA questionnaire met 
our selection criteria for PPV of more than 0.90 and/or a positive likelihood ratio of 
more than 1.5. These nine variables were: untreated attack duration between 15 minutes 
to three hours, average attack-free period of four months to three years, pain on top of 
the eyeball, unilateral miosis, moderate to good response to oxygen, good response to 
sumatriptan, male sex, and smoking. Of the nine variables incorporated in our regression 
analysis, three contributed significantly to the model (QATCH questionnaire): i) untreated 
attack duration between 15 minutes and three hours (p < 0.001); ii) pain-free period 
between four months and three years (p < 0.007); and iii) male gender (p = 0.053). The 
regression coefficients were rounded off and used to assign points to the three items. 
Predicted probabilities for CH were calculated for the validation set using the regression 
coefficients of the model.
Validation of the prediction rule. From the data of the validation sample, we generated 
an ROC curve by plotting the sensitivity against one-specificity of the new three-item 
questionnaire. This analysis resulted in an optimal cut-off value of 1.5 (Table 3). The area 
under the curve (AUC) value was 0.817. Using this optimal cut-off value, all cases with 
Table 3 -  Short diagnostic cluster headache questionnaire: QATCH.
Score
Untreated attack duration 15–180 minutes 2.5
Attack-free period (four months–three years) 1.5
Male gender 1
Female gender 0
QATCH: Quick Ascertainment of Cluster Headache; Cluster headache is diagnosed with a score ≥1.5 
(after fulfilling the screening questionnaire). Scores are regression coefficients of the model. P values can 
be found in the text in the Results section.
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a score equal to or higher than 1.5 are classified as positive CH (Table 3). The three items 
were weighted according to the calculated regression coefficients of the model; having an 
untreated attack duration between 15 and 180 minutes (2.5 points), having an attack-
free period between four months and three years (1.5 points) and male gender (1 point). 
In our 20% validation population (n = 48), 22 subjects were diagnosed as CH according 
to this three-item model. Our three-item questionnaire had a sensitivity of 53.8%, a 
specificity of 88.9%, a PPV of 95.5% and an NPV of 30.8% when compared to interview 
diagnoses (gold standard). This new three-item questionnaire was named the Quick 
AscerTainment of Cluster Headache (QATCH) questionnaire.
Discussion
The main objective of this study was to validate a web-based questionnaire to diagnose 
CH patients for future large-scale epidemiologic and genetic studies. The LUCA ques-
tionnaire proved to be a valid and reliable method for diagnosing CH in a population of 
self-reported CH patients. Our second objective was to construct a shorter questionnaire 
to diagnose CH in large samples. The QATCH questionnaire represents a practical alter-
native for diagnosing CH patients as the combination of the screening and QATCH 
questionnaire works as well as combining the screening questionnaire with the much 
longer LUCA questionnaire. The QATCH questionnaire indicates that males with untreated 
headache attacks lasting 15–180 minutes and attack-free periods of four months to three 
years are very likely to have CH under the condition that the including criteria are fulfilled. 
This does not imply that females or chronic CH patients are excluded by using this ques-
tionnaire, as the questions are weighted and not all three items are obligatory to receive 
the diagnosis of CH. Male gender alone is not enough to receive the diagnosis of CH. 
In fact, untreated attack duration of 15 minutes to three hours or attack-free periods of 
four months to three years are enough to receive the diagnosis of CH in a pre-screened 
population for research purposes.
 Regression analysis indicated that these three questions about gender, untreated attack 
duration and duration of attack-free periods are good predictors of CH diagnosis in our 
training set (80% of study population) and that the resulting QATCH questionnaire 
performed equally well in the validation set (20% of study population). A similar approach 
was successfully applied to select items for migraine questionnaires by our group as well 
as by others14,18. However, it is important to keep in mind that the QATCH question-
naire was developed in a population of self-reported CH patients with enriched CH 
prevalence by application of a screening questionnaire, resulting in a study population 
of only 48 non-CH subjects. Therefore, the screening questionnaire should be included 
as a primary step, and the results cannot be generalized to application in the general 
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population. The screening questionnaire was based on the validated migraine screening 
questionnaire and adapted for CH15. Its sole purpose is exclusion of self-reported CH 
patients that were highly unlikely to have CH, and it was validated in our outpatient 
headache clinic. A drawback is that the QATCH questionnaire is not validated without 
the use of a screening questionnaire as a first step. It is uncertain if our ultra-short three-
item QATCH questionnaire performs equally well without application of the screening 
questionnaire, which has 10 items and a more complicated algorithm. Another limitation 
could be the length of our LUCA questionnaire, which could have led to a low response. 
Despite the 20 minutes that it takes to fill in the questionnaire, we have a response rate 
of approximately 90%. In our opinion the length of our LUCA questionnaire would not 
be a major drawback.
 The LUCA questionnaire was designed to diagnose CH fulfilling all ICHD-2 criteria2. 
As a consequence, the questionnaire had high specificity but low sensitivity. This is mostly 
explained by the observation that many patients use medication to treat their attacks, 
resulting in unknown untreated attack duration, which makes it hard to establish a diag-
nosis that is in full agreement with ICHD-2 criteria as these require knowledge of untreated 
attack duration. Fifteen percent of participants responded to the question about attack 
duration without medication ‘‘do not know,’’ of whom 80% answered they did not know 
because they always use medication. This leads to an underestimation of the number of 
CH patients diagnosed by our LUCA questionnaire, resulting in a relatively low sensi-
tivity. Because of this shortcoming we also calculated sensitivity, specificity, PPV and 
NPV for the questionnaire using a more lenient algorithm. When altering the necessary 
item ‘‘duration of attack without medication use between 15 minutes and three hours’’ 
to ‘‘duration of attack without or with medication use between 15 minutes and three 
hours,’’ the sensitivity increased to ~70% with the PPV remaining as high as ~92%. For 
genetic studies in CH, both algorithms have advantages and disadvantages. The strict 
algorithm reduces the number of false-positives in this study, which is important for 
identifying genetic variants with a small effect on the disease. However, using the strict 
algorithm also means that many CH patients will be excluded because of the low sensi-
tivity. The lenient algorithm could be an attractive alternative because it has a much 
higher sensitivity and for GWAS recruitment of sufficient numbers of patients is a concern 
in rare disorders such as CH.
 The strength of our study consists of the large sample size in comparison with other 
questionnaire studies performed in CH that included only up to 30 CH patients and 
that did not validate their findings on a randomly selected validation sample as we 
did10–12. Secondly, the web-based step-wise procedure with a screening questionnaire as 
the first step prevents the collection of junk information and non-CH headache patients 
in a very easy and semi-automated way. Thirdly, the application of a semi-structured 
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telephone interview as a gold standard ensured precise categorization of CH patients. 
Our LUCA questionnaire focused on the detection of self-reported CH patients from 
the general adult population, but did not aim to diagnose CH in the naïve general popu-
lation. Further validation studies are needed to assess the generalizability of this model 
(screening questionnaire plus the QATCH) or using the QATCH on its own in other 
study designs.
 The LUCA questionnaire proved to be a valid and reliable method for diagnosing CH 
in a population of self-reported CH patients who filled out a screening questionnaire. 
Being a male and suffering from headache attacks of 15 minutes to three hours with 
pain-free periods (of four months to three years) are good predictors for a valid diagnosis 
of CH according to our QATCH questionnaire. Our web-based, step-wise procedure is 
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Background – Cluster headache is a severe neurological disorder with a 
complex genetic background. A missense single nucleotide polymorphism 
(rs2653349; p.Ile308Val) in the HCRTR2 gene that encodes the 
hypocretin receptor 2 is the only genetic factor that is reported to be 
associated with cluster headache in different studies. However, as there 
are conflicting results between studies we re-evaluated its role in cluster 
headache.
Methods – We performed a genetic association analysis for rs2653349 
in our large LUCA (Leiden University Cluster headache Analysis 
programme) study population. Systematic selection of the literature 
yielded three additional studies comprising five study populations, which 
were included in our meta-analysis. Data were extracted according to 
predefined criteria. 
Results – A total of 575 cluster headache patients from our LUCA study 
and 874 controls were genotyped for HCRTR2 SNP rs2653349 but no 
significant association with cluster headache was found (odds ratio  0.91 
(95% confidence interval 0.75-1.10), p=0.319). In contrast, the 
meta-analysis that included in total 1,167 cluster headache cases and 
1,618 controls from the six study populations, which were part of four 
different studies, showed association of the SNP with cluster headache 
(random effect odds ratio 0.69 (95% confidence interval 0.53-0.90), 
p=0.006). The association became weaker, as the odds ratio increased 
to 0.80, when the meta-analysis was repeated without the initial single 
South European study with the largest effect size. 
Conclusions – Although we did not find evidence for association of 
rs2653349 in our LUCA study, which is the largest investigated study 
population thus far, our meta-analysis provides genetic evidence for a 
role of HCRTR2 in cluster headache. Regardless, we feel that the 
association should be interpreted with caution as meta-analyses with 
individual populations that have limited power have diminished validity. 
Key Words:  Meta-analysis ■ Genetic association ■ HCRTR2 gene 
■ G1246A polymorphism ■ rs2653349  
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Introduction 
CLUSTER HEADACHE is a primary headache disorder of largely unknown aeti-ology that is characterized by severe, short-lasting headache attacks accompanied by 
ipsilateral facial autonomic symptoms and/or restlessness occurring up to eight times a 
day.1,2 A role for genetic factors in the aetiology of cluster headache was overlooked for 
a long time, but has been considered in several studies since the early 1990s.3-8 Four family 
studies showed that relatives of cluster headache patients have a higher disease risk,9-12 
but estimates of the relative risk varied considerably between studies, ranging from 14 to 
45.9-11,13 As cluster headache is not as rare as previously thought, it is likely that the disease 
risk in these studies may have been overestimated.11 In addition, one of the studies with 
the highest estimated relative risk9 may have overestimated the occurance of cluster head-
ache by partly using heteroanamnestic information instead of direct interview or ques-
tiannaire data from all affected relatives. Recalculation of the relative risk using a cluster 
headache prevalence of 0.2% showed a relative risk of 5-18 for first-degree relatives, and 
1-3 for second-degree relatives,13 suggesting a considerably smaller but still relevant 
contribution of genetic factors in cluster headache.11 Case reports3-7,14 on monozygotic 
twins, both affected by cluster headache, provide further support for a role of genetic 
factors in the disease. Complex segregation analysis suggested that low-penatrant auto-
somal dominant genetic risk factor may play a role in a small subset of patients.34 Most 
likely, cluster headache is a complex disorder caused by both genetic and environmental 
factors.13 
 Several genetic studies aimed to identify genes involved in cluster headache but were 
unsuccessful.15-18 The role of the CACNA1A gene was investigated both in a kindred with 
three affected family members16 as well as in an association study,15,16 but results were 
negative. Single nucleotide polymorphism (SNP) rs1801133 in MTHFR showed no 
association with cluster headache either.17 A mitochondrial mutation reported to cause 
MELAS was identified in a single cluster headache patient without a family history of 
this disorder,18 but later studies19,20 failed to replicate the involvement of mitochondrial 
mutations in cluster headache. Thus far, genetic research in cluster headache has only led 
to the identification of one replicated possible genetic susceptibility factor: SNP rs2653349 
(G1246A) in HCRTR2 that encodes the hypocretin type 2 receptor22-24. This receptor is 
expressed in the posterior hypothalamus, which is thought to play an important role in 
cluster headache.21 The role of the HCRTR2 SNP was investigated in five small cohorts 
in three studies22-24, comprising in total 593 cases and 599 healthy controls. The minor 
A allele of SNP rs2653349 was associated with a reduced risk for cluster headache (i.e. 
the A allele being more frequent in controls than in cases). Rainero et al. performed a 
meta-analysis of all five cohorts and reported association of the HCRTR2 SNP with cluster 
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headache25. However, the accuracy of the estimated effect size differed largely between 
studies and the meta-analysis is, therefore, difficult to interpret because (i) there were 
differences in the statistical models used (i.e. other models than the additive model that 
is thought to underlie genetic susceptibility of most complex disorders26) and ii) there 
was considerable statistical heterogeneity between the studies. 
Using our web-based Leiden University Cluster headache Analysis (LUCA) study popu-
lation,27 we re-evaluated the possible association of HCRTR2 SNP rs2653349 with cluster 
headache in the largest single study thus far and we subsequently performed new meta-
analyses combining our results with those of previous studies. 
Materials and Methods
Patient recruitment for the LUCA study
For the LUCA study, self-reported cluster headache patients aged 18 years or older were 
recruited via our Dutch headache research website (www.lumc.nl/hoofdpijn), which was 
developed for genetic and epidemiological research on primary headache disorders. Indi-
vidual diagnoses were established using an extended web-based questionnaire according 
to the International Classification of Headache Disorders, 2nd edition (ICHD-2)1 and 
were validated in a subset of patients by a telephone interview.27 The medical ethics 
committee of the Leiden University Medical Centre approved our study and all partici-
pants provided written informed consent. 
Genetic association study in the LUCA population
All participants that met our algorithm criteria27 for cluster headache and had provided 
a DNA sample were included. Our control population consisted of anonymous blood 
donors of whom no specific health information is available. Based on the low prevalence 
(0.2%) of cluster headache in the general population, we expected a negligible effect of 
possibly including one or two patients with cluster headache in our control group. Power 
calculations were performed using the Genetic Power Calculator (http://pngu.mgh.
harvard.edu/~purcell/gpc/),28 under the assumption of an additive model. 
 Genotyping of SNP rs2653349 (i.e. DNA variant G1246A) was performed using a 
TaqMan assay for which probes and primers were designed by Applied Biosystems. A 
standard PCR reaction was carried out using the TaqMan Universal PCR Master Mix 
reagent and the genotyping was performed on a Lightcycler LC-480 machine combined 
with LightCycler®480 1.5.0 software, version 1.5.0.39 (Roche Applied Science) to analyse 
the genotype clusters. Data analysis was performed using PLINK software version 1.07 
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(http://pngu.mgh.harvard.edu/~purcell/plink/) by calculating odds ratios (ORs) and 
95% confidence intervals (95% C.I.) for the association between the HCRTR2 SNP 
rs2653349 and cluster headache. We assumed an additive genetic model, and performed 
uncorrected and corrected analyses with age and sex as covariates. Association analysis 
was performed with the major allele (G) as reference. A significance level of 0.05 was 
used.
Meta-analysis: study selection
According to the guidelines for systematic reviews of genetic association studies29 two 
researchers (C.M.W. and L.A.W.) individually searched the literature for genetic studies 
on the role of HCRTR2 in cluster headache. We searched the MEDLINE, EMBASE, 
Pubmed, Web of science, CINAHL, PsychINFO, Academic search Premier, ScienceDi-
rect, LWW, Pubmed Central, Goand Science Citation Index databases (to July 6, 2012) 
using the following search terms: (“Cluster Headache”[Mesh] OR cluster headache OR 
Cluster Headaches OR Ciliary Neuralgia OR Ciliary Neuralgias OR Neuralgic Migraine 
OR Neuralgic Migraines OR Histamine Cephalgia OR Histamine Cephalgias OR Horton 
Syndrome OR Horton’s Syndrome OR Hortons Syndrome OR trigeminal autonomic 
cephalalgias OR trigeminal autonomic cephalalgia) AND (HCRTR2  OR hypocretin 
receptor-2 OR HCRTR-2 OR HCRTR 2  OR hypocretin receptor 2 OR HCRTR OR 
hypocretin receptor OR hypocretin receptors OR  OX2R OR orexin OR orexin B OR 
hypocretin 2 OR rs2653349 OR 2653349 OR G1246A OR G 1246 A OR G1246 A 
OR G 1246A OR G922A OR G 922 A OR G922 A OR G 922A). We considered all 
articles published in English. References of all primary articles and reviews on cluster 
headache genetics were manually searched. Studies were eligible for inclusion if they met 
the following pre-specified criteria:  
1. Study design: only cross-sectional, case–control or cohort studies are eligible.
2. Study must include cluster headache patients and healthy controls.
3. Genotype frequencies of the single nucleotide polymorphism (SNP) HCRTR2 
rs2653349 must be listed in the manuscript. Alternatively, sufficient data to calcu-
late the frequencies must be available from the paper or from the authors upon 
request.
4. The largest study with extractable data will be selected if multiple studies use the 
same study population.
Meta-analysis: statistical analysis
Meta-analysis of all study populations was performed in R version 2.15 using the metagen 
function from the meta package (www.r-project.org). We assumed an additive genetic 
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Table 2 -  Study populations included in the meta-analysis.
Genotype frequencies Allele frequencies Hardy-Weinberg 
equilibrium
Study Group N GG GA AA G A χ2-test p-value










































































































































model, and modelled the OR both as fixed effect, which assumes homogeneity across 
studies, and as random effect, which incorporates the between-study variability. The 
random effect model was defined as our primary model because of the high inter-study 
variability with respect to sample sizes and estimated effect sizes. The between-study 
heterogeneity was tested using the I2 statistic, a Cochrane’s Q statistic-based measure that 
describes the amount of variation due to heterogeneity rather than chance on a continuous 
scale from 0 to 1. I2 values of approximately 25%, 50% and 75% are indicative for low, 
moderate and high between-study heterogeneity, respectively.30 A funnel plot was gener-
ated using SPSS Statistics 20.0 (IBM, Armonk, NY, USA) to check for publication bias. 
All analyses were performed with the major allele (G) as reference, and a significance level 
of 0.05 was used.




Sex  (male, %) 404 (70.3)
Age (year [SD]) 49.6 (11.8)
Cluster headache type (episodic) 421 (73.2)
First-degree family member cluster headache (%) 133 (23.2)
Second-degree family member cluster headache (%) 27 (4.7)
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Results
A total of 587 participants from the LUCA study met our algorithm criteria27 for cluster 
headache, provided blood for DNA isolation, and were included in the study. The majority 
of patients (73%) had the episodic form of the disorder and approximately 1 in 4 patients 
reported familial occurrence of cluster headache. Genotypes were obtained from 575 
patients (clinical characteristics are summarized in Table 1) and 874 control subjects, and 
were in Hardy-Weinberg equilibrium (Table 2). No significant association between SNP 
rs2653349 and cluster headache was observed in our LUCA study (uncorrected OR: 
0.90 (95% CI 0.75-1.08), p=0.265; corrected OR 0.91 (95% CI 0.75-1.10) p=0.319).
 We identified 123 references meeting our aforementioned search criteria. Of these, a 
total of five studies reported on the association of SNP rs2653349 with cluster head-
ache.22-25,31 Three of these papers22,25,31 described the same Italian study population and 
only the original research paper was included.22 The Danish, Swedish and British popu-
lations from the study by Baumber et al.23 were included as separate populations, leading 
to a total number of six study populations for our meta-analysis. 
 Subsequently, a meta-analysis was performed of three previously published studies 
(that included five study populations) and our own study.22-24 These studies comprise in 
total 1,167 cluster headache patients and 1,618 control subjects. Genotype and allele 
frequencies of the various study populations are shown in Table 2. Genotype frequencies 
in the controls were in Hardy-Weinberg equilibrium in all studies. Our meta-analysis, 




Heterogeneity: I2=56.5%, tau2=0.0545, p=0.0424
This study (Netherlands)
Rainero et al. (Italy)
Schürks et al. (Germany)
Baumber et al. (UK)
Baumber et al. (Denmark)
Baumber et al. (Sweden)



















Figure 1 - Forest plot representing the results of the meta-analysis of the rs2653349 polymorphism of the 
HCRTR2 gene assuming an additive model.
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Table 3 -  Association with cluster headache in the study populations and the meta-analysis (additive model).
Risk of cluster headache 
for carriers of A allele of 
rs2653349
Power for a given odds ratio
Study Group N OR p-value OR 0.90 OR 0.80 OR 0.67 OR 0.50 OR 0.25






0.90 (0.75-1.08) 0.2646 0.16 0.43 0.97 1.00 1.00






0.27 (0.12-0.57) 0.0003 0.07 0.15 0.37 0.77 1.00













0.71 (0.51-1.59) 0.7092 0.06 0.23 0.25 0.66 1.00






0.75 (0.46-1.25) 0.2694 0.06 0.12 0.30 0.73 1.00











0.69 (0.53-0.90) 0.0056 0.36 0.89 1.00 1.00 1.00
Power calculations were performed using a cluster headache prevalence of 0.02% with D’ set to 1 (assuming 
perfect linkage disequilibrium of the marker allele and the disease allele) and equal prevalence of marker and 
high risk allele. Odds ratios are displayed below 1 because of the observed effect size of the A allele of 
rs2653349. The range of odds ratios used for the power calculations correspond to ORs of 1.11 – 1.25 – 2 – 4 
for heterozygous carriers of the G allele.
A allele of the HCRTR2 SNP and a decreased risk of cluster headache (random effect 
OR 0.69 (95% CI 0.53-0.90), p=0.006) (Figure 1)). The results of our meta-analysis 
indicated the presence of low to moderate between-study heterogeneity (I2=0.57, p=0.042). 
Notably, the funnel plot graphically demonstrates asymmetry, indicating a publication 
bias favouring studies with an OR significantly deviating from 1, mainly caused by the 
initial study from Rainero et al.22 (Figure 2). That study population is the only study 
from Southern Europe with allele frequencies that differ greatly from the other investi-
gated populations that were all from Northern Europe. Remarkably, the absolute number 
of A alleles (8/218 alleles) among the cluster headache cases in the study population from 
Rainero et al. is very low compared to the other populations which makes it difficult to 
get reliable estimates of the allele frequency. We, therefore, performed an additional meta-
analysis that contained only the populations from Northern Europe, so combining only 
data of Danish, Swedish, British, German and Dutch populations. The heterogeneity 
across these studies was negligible (I2=0%, p=0.437), hence the random effect estimates 
correspond to the fixed effect estimates (OR 0.80 (95% CI 0.70-0.93), p=0.0031). 
Although the effect size decreased, the association remained.
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Discussion
Genetic factors have been implicated in cluster headache and several candidate gene 
association studies have been performed16-21,22-24 aimed at identifying such factors but 
most studies did not produce convincing results, except for the genetic association with 
SNP rs2653349, which is located in the HCRTR2 gene, that showed association for the 
(protective) A allele when using additive models. We decided to re-evaluate the associa-
tion with this SNP by performing (i) a genetic association study in our LUCA population 
and (ii) meta-analyses of data from the LUCA study with data from earlier studies. 
 Our LUCA programme using validated questionnaire-based diagnoses28 gave us the 
opportunity to include the largest number of cluster headache patients to date in a genetic 
study. Despite having adequate power (Table 3) to detect associations with similar effect 
sizes as reported by Rainero et al.22 and Schürks et al. 24 no association (p=0.26) was found 
between the HCRTR2 SNP rs2653349 and cluster headache. A subsequent meta-analysis 
of all selected previous studies together with the LUCA study revealed, however, a signif-
icant association of rs2653349 with cluster headache, but validity of the meta-analysis is 
questionable because all previously published studies had insufficient power due to small 
numbers of cases and controls (Table 3). The first study, by Rainero et al.22, reported an 
association with a much larger effect than the other studies and seemed to drive the 
observed association effect. However, a second meta-analysis in which we removed that 
study from the analysis resulted in a large reduction of between-study heterogeneity with 
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Figure 2 - Funnel plot of the six studies included in the meta-analysis of the rs2653349 (G1246A) poly-
morphism of the HCRTR2 gene. The vertical axis shows the standard error of the log odds ratio for each 




odds ratio (from 0.69 to 0.80). This indicates that the effect of the association is smaller 
when the first study is removed. Although our LUCA study a priori had by itself sufficient 
power to detect moderate effects on disease risk and has an acceptable power of 80% for 
detecting variants with an OR ≥ 1.31 (which is equivalent to OR ≤ 0.76 in case of a 
protective effect) (Table 3), it is underpowered to study genetic variants with small effect 
sizes that have been shown to underlie many genetic complex diseases.26 Notably, a 
Cochrane review demonstrated that underpowered studies tend to have a large influence 
on the outcomes of meta-analyses if not at least two well-powered studies were included.32 
Moreover, a recent review, provocatively entitled “power failure: why small sample size 
undermines the reliability of neuroscience”, addressed the important notion that low 
power not only decreases the chance to detect a true effect, but also decreases the chance 
that a significant finding from a small study reflects a true effect.33 Such random fluctu-
ations in allele frequencies may be driving the results of our meta-analyses. Thus, despite 
the apparent positive outcome of our meta-analyses, in our opinion, there is still no robust 
evidence for a true association between HCRTR2 SNP rs2653349 and cluster headache.
   In conclusion, our LUCA study and subsequent meta-analysis illustrate that even 
doubling of the sample size does not lead to a definite conclusion on the role of the 
HCRTR2 gene in cluster headache. We demonstrated that such a role (if any) is likely 
smaller than previously reported. Future genetic studies in cluster headache patients need 
to include much larger numbers of patients and controls and may benefit also from 
focusing on hypothesis-free gene variant discovery, as is the case with GWAs. 
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Aim – Migraine, in particular with aura, has been associated with an 
increased risk for ischemic stroke and coronary heart disease. The 
underlying mechanism is unknown. In a cross-sectional case control 
study we investigated whether an enhanced risk of atherosclerosis in 
migraineurs explains this increased cardiovascular risk.
Methods – Subjects were participants from the population-based Erasmus 
Rucphen Family study. Atherosclerosis was assessed in 360 migraineurs 
(209 without aura and 151 with aura) and 617 subjects without migraine 
or severe headache. Atherosclerosis was quantified by Intima Media 
Thickness, Pulse Wave Velocity and Ankle-Brachial Index. 
Results – Migraineurs, especially with aura, were found more likely to 
smoke, have diabetes or a modestly decreased HDL-cholesterol. No 
differences were found for the atherosclerosis parameters. 
Conclusions – In this large population-based study, migraineurs have no 
increased risk of atherosclerosis. Therefore, enhanced atherosclerosis is 
an unlikely explanation for the increased cardiovascular risk seen in 
migraineurs.
Key Words:  all cerebrovascular disease ■ stroke ■ migraine 
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Introduction
MIGRAINE is a prevalent neurovascular brain disorder that is characterized by recurrent disabling attacks of headache associated with nausea, vomiting, and 
photoand phonophobia (migraine without aura) (MO); in one-third of migraineurs, 
attacks may be preceded by transient focal neurological aura symptoms (migraine with 
aura) (MA).1 Both neuronal as well as vascular mechanisms have been implicated. There 
is observational, prospective and imaging evidence that migraine increases the risk of 
ischemic stroke almost two fold.2-4 Patients may also be at increased risk for major cardio-
vascular disease, including coronary heart disease and peripheral artery disease.2,5,6 This 
suggests that vascular dysfunction in migraineurs is not restricted to the cerebral vascu-
lature, but is also systemically present.
 The underlying mechanism for the association between migraine and ischemic cardio-
vascular disease is unknown. An adverse cardiovascular risk profile and associated athero-
sclerosis has been suggested. Some studies found an unfavorable cardiovascular risk profile, 
in particular for MA patients5,7,8, while other studies did not find any9 or only a modest 
association10. Framingham Risk Scores for coronary heart disease (FRS-CHD) were 
elevated in migraineurs in most5,7,8,11, but not all studies9,12. None of the studies reported 
on the Framingham Risk Score for ischemic stroke (FRS-Stroke) in migraine patients, 
probably because the electrocardiogram (ECG) data that are necessary to calculate this 
risk score were not available.
 The atherosclerotic process, one of the strongest risk factors for stroke and coronary 
heart disease, can be assessed by means of non-invasive preclinical functional and struc-
tural markers of changes in the vessel wall.13 In the present study, we investigated athero-




We performed a case-control study nested within the population-based ERF study. The 
ERF study is a family-based cross-sectional study in a genetically isolated community in 
the Southwest of the Netherlands.14 The study population includes 3465 individuals who 
were ascertained for genetic-epidemiological studies based on their genealogical back-
ground (i.e. not selected on phenotypes of interest). All individuals 18 years or older were 
invited to participate. For this epidemiological study we did not use genetic or genea-
logical data, but the genetic and environmental homogeneity of the population can be 
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an advantage. The study was approved by the Medical Ethical Committee of the Erasmus 
Medical Centre Rotterdam and all participants gave written informed consent.
Migraine patients and controls
Migraineurs were identified using a three-stage screening procedure assessing lifetime 
occurrence of migraine, which was previously validated in a population-based study15 
and which was based on the second edition of the International Classification of Head-
ache Disorders (ICHD-II).1 The sensitivity of this casefinding procedure was 0.93 and 
the specificity was 0.36. The positive predictive value was 0.65 and the negative predic-
tive value was 0.91. Thus the screening procedure picked up many false-positives and 
missed some true-positives.15 Only patients with ‘‘definite’’ MA and MO are included. 
Patients with probable migraine are excluded from the study.
 Details on the migraine case-finding procedure have been published before.16 In brief, 
in the first stage, participants were asked to fill out five screening questions on headache 
and aura symptoms. Then, screenpositives received a detailed questionnaire on headache 
and aura symptoms. Finally, screen-positives were interviewed by telephone for further 
clarification of their answers. Subjects who were screen-positive but did not return the 
extensive headache questionnaire and subjects who could not be screened because they 
did not (completely) fill out the screening questions were directly contacted by telephone. 
Telephone interviews were performed by the principal study physician (A.H.S.), who is 
experienced in diagnosing migraine patients, and by well-trained medical students super-
vised by A.H.S. A final diagnosis was made only after the telephone interview and in 
consultation with a neurologist specializing in headache (G.M.T.).
 The control group consisted of subjects who 1) did not report severe headache in their 
lifetime (only headache up to pain severity score ≤4 on a scale from 0 to 10); 2) did not 
report visual aura symptoms; 3) had never been diagnosed with migraine by a physician; 
and 4) never used specific antimigraine medication. Thus, subjects with mild headache 
in combination with visual aura are excluded from the control group. To exclude false-
negative control cases, we used an even more conservative definition for non-migraineurs 
than in our previous population-based study, as from this study we know that about 10% 
of migraineurs are missed using this screening procedure.15
Assessment of cardiovascular parameters
Participants (n=3465) were asked to attend the research center located within the commu-
nity. Extensive clinical examinations were performed, including the collection of fasting 
blood samples, anthropometric measurements, cardiovascular assessments, and personal 
interviews by physicians. Participants were also asked to fill out questionnaires assessing 
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various variables, including symptoms of headache and their level of education. The 
interview included questions on cigarette smoking status, alcohol consumption, and 
medical history. Alcohol consumption was measured in units per week and was catego-
rized as <28 consumptions per week and ≥28 consumptions per week. Current smoking 
was categorized as yes or no. Participants took all prescription medication to the research 
center, and antihypertensive treatment and the use of oral contraceptives (OAC) was 
verified by a physician. Height and weight were measured with the participant in light 
underclothing and body mass index (kg/m2) was computed. An ECG was performed, 
and each was scored by an experienced cardiologist. Blood pressure was measured twice 
on the right arm in a sitting position after at least 5 minutes of rest using an automated 
device (OMRON 711, Automatic IS; Vernon Hills, IL, USA). The average of the two 
measures was used for the brachial blood pressure in the analyses. Plasma concentrations 
of triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipo-
protein cholesterol (LDL-C) and total cholesterol (TC) were determined according to 
standard procedures, as described previously.14 Diabetes was defined as the use of blood 
glucose-lowering medication or sober glucose levels of ≥7mmol/l or both. Total plasma 
adiponectin was analyzed with the Human Adiponectin radioimmunoassay (RIA) kit 
(catalog number: HADP-61HK) of Linco Research (St. Charles, MO, USA). Total plasma 
C-reactive protein (CRP) was analyzed with the US C-reactive protein enzyme-linked 
immunosorbent assay (ELISA) (catalog number: DSL-10-42100) of Diagnostic Systems 
Laboratories Inc. (Webster, TX, USA). All measurements were performed according to 
the manufacturers’ protocol. Plasma CRP levels showed a high level of kurtosis. Therefore, 
upper plasma CRP levels exceeding three times the standard deviation of the mean were 
removed from further analyses.
 We used the FRS-CHD17 and FRS-Stroke18 to summarize the data. The FRS-CHD 
estimates the 10-year probability of CHD, defined as myocardial infarction or CHD 
death. The score assigns points for age, HDL-C, TC, smoking status, and systolic blood 
pressure stratified by sex and treatment for hypertension. The FRS-Stroke estimates the 
10-year probability of stroke. The score assigns points for age, systolic blood pressure, 
treatment for hypertension, history of diabetes mellitus, smoking status, cardiovascular 
disease (i.e. history of myocardial infarction, angina pectoris, coronary insufficiency, 
intermittent claudication or congestive heart failure), and atrial fibrillation and left 
ventricular hypertrophy on ECG, all stratified by sex. The individual points for both the 




Functional and structural vascular assessment
The atherosclerotic process can be assessed by means of non-invasive preclinical functional 
and structural markers of changes in the vessel wall, including intima media thickness 
(IMT), pulse wave velocity (PWV, measure of arterial stiffness), and ankle-brachial index 
(ABI).13 These measures correlate with central (IMT, PWV) or peripheral (ABI) athero-
sclerosis.13 IMT was measured by ultrasonography with a 7.5 MHz linear array transducer 
(ATL Ultra-Mark IV; Advanced Technological Laboratories, Bothell, WA, USA) of the 
left and right common carotid artery. The maximum carotid IMT was determined as the 
mean of the maximum IMT of near and far wall of both common carotid arteries.14 
Carotid-femoral PWV was measured by means of an automatic Complior SP device with 
subjects in the supine position. The time delay between the rapid upstroke from the base 
point of simultaneously recorded pulse wave curves in the carotid and the femoral arteries 
was assessed, and the distance between the carotid and the femoral arteries was measured 
over the surface of the body with a tape measure. PWV was calculated as the ratio between 
the distance traveled by the pulse wave and the time delay and expressed in meters per 
second.14 Ankle blood pressure was measured in both the posterior tibial arteries by using 
an 8-MHz continuous Doppler probe. Blood pressure was measured twice in the right 
arm in the sitting position. The ABI was calculated for each leg by dividing the ankle 
systolic pressure by the mean brachial systolic pressure. The lowest of the two ABI values 
was used in the analysis. Patients with ABI >1.4 were excluded from the analysis as this 
indicates non-compressible vessels.19
Statistical methods
Analyses were performed separately for all migraine, MO and MA. A two-sided p value 
of alpha <0.05 was considered significant. General characteristics were compared between 
groups using a Student’s t test for age and a Chi-square test for sex and education. Means 
for continuous variables and proportions for dichotomous variables were calculated for 
cardiovascular risk parameters. Means of cardiovascular parameters were compared 
according to migraine status using analyses of covariance, adjusted for age, sex and educa-
tion. Mean PWV, IMT and ABI were corrected for age, sex, education, HDL-C and 
smoking. Proportions were compared by binary logistic regression with the risk factor as 
the outcome (dependent) variable and migraine status as the independent variable, 
adjusted for age, sex and education. Odds ratios for having an FRS-CHD or FRS-Stroke 
>10% were calculated using logistic regression adjusted for age, sex and education. We 
had 80% power to detect a difference of 0.23 m/s for PWV, 0.03 mm for IMT and 0.016 
for ABI. These power calculations are based on the number of participants with data 
available for that parameter.
 Analyses were performed using SPSS version 16.0 (SPSS, Chicago, IL, USA). Signif-
icant results were corrected for inbreeding using the SOLAR 2.1.2 software package 
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(Southwest Foundation for Biomedical Research, San Antonio, TX, USA), which is 
necessary because subjects are part of a genetic isolate. The absolute numbers of cases and 
controls with diabetes was too small to correct for inbreeding. The coefficient of inbreeding 
per individual was calculated based on available genealogical information using PEDIG 
software. The inbreeding coefficient indicates, for each person in ERF, the probability 
that two alleles at a given locus in an individual are identical by descent and thus is a 
measure for relatedness. Subjects of the ERF population are the living descendants of 22 
couples with at least six children baptized in the community church between 1850 and 
1900. Thus, they are part of a large extended pedigree and therefore are more related 
than individuals from the general population. In isolated populations such as ERF, genetic 
drift may lead to an increased risk of allele frequencies, which may (falsely) increase asso-
ciations between traits. Correction for relatedness prevents this and better reflects the 
association in the general population.
n=360  
Migraine  
(‘All migraine group’) 
n=437  







(‘MO group’)  




n=813 Did not return 
questionnaire  










 No interview* 
 
n=572   n=286 
Screen-pos      Screen-inc 
       
 n=858 interview 
n=61  
Unclear symptoms  
 
Figure 1 - Flowchart of ascertainment of migraine cases and controls in the Erasmus Rucphen Family 
study. *Subjects were deceased or declined participation (n=122), had an incorrect (n=140) or unavail-
able (n=10) telephone number, gave no permission for a telephone interview (n=130), were not answering 
the phone (at least 3 attempts were made) (n=72) or indicated on the phone that they did not want to 
cooperate with the interview (n=29).
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Table 1 -  Baseline characteristics of the study population by migraine subtype
All migraine MO MA Controls
n=360 p-value n=209 n=151 p-value n=617
Age , yr 46.2 (12.3) 0.149 47.0 (12.7) 45.1 (11.6) 0.105 47.8 (15.3)






















Body Mass Index, 
kg/m2
27.1 (5.1) 0.10 27.2 (5.3) 26.9 (4.9) 0.24 26.8 (4.5)
SBP, mm Hg 135.3 (18.2) 0.22 135.4 (18.6) 135.2 (17.6) 0.42 139.4 (19.5)
DBP, mm Hg 79.2 (9.2) 0.13 79.3 (9.5) 79.0 (8.8) 0.33 79.7 (9.8)
LDL-C, mmol/L 3.75 (0.97) 0.10 3.73 (1.01) 3.78 (0.93) 0.19 3.66 (0.94)
HDL-C, mmol/L 1.30 (0.35) 0.02 1.35 (0.36) 1.23 (0.34) MA: <0.001
MO: 0.53
1.28 (0.34)
Triglycerides, mmol/L 1.27 (0.67) 0.36 1.25 (0.66) 1.31 (0.69) 0.46 1.31 (0.77)
Total cholesterol, 
mmol/L
5.6 (1.1) 0.32 5.6 (1.1) 5.6 (1.0) 0.60 5.5 (1.0)
Diabetes, % 5.5 0.01 5.5 5.4 MA: 0.02
MO: 0.04
3.2





5.4 (7.8) 0.06 5.0 (7.8) 5.8 (7.8) 0.15 8.2 (10.4)
CRP, mg/L 5.3 (4.3) 0.24 5.0 (4.1) 5.6 (4.4) 0.23 5.4 (4.5)
Adiponectin, mmol/L 11.1 (6.0) 0.58 11.3 (6.0) 10.8 (6.1) 0.69 10.2 (5.2)
FRS-Stroke, % 5.7 (0.3) 0.55 5.8 (0.4) 5.6 (0.3) 0.80 5.9 (0.2)
FRS-CHD, % 5.0 (0.2) 0.82 5.0 (0.4) 5.0 (0.3) 0.97 5.1 (0.2)
FRS-CHD > 10% 
(% of subjects)
12 12 11 22
Continuous values are mean (SD), categorical values are proportions. P-values are adjusted for age, sex 
and education. Significant p-values were adjusted for inbreeding as well, except for diabetes. SD is 
standard deviation,  u/w = units (glasses) per week, MA is migraine with aura, MO is migraine without 
aura, SBP is systolic blood pressure, DBP is diastolic blood pressure, LDL-C is low density lipoprotein 
cholesterol, HDL-C is high density lipoprotein cholesterol, CRP is C-reactive protein. Education level was 
divided in lower (primary or elementary school or unfinished secondary school), medium (secondary 
school or vocational technical training) and higher (college or university). FRS-Stroke is Framingham risk 
score for stroke, FRS-CHD is Framingham Risk Score for coronary heart disease; percentages for these 
scores represent the 10 year risk of stroke or coronary heart disease. 
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Results
Recruitment of migraine cases and controls
Results on ascertainment of migraine cases and controls have been described elsewhere 
and are depicted in the flowchart (Figure 1).18 In total, 3465 subjects participated in the 
study, from wtahom we recruited 360 migraine patients (151 MA, 209 MO) and 617 
control subjects. Comparing subjects included (n=977) versus those not included (n=2488) 
in the present study showed that included subjects were significantly younger (p<0.001) 
and higher educated (p<0.03) compared with those not included, but there was no differ-
ence with regard to gender (p=0.20).
Cardiovascular parameters
Baseline characteristics are shown in Table 1. In line with the higher prevalence of migraine 
in women, more women were present in the migraine group. Migraineurs, in particular 
MA, had lower levels of education. Smoking was more prevalent in migraineurs, in 
particular in MA (49% versus 31% of controls, p<0.001). MA patients had a modestly 
decreased HDL-C (uncorrected difference 0.05 mmol/l, p<0.001). After correction for 
menopause status, alcohol consumption and smoking status, which are known to influ-
ence HDL-cholesterol levels, the difference between MA patients and controls remained 
significant. Migraine patients were more likely to have diabetes (5.4% MA, 5.5% MO 
versus 3.2% controls, p<0.05). The mean 10-year probability of CHD (FRS-CHD) or 
stroke (FRS-Stroke) was similar in migraine patients and controls (Table 1). None of the 
odds ratios for having a 10-year risk for FRS-Stroke or FRS-CHD larger than 10% 
reached statistical significance (data not shown).
Functional and structural measures for atherosclerosis
ABI data were available for 408 control subjects, 179 MO patients and 140 MA patients, 
IMT data for 470 control subjects, 167 MO patients and 123 MA patients, PWV data 
for 542 control subjects, 185 MO patients and 133 MA patients. Baseline characteristics 
including a predicted 10-year FRS-Stroke and FRS-CHD were not significantly different 
between the subjects with and without missing data. No difference was observed in mean 
IMT, carotid-femoral PWV, or ABI between migraineurs and controls (Table 2). All 




The aim of this study was to investigate whether migraine patients are at increased risk 
for atherosclerosis. Our main finding is that atherosclerosis, assessed by three comple-
mentary noninvasive measures, is no more prevalent in migraineurs than in controls.
 Several studies assessed atherosclerosis in migraine patients using comparable functional 
and structural markers, but with contradictory results. One clinic-based study found a 
small decrease in ABI in migraine patients compared to controls.20 In line with our find-
ings, another larger clinic-based study found no difference.21 Three studies on PWV 
found increased values in migraine patients but were clinic based and excluded patients 
with known cardiovascular risk factors21–23, which hampers comparison of results with 
our population-based study, where no selection for migraine or cardiovascular disease 
risk was made. Seven studies measured IMT in migraine patients with conflicting 
results.9,23–27 Comparison between these studies is hampered by different case selection 
methods, such as clinic based23,25–28 versus population based9,24, and exclusion of partici-
pants with known cardiovascular risk factors23,25–28 versus correction for these risk factors9,24. 
The two largest population-based studies9,24, with more than 100 migraine patients 
(unselected with regard to cardiovascular risk factors), found slightly decreased values of 
IMT, which is in line with our findings.
 Compared to previous studies, our study has important strengths. We assessed the 
largest group of migraine patients thus far, including a large group of MA patients (n=120). 
Three complementary measurements that quantified both central and peripheral athero-
sclerosis were used. Migraine diagnoses were made after a telephone interview in consul-
tation with a neurologist and according to criteria of the International Headache Society. 
Our sample was unselected for a particular disease phenotype, and included a broad age 
range of adults (18–87 years), thus preventing ascertainment bias. Participants were from 
a population-based study with a relatively homogenous genetic and environmental back-
ground. Finally, data on a large number of cardiovascular risk factors were available and 
allowed us to calculate the FRS-CHD as well as the FRS-Stroke.
 Our study has some limitations. First, we were unable to assess directly the mediating 
effect of atherosclerosis in migraineurs with a cardiovascular event because of the size of 
the study population (i.e. ≤10 migraineurs had a myocardial infarction or stroke). Second, 
data on functional and structural measures for atherosclerosis were missing for a substan-
tial proportion of cases and controls. We do not think this affected our outcome since 
power calculations were based on the available number of participants and showed a 
reasonable power to detect differences in mean values. Moreover, baseline characteristics 
were not significantly different between subjects with and without missing data, making 
selection bias unlikely. Third, we were unable to assess the effect of migraine attack 
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frequency. This would have been interesting as the association of migraine with cardio-
vascular disease varies by attack frequency.29 Fourth, IMT and ABI are indicative of 
clinical atherosclerotic disease and perhaps limit conclusions on variability in the normal 
range. However, we have also included a measure that measures subclinical arterial stiff-
ness (PWV). Last, as our study population has a homogeneous genetic and environmental 
background, future studies are needed to assess to what extent our findings can be repli-
cated in other populations of migraine patients. Although our study has a larger percentage 
of MA, we feel this is not a disadvantage of our study as the risk for cardiovascular events 
is highest among MA cases.
 We assessed the FRS-Stroke in migraineurs and showed no increased odds for a higher 
score, which suggests that traditional cardiovascular stroke predictors are not relevant in 
the migraine-stroke association. This is in line with our data on atherosclerosis parameters. 
In addition, several previous observations support this conclusion. First, in most prospec-
tive cohort studies the increased risk of ischemic stroke appeared independent from 
traditional cardiovascular risk factors30 with the exception of use of OAC and smoking 
in women. Second, population-based magnetic resonance imaging (MRI) studies showed 
no difference in cardiovascular risk factors between migraineurs with and without poste-
rior circulation territory infarct-like lesions and white matter lesions.31,32 Third, the 
Women’s Health Study showed an increased risk for myocardial infarction in migraine 
patients with a high FRS-CHD, while increased stroke risk was observed among migraine 
patients with a low FRS-CHD.11 This supports the idea that the mechanisms underlying 
the migraine-stroke association are different from atherosclerosis.
 Based on these data, it seems unlikely that the higher risk of cerebroand cardiovascular 
disease in migraineurs is mediated by atherosclerosis, although it might be possible that 
the process of atherosclerosis plays a role on a subclinical level with endothelial dysfunc-
tion as a presumed early marker.33 Larger, preferably prospective studies are necessary to 
further clarify the role of atherosclerosis in incident vascular events in migraineurs. 
Potential other explanations for the migraine-stroke relationship include the association 
of migraine with specific etiologies of stroke (i.e. micro emboli caused by patent foramen 
ovale), the association with a pro-inflammatory, pro-coagulatory state, the use of vaso-
constrictive drugs in migraineurs or the (genetic) lowered threshold for spreading depres-
sion leading to either MA or ischemia.34 The latter hypothesis is supported by recent data 
in migraine (familial hemiplegic migraine (FHM)1 CaV2.1) transgenic mice that, after 
transient ischemia, developed earlier onset of anoxic depolarization and more frequent 
peri-infarct depolarization resulting in larger infarcts and worse neurological outcomes 
compared to wild-type mice.35 These data suggest that enhanced susceptibility to ischemic 
depolarization akin to spreading depression predisposes migraineurs to infarction during 
mild ischemic events, thereby increasing the stroke risk. In humans, MA is associated 
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with strokes with good functional outcome36, which seems contradictory to these mouse 
data. However, disability might be related to the size and type of the infarcts rather than 
of their specific underlying mechanism and thus does not rule out susceptibility to 
spreading depression as a causal factor in humans as well. More translational studies are 
needed to provide more insight in the migrainestroke relationship and to develop prophy-
lactic treatment strategies to prevent cerebroand cardiovascular events in migraine patients.
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Objective – Migraine is a prevalent neurovascular disorder that is 
diagnosed based on consensus criteria due to the lack of reliable 
biomarkers. We here used a single-point measurement of serum 
samples to identify low-molecular-weight metabolites associated with 
migraine, which may help unraveling pathophysiological mechanisms 
involved in the disease. 
Methods – From 289 migraine patients and 1,360 controls without 
severe headache from the Erasmus Rucphen Family (ERF) study 
fasting serum samples were available for proton nuclear magnetic 
resonance (1H-NMR) spectroscopy. A total of 100 signals representing 
at least 49 metabolites were detected. Using elastic net regression 
analysis we identified a subset of metabolites associated with lifetime 
or active migraine and cross-validated these analyses two-fold. Odds 
ratio, p-values and explained variance of the scores were calculated 
using logistic regression analysis. 
Results – The subset of peaks that was identified for lifetime migraine 
status was not significantly associated with the outcome after age and 
sex correction. However, for active migraine we identified a set of 20 
peaks, containing amino acids, lipids, pyruvate, dimethylglycine, 
1,5-anhydrosorbitol and glucose, which significantly (p = 6.2*10-3) 
associated with active migraine status after correction for age and 
sex. 
Interpretation – Our results show that serum concentrations of several 
low-molecular weight metabolites measured by 1H-NMR spectros-
copy differ between migraine patients and controls, especially in 
active migraineurs. Future studies with similar NMR data containing 
all associated peaks could validate our findings. The associated metab-
olites provide important information that might help elucidate the 
pathophysiological processes underlying this disorder. 
Key Words:  1H-NMR spectroscopy ■ Migraine ■ Biomarker  
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Introduction
MIGRAINE IS A HIGHLY PREVALENT episodic neurovascular disorder that is characterized by recurrent throbbing, unilateral headache of moderate to severe 
intensity, which is aggravated by physical exercise and lasts 4-72 hours.1 Attacks are 
accompanied by nausea, vomiting, photophobia, and/or phonophobia. Due to the lack 
of reliable biomarkers, migraine diagnoses is still based on history taking and interviews 
according to the consensus criteria of the International Classification of Headache Disor-
ders (ICHD-2) from the International Headache Society.2 
 Various studies have attempted to find reliable clinical, genetic, radiological and CSF 
biomarkers to diagnose migraine patients.3 Studies that focused on identifying biochem-
ical biomarkers in blood until now focused on only a limited amount of molecules and 
these studies have been hypothesis-driven, that is they focused on e.g. neuroexcitatory 
amino acids,4,5 inflammatory markers,6-10 vasoactive neuropeptides,11 and cardiovascular 
risk factors.12,13
 In order to search for migraine biomarkers in serum in a hypothesis-free manner, we 
performed proton nuclear magnetic resonance (1H-NMR) spectroscopy, which is widely 
used to acquire metabolic profiles from large groups of patients because of the robustness 
and relatively low costs of this method.14 With 1H-NMR spectroscopy it is possible to 
quantify up to several hundreds of low-molecular weight metabolites in a single measure-
ment in serum or plasma. We analyzed metabolite profiles in serum samples of migraine 
patients and controls from the Erasmus Rucphen Family population, a large Dutch 
population-based family study from the Southwest of the Netherlands in which we previ-
ously had identified migraine cases.15 By comparing metabolic profiles of migraine patients 
and control individuals we set out to identify potential (sets of ) biomarkers that may also 
provide valuable insights into pathophysiological mechanisms underlying migraine.
Material and Methods
Study population
The study flow is depicted in Figure 1. Subjects were participants of the Erasmus Rucphen 
Family (ERF) study. This is a population-based family study from a genetically isolated 
community in the Southwest of the Netherlands. The ERF study population includes 
3,465 living descendants of 22 couples that had at least six children baptized in the 
community church between 1850 and 1900. Participants were not selected based on 
disease of interest. The extensive genealogy and pedigree of the population has been 
published previously.16 The Medical Ethical Committee of the Erasmus Medical Center 




Participants were selected between 2005 and 2007 using a validated three-stage screening 
procedure17 assessing lifetime occurrence of migraine based on the second edition of the 
International Classification of Headache Disorders (ICHD-2).2 Details on the migraine 
case-finding procedure have been published.15 In short, stage one consisted of a five-item 
screening questionnaire on headache and aura symptoms. If the screening criteria were 
met, participants entered the second stage and completed a detailed questionnaire on 
headache and aura symptoms. The final stage consisted of telephone interviews with 
Study population
360 cases
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Figure 1 - Study flow.
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participants meeting the screening criteria specified by step one. In addition, two groups 
of subjects were contacted by telephone directly: (i) screen-positives subjects who did not 
return the extended questionnaire and (ii) subjects providing no or incomplete data on 
the screening questionnaire. A study physician, who consulted a headache specialist in 
case of ambiguous symptoms, made final diagnoses. A total of 360 lifetime migraineurs 
and 1,728 controls were identified. Fasting serum samples were available from 313 of 
these migraine patients and 1,512 controls without severe headache, which were used 
for 1H-NMR spectroscopy profiling.
1H-NMR spectroscopy metabolite profiling: data processing and 
quality control
Details on the acquisition of NMR spectra can be found in the Supplementary Materials 
and Methods section. Good-quality NMR spectra were obtained from 289 migraine 
patients and 1,360 controls. Post-acquisition data processing and quality control (QC) 
on the set of 1H-NMR spectra were carried out in Matlab® (R2009a, The Mathworks 
Inc., Natick, MA, USA). For QC, a set of spectroscopic parameters (i.e. shim values and 
intensity of the water signal) was examined and spectra were visually inspected. Spectra 
that failed the QC were not included for further analysis. Subsequently, the spectra that 
passed the QC were scaled with respect to the sensitivity of the experiment, which is 
inversely proportional to the pulse length. After subtracting a constant value as a simple 
baseline correction, the spectra were calibrated to the anomeric resonance of α-D-glucose 
(δ = 5.23 ppm).18 Since there are small deviations of the peak position in the different 
1H-NMR spectra, alignment was performed using the correlation optimized warping 
algorithm by Tomasi et al.19 This was performed actively for the Carr–Purcell–Meiboom–
Gill (CPMG) spectra, after which the same warping was applied to the J-resolved spectra 
(JRES) projection. The peaks in the JRES projection were automatically deconvoluted 
by fitting the spectra with mixed Gauss-Lorentz lineshapes using the Simplex method. 
As the fitting algorithm incidentally converges to a local minimum, values further from 
the median than three times the interquartile range were discarded. Using partial least 
square regression, the remaining peak intensities were used to build a linear model that 
predicts the intensities directly from the unwarped spectrum, yielding also reasonable 
values for the cases where the deconvolution or warping algorithms failed.
 Using the abovementioned procedure, 100 metabolite peaks were detected in the JRES 
projection and quantified in the 1H-NMR spectra. In total, we had available spectra of 
289 migraine patients and 1,360 controls for further analysis. For 82 peaks, metabolites 
could be assigned using information from the Human Metabolome Database (HMDB)20 
and the Pearson correlation coefficients between the peaks intensities. These 82 peaks 
represented 49 different metabolites (i.e. after subtracting the peaks representing EDTA, 
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1 0,85113 unknown none 51 2,93035 asparagine none
2 0,87072 lipids CH3 LN 52 3,02340 lysine none
3 0,89006 cholesterol LN 53 3,03376 creatine/creatinine none
4 0,92847 isoleucine none 54 3,04941 ornithine none
5 0,94597 leucine none 55 3,14304 unknown SD
6 0,95118 unknown none 56 3,20231 choline none
7 0,95702 leucine none 57 3,21429 phosphorylcholine none
8 0,97200 unknown none 58 3,24004 glucose none
9 0,98082 valine none 59 3,26710 1,5-anhydrosorbitol none
10 0,98612 unknown none 60 3,33236 proline LN
11 0,99919 isoleucine none 61 3,34504 1,5-anhydrosorbitol none
12 1,03145 valine none 62 3,35396 unknown none
13 1,06258 unknown none 63 3,38052 unknown none
14 1,11139 ketoisovalerate none 64 3,40064 glucose none
15 1,13461 unknown SD 65 3,48648 glucose none
16 1,16301 isopropyl alcohol SD 66 3,53111 glucose none
17 1,17437 ethanol SD 67 3,55110 glycine none
18 1,19057 3-hydroxybutyrate SD + LN 68 3,55914 glycerol none
19 1,21117 unknown none 69 3,58832 1,5-anhydrosorbitol none
20 1,26482 lipids CH2 LN 70 3,59782 valine none
21 1,31981 lactate none 71 3,62232 myoinositol SD
22 1,38997 unknown none 72 3,65021 ethanol SD + LN 
23 1,40660 unknown none 73 3,65855 isoleucine none
24 1,42426 unknown none 74 3,71204 glucose none
25 1,47045 alanine none 75 3,72103 glucose none
26 1,70571 unknown none 76 3,74475 unknown none
27 1,90859 acetate SD 77 3,75932 glucose none
28 1,99964 lipids none 78 3,77643 alanine none
29 2,03401 N-acetyl glycoproteins none 79 3,80094 glucose none
30 2,06653 O-acetyl glycoproteins none 80 3,81746 unknown none
31 2,10168 glutamine/glutamate none 81 3,82382 glucose SD
32 2,11814 glutamine/glutamate none 82 3,83140 unknown none
33 2,13291 acetylcarnitine none 83 3,83856 glucose SD
34 2,22215 lipids (CH2CO) LN 84 3,87709 1,5-anhydrosorbitol none
35 2,26037 valine none 85 3,89397 glucose none
36 2,27276 acetoacetate SD 86 3,92001 creatine none
37 2,30052 3-hydroxybutyrate SD 87 3,93298 unknown none
38 2,34857 glutamate SD 88 3,95567 serine none
39 2,36196 pyruvate none 89 3,97538 phenylalanine/histidine none
40 2,39235 3-hydroxybutyrate SD 90 4,04386 creatinine none
41 2,42815 glutamine none 91 4,10334 lactate LN
42 2,44561 glutamine none 92 4,12106 proline none
43 2,46282 glutamine none 93 4,23715 threonine none
44 2,52733 citrate SD 94 4,50117 unknown SD
45 2,59803 unknown none 95 5,17855 mannose none
46 2,63742 methionine none 96 5,22921 glucose SD
47 2,66908 citrate SD 97 5,29802 lipids (CH=CH) LN
48 2,70842 dimethylamine none 98 6,89014 tyrosine none
49 2,89562 unknown none 99 7,18628 tyrosine none
50 2,91618 dimethylglycine SD 100 8,44976 formate none
LN: log transformation performed; SD: outliers > 4 standard deviations from the mean removed. 
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see Table 1 for peak assignment). The other 18 peaks could not be annotated yet and 
were discarded from further analysis.
1H-NMR metabolite profiling: acquisition of NMR spectra
Stored fasting serum EDTA samples were thawed at 4°C and were mixed by inverting 
the containers ten times. Samples (300 µL) were mixed with 300 µL 75 mM disodium 
phosphate buffer in H2O/D2O (80/20) with a pH of 7.4 containing 6.15 mM NaN3 and 
4.64 mM sodium 3-[trimethylsilyl] d4-propionate (TSP) using a Gilson 215 liquid 
handler in combination with a Bruker SampleTrack system (Bruker, Karlsruhe, Germany). 
Samples were transferred into 5mm SampleJet NMR tubes (Bruker, Karlsruhe, Germany) 
in 96 tube racks using a modified Gilson 215 tube filling station (Gilson, Middleton, 
WI, US) and kept at 6°C on a SampleJet sample changer (Bruker, Karlsruhe, Germany) 
while queued for acquisition. 
 All proton nuclear magnetic resonance (1H-NMR) spectroscopy experiments were 
acquired on a 600 MHz Bruker Avance II spectrometer (Bruker, Karlsruhe, Germany) 
equipped with a 5 mm TCI cryogenic probe head with Z-gradient system and automatic 
tuning and matching. All experiments were recorded at 310K. Temperature calibration 
was done prior to each batch of measurements using the method of Findeisen et al.21 The 
duration of the π/2 pulses were automatically calibrated for each individual sample using 
a homonuclear-gated nutation experiment on the locked and shimmed samples after 
automatic tuning and matching of the probe head.22
 For water suppression pre-saturation of the water resonance with an effective field of 
γB1 =  25 Hz was applied during the relaxation delay.18 J-resolved spectra (JRES)23 were 
recorded with a relaxation delay of 2 s and a total of one scan for each increment in the 
indirect dimension. A data matrix of 40 x 12,288 data points was collected covering a 
sweep width of 78 x 10,000 Hz. A sine-shaped window function was applied and the 
data was zero-filled to 256 x 16,384 complex data points prior to Fourier transformation. 
The resulting data matrix was tilted along the rows by shifting each row (k) by 0.4992*(128-k) 
points and symmetrised about the central horizontal lines in order to compensate for the 
skewness of the multiplets in the F1 dimension. For T2-filtered 1H-NMR spectra a stan-
dard 1D CPMG pulse sequence,24,25 was used with a relaxation delay of 4 s. A pulse train 
of 130 refocusing pulses with individual spin echo delays of 0.6 ms were applied resulting 
in a total T2 filtering delay of 78 ms. 73,728 data points covering a spectral width of 
12,019 Hz were collected using 16 scans. The FID was zero-filled to 131,072 complex 
data points and an exponential window function was applied with a line broadening 
factor of 1.0 Hz prior to Fourier transformation. The spectra were automatically phase 
and baseline corrected. 
Chapter 8
126
Quality control, scaling and calibration of the NMR spectra
Further data processing was performed in Matlab® (R2009a, The Mathworks Inc., Natick, 
MA, USA). The spectra and associated data were converted into Matlab files using in-house 
code These files can be quickly loaded into Matlab for further processing. First, the spectra 
were combined into one file while removing superfluous information. For CPMG this 
included dropping the imaginary part of the spectrum, while for the JRES spectra the 
sum projection along the indirect dimension was taken. Quality control (QC) on the set 
of 1H-NMR spectra was carried out by examining a set of spectroscopic parameters such 
as shim values and intensity of the water signal, and subsequently visually inspecting the 
spectra. The spectra that failed the QC were not included for further analysis. The spectra 
were then scaled with respect to the sensitivity of the receiver coil. This sensitivity is 
inversely proportional to the pulse length, which is dependent on the tuning of the RF 
coil. After subtracting a constant value as a simple baseline correction, the spectra were 
calibrated with respect to the anomeric resonance of α-D-glucose (δ = 5.23 ppm).20 Since 
there are small deviations of the peak position in the different 1H-NMR spectra, align-
ment was performed using the correlation optimized warping algorithm by Tomasi et 
al.19 This was performed actively for the CPMG spectra, after which the same warping 
was applied to the JRES projection. The peaks in the JRES projection were automatically 
deconvoluted by fitting the spectra with mixed Gauss-Lorentz lineshapes using the Simplex 
method. As the fitting algorithm incidentally gets stuck in local minima, values further 
from the median than 3 times the interquartile range are discarded. Using PLS regression, 
the remaining peak intensities were used to build a linear model that predicts the inten-
sities directly from the unwarped spectrum, yielding also values for the cases where the 
deconvolution values were discarded and eliminating the problem of faulty warping.
 The peaks were assigned using information from the Human Metabolome Database26 
and the Pearson correlation coefficients between the peaks intensities.
1H-NMR spectroscopy metabolite profiling: statistical analyses
Demographic characteristics of cases and controls were compared using a Student t test 
for continuous variables and χ2 statistics for dichotomous variables. Raw 1H-NMR peak 
data were processed in four steps. First, we removed outliers from the data by filtering 
out all data points more than four standard deviations (SD) away from the mean. This 
was necessary for 19 of the 100 peaks. Second, the distribution was checked for normality, 
and data were transformed if necessary. We performed log-transformations on nine peaks 
(of which two were also processed in the first step). For the remaining 74 peaks additional 
processing was not necessary. Analyses were performed using SPSS software version 20.0 
(SPSS-IBM, NY). Third, we adjusted the peak data for family structure by using the 
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information from the kinship matrix in a linear regression analysis in GenABEL.27 Fourth, 
the residuals from this linear regression model were transformed into Z-scores and used 
for further analyses. 
 After processing of the raw data we aimed to identify subsets of predictive peaks for 
(1) life-time diagnosis and (2) a diagnosis of active migraine (defined as having migraines 
in the last 12 months). We used a special form of regression analysis, called elastic net 
regression analysis, to overcome the problems encountered in conventional logistic regres-
sion analyses in studies like ours where the number of predictors (i.e. the 1H-NMR peak 
data, age and sex) is much larger than the number of observations on the outcome measure 
(i.e. migraine status). We used the glmnet package for elastic net regression analysis28 
with alpha set to 0.5 and 50-fold cross-validation using R software version 2.14.2 
(www.r-project.org). In this first cross-validation step we validated the selection of the 
peaks by performing our regression analysis on 50 randomly chosen samples of our study 
population. We performed an additional cross-validation step to assess the fit of the 
selected model on different subpopulations of our sample. 
 After identification of the set of associated peaks we entered these variables in a logistic 
regression model to determine the weights for each peak for this population. Subsequently, 
we used the betas from this regression analysis to transform the set of associated peaks 
into a weighted score per individual participant. This score was used in a second logistic 
regression analysis to calculate odds ratios, p-values and the proportion of explained 
variance. To correct for confounding by differences in age and gender distribution we 
also calculated adjusted odds ratios and p-values by performing a logistic regression anal-
ysis with these confounders as covariates.
 To validate the findings from the previous analysis we performed analysis of variance 
(ANOVA) in which we compared the performance of the identified scores for migraine 
with the performance of a model containing only information on age and sex. The 
resulting p-value can be interpreted as the likelihood that all peaks identified by the elastic 
net analysis are only associated with migraine status by chance. 






Age (years) 46.5 ±12.1 48.7 ±14.5 0.013*












*Difference significant between migraine cases and controls (p < 0.05).
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Table 3 - 1H-NMR peaks associated with lifetime prevalence of migraine






Table 4 - 1H-NMR peaks associated with active migraine
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Results
Demographic characteristics
We compared several demographic characteristics in our migraine patients compared to 
the control group (see Table 2). Migraine patients tended to be younger and, as can be 
expected, they were more often female than the controls. There was no significant differ-
ence in educational level between cases and controls. Of the 289 migraineurs in our study, 
150 patients (58%) reported at least one migraine attack in the 12 months preceding the 
interview and were assigned to the group of “active migraineurs”.
 
1H-NMR score for life-time diagnosis of migraine
Using the complete group of 289 migraineurs we identified a subset of five peaks that 
were associated with migraine status using the elastic net regression analysis (see Table 
3). One of these peaks could not be annotated yet, so it is unclear which metabolite it 
represents. The other four peaks represent isoleucine (2 peaks), methionine and 1,5-anhy-
drosorbitol. This score containing these five metabolites explained 3.6% of the variance 
in migraine status and was significantly associated with migraine status in the uncorrected 
analysis (OR = 2.72 (1.94 – 3.81), p = 6.8*10-9). As it is known that NMR spectra are 
highly dependent on age and sex we corrected the score for these confounders. Unfortu-
nately, after correction the association with migraine was no longer significant (OR = 
1.40 (0.95 – 2.06), p = 0.088). 
1H-NMR score for diagnosis of active migraine
When including only the 150 active migraineurs, we identified a subset of 20 associated 
peaks using elastic net regression analysis (see Table 4). Notably, all five peaks that were 
part of the subset associated with lifetime migraine were also part of the 20 peaks that 
associated with active migraine status. Three of these 20 peaks have not been annotated 
yet. The remaining 17 peaks represent 14 metabolites: leucine, isoleucine (2 peaks), 
methionine, proline, serine, valine, dimethylglycine, glucose (two peaks), 1,5-anhydro-
sorbitol, cholesterol, lipids CH2, lipids CH2CO, creatinine and pyruvate. This score 
explained 8.7% of the variance and was significantly associated with active migraine status 
in the uncorrected analysis (OR = 2.72 (2.09 – 3.53), p = 9.5*10-14). After correcting the 
score for age and sex it remained strongly associated (OR = 1.74 (1.27 – 2.40), p = 
6.2*10-3). The outcome of our ANOVA analysis was also significant (p = 1.5*10-12), 




The aim of this study was to search for (a set of ) serum metabolites associated with 
migraine status. Using 1H-NMR spectroscopy metabolic profiling we were able to iden-
tify a subset of metabolites significantly associated with active migraine, but not with 
lifetime migraine in the large population-based Erasmus Ruchen Family (ERF) sample. 
Our study has several strengths compared with previous studies on plasma concentrations 
of metabolites in migraine patients. Our sample consists of a large number of well-char-
acterized migraine patients and controls that are not affected by severe headaches. Partic-
ipants were selected based on their ancestry and came from a relatively homogeneous 
population. Using 1H-NMR  spectroscopy, which is considered a highly robust method 
14, we were able to test a large number of metabolites for their association with migraine 
in a hypothesis-free manner.  
 In our 150 migraine patients with active migraine in the year preceding the interview 
and the 1,360 controls we found an association with 22 peaks representing 16 known 
metabolites. In contrast, in the combined analysis of the same controls with our 150 









Creatinine No difference 5,087 22,539 Kurth, Ridker & Buring 2008
Glucose (fasting) No difference 111 463 Schwaiger et al. 2008
HDL-cholesterol No difference 620 5135 Scher et al. 2005
No difference 111 463 Schwaiger et al. 2008
No difference 165 1285 Benseñor et al. 2011
Decreased 5,087 22,539 Kurth et al. 2008
Decreased 3,412 28,115 Winsvold et al. 2011
Total cholesterol Increased 620 5,135 Scher et al. 2005
Increased 5,087 22,539 Kurth et al. 2008
No difference 111 463 Schwaiger et al. 2008
No difference 165 1,285 Benseñor et al. 2011
Decreased 3,412 28,115 Winsvold et al. 2011
Pyruvate Increased 14 12 Okada et al. 1998
Leucine No difference 31 9 Ferrari et al. 1990
Isoleucine No difference 31 9 Ferrari et al. 1990
Methionine No difference 31 9 Ferrari et al. 1990
Proline No difference 31 9 Ferrari et al. 1990
Serine No difference 31 9 Ferrari et al. 1990
Valine No difference 31 9 Ferrari et al. 1990
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patients with active and 139 patients with inactive migraine (i.e. lifetime migraine status) 
the subset of peaks associated with lifetime migraine was no longer significant after 
correcting for age and sex. The five peaks that showed some association with lifetime 
migraine status were also present among the 22 peaks that were associated with active 
migraine. The fact that we only saw significant association with active migraine may be 
due to the fact that that group is more homogeneous compared to the group with lifetime 
migraine, which allows smaller concentration differences to be detected. Alternatively, 
one could envisage that some metabolites undergo persistent concentration changes and 
are therefore picked up in our lifetime migraine analysis, while concentrations of other 
metabolites alter only temporarily, explaining why these metabolites are only significantly 
associated with active migraine status. 
 The 22 peaks associated with active migraine represent 19 annotated peaks and three 
unknown metabolites, which is a common problem in this type of studies, as the human 
metabolome has not been annotated completely.14 The 19 annotated peaks represent 
leucine, isoleucine, methionine, proline, serine, valine, dimethylglycine, glucose, 1,5-anhy-
drosorbitol, cholesterol, lipids CH2, lipids CH2CO, creatinine, myoinositol, acetate and 
pyruvate. Of these metabolites, 1,5-anhydrosorbitol (inert metabolite from the diet that 
competes with glucose for reabsorption in the kidneys), myoinositol (involved in cerebral 
calcium homeostasis) and dimethylglycine (produced upon metabolizing choline into 
glycine) have not been studied in the serum of migraine patients before (www.hmdb.
com). The other metabolites have been studied to some extent in migraine (for overview, 
see Table 5). Comparing the previous studies with our study is difficult, because they all 
used conventional platforms to assess metabolite concentrations. For the cardiovascular 
disease markers (total cholesterol, HDL-cholesterol, creatinine), results of these studies 
are not unequivocal. In our study, all lipid levels were decreased in migraine patients, 
which is in line with the findings from another European population-based study,29 but 
is different from findings in other studies.12,30-32 It should be noted, though, that compar-
ison of these results is hampered because 1H-NMR spectroscopy subdivides the lipids in 
different subclasses than conventional analyses.
 Pyruvate levels in our migraine patients were higher than in controls. A small study 
with only 14 migraine patients also found increased plasma concentrations of pyruvate 
and suggested a role for abnormal mitochondrial metabolism in the pathophysiology of 
migraine.33 Interestingly, lactate and pyruvate concentrations are also raised in patients 
with mitochondrial myopathy, encephalopathy, lactic acidosis with stroke-like episodes 
(MELAS) in which migraine frequently occurs as one of the presenting symptoms.34
Lastly, we found an association of migraine status with several amino acids. We found 
decreased concentrations of leucine, isoleucine, methionine and proline and increased 
concentrations of serine and valine in our migraineurs compared to controls. Some studies 
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from the early nineties addressed the role of neuroexcitatory amino acids in migraine 
patients and measured interictal serum levels using conventional assays.4,35-37 Most of 
these studies focused mainly on plasma levels of glutamate and glutamine, but all amino 
acids associated with migraine in the ERF population were also measured in the study 
by Ferrari et al.4 No differences were found between cases and controls in that study. This 
may be due to the small sample size of this study (including only 31 migraine patients) 
and the technical advances in 1H-NMR spectroscopy that made it possible to detect 
much smaller differences in concentration than with the older met, but future studies 
using state of the art detection methods are necessary to seek confirmation of the asso-
ciation of migraine with these various amino acids.   
 Over the years, the important role of glutamate in monogenic and complex forms of 
migraine has been established firmly in several genetic and functional studies.38 Interictal 
plasma glutamate levels also have been studied in several studies. Glutamate levels were 
shown to be increased in three of the four studies, either in the migraine without aura 
patient group35 or in all migraine patients.4,37 In contrast, a small study in 34 children 
with migraine found decreased plasma glutamate concentrations compared to controls.36 
Since all studies had relatively small sample sizes, it remains unclear to what extent plasma 
glutamate concentrations are altered in migraineurs. In our study, glutamine/glutamate 
and glutamate peaks were not associated with migraine status. It could be that there is 
indeed no difference between migraine patients and controls. An alternative explanation 
would be that our group with active migraine is too heterogeneous to pick up differences 
that could occur shortly after a migraine attack and do not persist for a long time. 
 Several limitations of our study have to be acknowledged as well. First, the set of 
metabolites that we studied covered only a small part of the human metabolome using 
our single metabolic profiling method.14 Future complementary studies using different 
platforms may identify additional metabolites associated with migraine status. The second 
limitation is that our group of active migraine patients is defined by migraine attacks 
occurring in the last twelve months prior to the interview. Transient changes occurring 
shortly after a migraine attack in plasma concentrations may therefore be detectable in 
this study. The third limitation of our study is that we used the same population for 
discovery of the associated peaks as well as for assessing the magnitude of the association. 
Ideally, we would have been able to perform a replication study to validate our findings, 
but no 1H-NMR spectroscopy study is currently available that measured at least the vast 
majority of the associated metabolites. We took specific precautions in our statistical 
analysis to minimize the lack of replication problem by using two cross-validations and 
performing the ANOVA analyses. In addition, the ANOVA analysis indicated that it is 
highly unlikely that none of these peaks has any association with active migraine. This 
shows that our set of associated peaks is an interesting starting point for further studies. 
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In conclusion, using 1H-NMR spectroscopy, we were able to measure a large set of metab-
olites and perform a hypothesis-free metabolic-profiling study in migraine. We identified 
a subset of 22 metabolites that is associated with active migraine in our ERF population. 
For most of these metabolites, the relationship with migraine has not been studied before. 
Further studies are needed to validate our findings and to elucidate the possible patho-
physiological basis of the association between migraine and each of these metabolites. 
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MIGRAINE IS A HIGHLY PREVALENT neurovascular disorder characterized by recurring attacks of severe headache with autonomic and other neurological 
symptoms.1,2 Cluster headache is another, much rarer primary headache disorder with a 
lifetime prevalence of only 0.12%.3 Current prophylactic and abortive treatment for both 
primary headache disorders is not optimal and novel drug targets should be identified to 
reduce the burden of the disease in many patients. Understanding the genetic factors 
involved in these disorders will advance our knowledge of the underlying molecular 
pathways that can point to useful targets for future drug discovery.  
The research presented in this thesis had a number of aims to fill some of the gaps. The 
first aim was to search for mutations in the SCN1A gene that had already been linked to 
monogenic Familial Hemiplegic Migraine (FHM) and in the SLC2A1, ATP1A3, PRRT2 
genes that have been identified in diseases with overlapping symptoms with migraine 
types and/or are comorbid with migraine: autosomal dominant GLUT1 Deficiency 
Syndrome (GLUT1DS), Alternating Hemiplegia of Childhood (AHC), and Benign 
Familial Infantile Convulsions (BFIC), respectively. Mutation analyses in these genes 
were performed in various patient groups relevant to migraine. The second aim was to 
develop and validate web-based questionnaires for reliable ascertainment of ICHD-2 
compatible diagnoses, that is migraine and cluster headache, which is of great use for 
recruitment of large numbers of patients for (large-scale) genetic studies. The third aim 
was to test a single nucleotide polymorphism in the hypocretin receptor type 2 gene 
HCRTR2 that had been reported as the only replicated genetic susceptibility factor in 
cluster headache.4-7 The fourth aim was to investigate whether atherosclerosis can explain 
the increased risk of ischemic stroke, myocardial infarction and peripheral arterial disease 
that is frequently reported in epidemiological and clinical studies on migraine, using the 
Erasmus Rucphen Family (ERF) study.  The fifth, and final, aim is to use serum of partic-
ipants of the ERF study for metabolomic profiling using proton nuclear magnetic reso-
nance (1H-NMR) spectroscopy in order to identify a set of compounds that was able to 
predict a migraine diagnosis. 
Mutation analysis in monogenic syndromes with       
relevance to migraine
The identification of causal gene mutations, and their subsequent functional character-
ization, in monogenic subtypes of a disease can be a useful approach to unravel biological 
pathways that may also have relevance to the complex disease form. Familial hemiplegic 
migraine (FHM) is a monogenic subtype of migraine with aura and serves as an auto-
somal dominant model for common migraine. Apart from the hemiparesis, aura symp-
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toms in patients with hemiplegic migraine are identical to those in patients with migraine 
with aura and the headache characteristics are identical to those in patients with migraine 
with aura or without aura.1,2,8 Moreover, many patients with hemiplegic migraine also 
have attacks of the common forms of migraine.9 Thus far, mutations in the CACNA1A 
(FHM1), ATP1A2 (FHM2) and SCN1A (FHM3) genes are known to cause FHM. 
CACNA1A encodes the pore-forming α1 subunit of CaV2.1 channels that are expressed 
at the plasma membrane of neurons in the central and peripheral nervous system. These 
channels control the flow of calcium across membranes and thereby release of neurotrans-
mitters into the synaptic cleft.10,11 ATP1A2 encodes the α2 subunit of sodium-potassium 
pumps (Na+,K+-ATPase). These pumps catalyze the exchange of Na+ and K+ across the 
cell membrane and provide the steep sodium gradient that is essential for the transport 
of calcium and glutamate from the synaptic cleft.12 And finally, SCN1A codes the pore-
forming subunit of voltage-gated NaV1.1 sodium channels that are mainly—but not 
exclusively—expressed on inhibitory neurons, where they are essential for generation and 
propagation of action potentials.11,13,14 
Notably, hemiplegic migraine can also occur in isolated cases and is then called Sporadic 
Hemiplegic Migraine (SHM).1,2 Mutations in the CACNA1A and ATP1A2, but not the 
SCN1A, gene have been identified in a significant proportion of SHM patients, partic-
ularly in severely affected patients with additional symptoms and early onset of disease.4-7 
Many mutations in CACNA1A (29 until now) and ATP1A2 (over 30 until now) have 
been found associated with FHM or SHM. CACNA1A mutations found in patients with 
hemiplegic migraine are thought to cause increased activity of CaV2.1 channels with 
mutated channels opening more readily than normal channels.19-21 Studies in transgenic 
knock-in mice confirmed that FHM1 is caused by hyperactive CaV2.1 channels.15,16 Other 
mutations in this gene are associated with episodic ataxia type 2 (caused by decreased 
CaV2.1 channel activity17) or spinocerebellar ataxia type 618 (functional consequences of 
the causal CAG repeat expansion have not been elucidated yet19). Most mutations in 
ATP1A2 lead to hemiplegic migraine and are associated with a reduced Na+,K+-ATPase 
function,20-25 but certain mutations in ATP1A2 have been reported to cause other neuro-
logical phenotypes, such as basilar migraine,26 Alternating Hemiplegia of Childhood 
(AHC),27 Benign Familial Infantile Convulsions (BFIC),28 or even common migraine 
without aura.29 Even mutation carriers with complex phenotypes presented as a combi-
nation of hemiplegic migraine and AHC have been reported.30 This suggests that specific 
functional consequences of mutations in these genes affect the protein function of the 
gene product in a specific, yet largely unknown manner, resulting in the diverse spectrum 
of clinical phenotypes. 
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Chapter 2 focuses on the identification of novel SCN1A mutations in two families with 
FHM. Only five SCN1A mutations had been identified in FHM thus far.31-35 An addi-
tional mutation was reported, but from the clinical description it is far from certain that 
this leads to hemiplegic migraine in the mutation carriers.33,36,37 Of the five FHM3 muta-
tions, p.L1649Q and p.Q1489K are associated with pure familial hemiplegic migraine,35 
whereas mutations p.Q1489H and p.L263V have been associated with childhood epilepsy 
and generalized tonic-clonic seizures,31,32,34 in addition to hemiplegic migraine in the 
patient. Some patients with FHM3 mutations p.Q1489H and p.F1499L were also 
reported to suffer from “elicited repetitive daily blindness” (ERDB), which occurred apart 
from their hemiplegic migraine attacks.34,38 The overwhelming majority of mutations in 
SCN1A, however, are association with various non-FHM phenotypes of severe childhood 
epilepsy, i.e. Dravet syndrome (also known as severe myoclonic epilepsy of infancy (SMEI)) 
or generalized epilepsy with febrile seizures plus (GEFS+).39 Like with CACNA1A and 
ATP1A2, the genotype-phenotype associations seen with SCN1A are complex.  
The p.1498M and p.F1661L mutations that were identified in Chapter 2 are only the 
sixth and seventh causative FHM3 mutations. Both mutations cause pure FHM with 
highly variable severity and frequency of attacks in two Spanish families. With respect 
to the functional consequences of FHM3 mutations it seems that p.Q1489K and p.
L1649Q  show reduced activity of Na V1.1 channels.32,35,40 The third functionally tested 
FHM3 mutation, p.L263V, that in patients causes FHM and in the majority of mutation 
carriers also generalized tonic-clonic epilepsy, essentially revealed hyperactivity effects on 
NaV1.1. channel functioning.40 It was hypothesized that loss of NaV1.1 activity primarily 
disturbs the functioning of inhibitory neurons, where NaV1.1 channels are normally 
expressed13,14, whereas increase of NaV1.1 activity predominantly would affect excitatory 
neurons. The exact functional consequences of the p.F1661L mutation are difficult to 
predict, but the p.I498M mutation likely affects fast inactivation of NaV1.1 channels, 
supporting decreased channel function as the underlying cause of FHM in SCN1A muta-
tion carriers. From a recent in vitro study in which FHM3 mutation p.Q1489K was 
expressed in cultured neurons, however, it became clear that the functional consequences 
of FHM3 mutations can be very complex. Depending on the test paradigm, the mutation 
had functional consequences compatible with either a hyperexcitability or hypoexcitability 
(self-limiting hyperexcitability capacity) phenotype,41 but this has not been tested in e.g. 
knock-in mice with FHM3 mutations, as they are not available. 
The research performed in Chapter 3 and an additional genetic study from our group42 
shows that knowledge on migraine genetic mechanisms can indirectly come from inves-
tigating genes that had been identified in diseases with overlapping symptoms with 
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migraine types and/or had been found to be comorbid with migraine. Chapter 3 describes 
a study that combines and builds on knowledge that comes from various studies. In one 
Dutch study an FHM1 gene mutation in German twins lead to overlapping clinical 
symptoms of hemiplegic migraine and rather atypical AHC and it was concluded that 
hemiplegic migraine and AHC to some extent may share pathophysiological mecha-
nisms.43 The link with hemiplegic migraine is further strengthened by the fact that also 
a mutation in the FHM2 ATP1A2 gene was found in atypical AHC patients.27,30 Due to 
the overlapping clinical features, advances in genetic research of AHC may therefore 
provide important information about the genetics of migraine. Typical AHC is a rare 
syndrome with such considerable clinical overlap with hemiplegic migraine that it is 
sometimes impossible to determine the correct diagnosis in very severely affected patients.44 
In addition to recurrent hemiplegic attacks, patients with AHC suffer from movement 
disorders, seizures, and developmental delay starting before the age of 18 months.1 
Recently, the ATP1A3 gene was identified as the major cause of AHC as over 70% of 
patients carry a mutation in that gene.45-47 This gene is a close homologue of the FHM2 
ATP1A2 gene and encodes a Na+/K+ ATPase expressed in neurons of the basal ganglia, 
cerebellum and hippocampus. AHC-causing mutations in this gene are thought to reduce 
the activity of the pump, possibly via alteration of the three-dimensional structure of the 
protein45,46, thereby affecting osmoregulation, sodium-coupled ion transport and neuronal 
excitability.
In 2009, Rotstein et al.48 identified an SLC2A1 mutation in an atypical AHC patient 
who had presented with intellectual disability, hemiplegic attacks, episodes of ataxia, 
microcephaly and hypoglycorrhachia. Until then mutations in SLC2A1 had been iden-
tified in patients with autosomal dominant GLUT1 Deficiency Syndrome (GLUT1DS).49 
A diagnosis of GLUT1DS is suspected by hypoglycorrhachia (a low cerebrospinal fluid 
glucose in a normoglycaemic patient) but needs to be confirmed by a positive SLC2A1 
mutation analysis. The SLC2A1 gene encodes the GLUT1 protein that is pivotal for 
glucose transport into the brain. Recent research has indicated that the phenotype of 
GLUT1DS is much broader than the classical presentation with developmental delay, 
medication-resistant epilepsy, ataxia and dystonia.50,51  Rotstein et al. illustrated this in 
their description of a patient with an SLC2A1 mutation, presenting with GLUT1DS and 
AHC48 Because of the overlapping clinical symptoms in FHM, AHC and GLUT1DS 
and because some of the genes (ATP1A2 and ATP1A3) of some of these disorders suggest 
also some molecular overlap, we searched for causal mutations in ATP1A3 and SLC2A1 
in i) patients that with overlapping clinical features of  AHC and hemiplegic migraine, 
and ii) patients with familial or sporadic hemiplegic migraine. In addition, we searched 
for SLC2A1 mutations in AHC patients tested negative for ATP1A3 mutations. 
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In the study presented in Chapter 3 it was shown that the SLC2A1 and ATP1A3 genes 
do not play a major role in hemiplegic migraine patients in which we previously had not 
identified any mutations in CACNA1A, ATP1A2 or SCN1A. Notably, a novel p.Gly18Arg 
mutation was identified in a severely affected patient that had an atypical clinical presen-
tation of hemiplegic migraine and was initially diagnosed with atypical AHC. By genetic 
analysis the phenotypic spectrum associated with SLC2A1 mutations could be extended 
with (sporadic) hemiplegic migraine and exercise-induced dystonia improving on corti-
costeroid treatment. Our results also indicate that ATP1A3 and SLC2A1 mutation screening 
is not indicated in typical hemiplegic migraine, nor is SLC2A1 mutation screening indi-
cated in patients with classical AHC. However, in patients with a complex, atypical 
phenotype with overlapping symptoms of AHC and HM a lumbar puncture should be 
considered in order to detect a low cerebrospinal fluid glucose concentration, followed 
by SLC2A1 mutation analysis.
The additional genetic study from our group42 may have relevance to migraine, since 
Benign Familial Infantile Convulsions (BFIC) was shown to co-occur with FHM. In 
fact, an ATP1A2 mutation that was identified in a Dutch-Canadian family was presented 
as the cause of both hemiplegic migraine and BFIC.28 Since the identification of genes 
involved in such comorbid seizure disorders can also improve our understanding of 
migraine genetics, we aimed to determine the cause of the symptoms in four families 
with BFIC without any additional symptoms. The additional genetic study42 describes 
the identification of the p.R217PfsX8 mutation in the PRRT2 gene as the underlying 
cause in three of these families. The mutation affects a proline-rich transmembrane protein 
with unknown function that is thought to interact with the presynaptic synaptosomal-as-
sociated protein 25 kDA (SNAP25) that plays a role in calcium-triggered exocytosis by 
regulating fusion of synaptic vesicles to the plasma membrane.52 Notably, recently (recur-
rent) mutations in PRRT2 were shown to cause a variety of paroxysmal neurological 
phenotypes occurring in isolation or in various combinations.53 PRRT2 mutations were 
identified in a large proportion of patients with infantile seizures and/or paroxysmal 
dyskinesia, but thus far mutations were only identified in less than 1% of patients with 
hemiplegic migraine and episodic ataxia.54-59 Although mutations in PRRT2 account for 
only a few hemiplegic migraine cases in these studies and the relation between hemiplegic 
migraine and BFIC was shown recently to be more complex than previously thought,60 
these findings highlight that despite different phenotypes, these paroxysmal neurological 
disorders may in part have overlapping genetic characteristics. As the phenotype associ-
ated with PRRT2 mutations is broad, unravelling the role of this protein can help improving 
our understanding of many episodic neurological disorders. 
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Validation of questionnaires for genetic studies of    
primary headache disorders 
At the start of this thesis, rapid advances in genomic technologies had rendered it feasible 
to perform genome-wide association (GWA) studies testing hundreds of thousands of 
genetic variants in several thousand cases and controls in a single experiment. Statistical 
power is a major concern in such studies, because of stringent multiple testing correction 
combined with the limited effect size of common variants underlying common disease. 
Valid ascertainment of cases and controls is essential to prevent additional loss of power 
due to clinical heterogeneity. Obtaining valid ICHD-2 based diagnoses in large-scale 
population-based studies is challenging, as diagnoses in primary headache disorders are 
based on consensus criteria for which the gold standard is a careful history taken by a 
headache specialist. Because face-to-face examinations are too time-consuming and too 
costly in this setting, a different diagnostic strategy was needed. Several groups had 
reported on the use of internet to recruit (headache) patients for clinical research61-65 and 
in Chapters 4 and 5 we describe our recruitment strategy for collecting large numbers 
of self-reported primary headache patients from the general Dutch population using 
web-based questionnaires.
In Chapter 4 the recruitment strategy is reported for the Leiden University Migraine 
Neuro-Analysis (LUMINA) program for inclusion of a large number of self-reported 
migraine patients for genetic and epidemiological studies through the project’s website 
(www.lumc.nl/hoofdpijn). Self-reported migraine patients from the Dutch population 
were invited to complete a previously validated screening questionnaire. Screen-positives 
were subsequently asked to complete a newly developed extended web-based question-
naire aiming to diagnose migraine based on the ICHD-2 criteria. After the first year, we 
had recruited 2,397 self-reported migraine patients, of which we selected 1,067 partici-
pants for validation of the extended questionnaire using semi-structured telephone inter-
views. Nearly all patients meeting the screening criteria (95%) were diagnosed with 
migraine upon interview, so we decided to regard the entire group as being a migraine 
patient. The good performance of our screener with respect to headache characteristics 
is in agreement with many previously developed questionnaires, but making reliable aura 
diagnoses based on questionnaire data is notoriously difficult. Discriminating between 
migraine with and without aura is of particular interest in genetic studies and we hoped 
to improve questionnaire-based aura diagnoses with our LUMINA questionnaire. Upon 
validation we found it to be a valid instrument for making aura diagnoses as well, with 
a positive predictive value of 86%. We attempted to make an equally well or even better 
prediction of aura status using a subset of items from the extended questionnaire, which 
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were selected based on clinical relevance, sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV), and likelihood ratios. Using multivariate logistic 
regression analysis with a forward selection strategy we identified a seven-question subset 
with similar PPV in assessing aura diagnosis as compared to the ICHD-2 based algorithm. 
This subset of aura questions represents an attractive way to reliably diagnose aura status 
in large epidemiological studies. Currently, clinical data have been collected from approx-
imately 5,000 migraine patients. In the large LUMINA study more than 3,500 DNA 
samples are present and the study population contributed significantly to the identifica-
tion of susceptibility genes for both migraine with aura,66, migraine without aura,67 and 
the subsequent migraine meta-analysis (for specific details see section 10.3).68
In contrast to the rapid advances in the migraine field, the genetic basis of cluster head-
ache (CH) remained poorly studied in candidate-gene based studies with a high risk of 
false-positive associations due to small sample sizes and lack of a replication cohort. 
Genetic studies in cluster headache are greatly hampered by the combination of low 
prevalence and putative complex genetic background of the disorder. To facilitate large-
scale genetic studies in CH, we launched the LUCA program as the CH counterpart of 
the LUMINA study. Via the project’s website self-reported cluster headache patients 
completed a screening questionnaire and screen-positives were asked to complete the 
newly developed web-based extended questionnaire. In Chapter 5 we report on the 
recruitment of the LUCA population and demonstrate that our extended questionnaire 
has positive predictive value of 96% and thus is a valid tool for diagnosing CH in a 
research setting. In addition, we constructed the shorter Quick Ascertainment of Cluster 
Headache (QATCH) questionnaire to diagnose CH in large samples as a practical alter-
native for diagnosing CH patients, because the combination of the screening and 
QATCH-questionnaire works as well as combining the screening questionnaire with the 
much longer LUCA-questionnaire. Validation in our own population showed promising 
results, but the QATCH-questionnaire should be validated in other populations as well. 
Genetic studies in complex migraine and cluster headache
Recent findings from genetic studies in migraine 
Identifying genes involved in complex disorders has proven difficult. Two main hypoth-
eses are used to explain the genetic origin of complex diseases, either “the common disease 
is caused by common variants (i.e., CD-CV)” or “the common disease is caused by rare 
variants” (CD-RV).69 The hypotheses propose that disease susceptibility is conferred by 
multiple genetic variants that either occur with a high frequency in the population but 
each only slightly increase disease risk or these genetic variants are much rarer but each 
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variant has a larger effect size. Genome-wide association studies (GWAS) typically test 
the common variant hypothesis as all tested variants have a frequency >5% in the general 
population. Next generation sequencing strategies can pick-up rarer disease variants.  To 
date, most findings in complex diseases come from GWAS and therefore capture only 
common variants. Only few examples have been reported of rare variants with a moderate 
effect, for example, factor V Leiden in deep venous thrombosis 70 or rare protective vari-
ants in IFIH1 for type 1 diabetes.71 
Gene identification studies in common migraine are particularly challenging because, 
apart from genetic heterogeneity, there is also extensive clinical heterogeneity caused by 
large variations in presenting symptoms and age of onset.  Due to the lack of reliable 
biomarkers, migraine diagnoses are based on questionnaire and/or interview data using 
the diagnostic criteria of the International Headache Society.1 These criteria are useful to 
diagnose the type of attacks patients in a clinical setting, but are less suited for genetic 
research as attacks may vary within patients with multiple combinations of symptoms 
leading to the same diagnosis, but not necessarily through the same pathophysiological 
mechanism.
Linkage and candidate gene association studies in common migraine
Initial genetic successes in common migraine came with family-based linkage analysis 
that led to the identification of many chromosomal regions that are shared by affected 
family members more often than can be expected by chance. However, no migraine genes 
were identified.72 Also candidate gene association studies were initially very popular. These 
studies tested for significant differences in allele frequencies between migraine cases and 
controls at locations in the genome with known variation in genes that were selected 
because they had been implicated in migraine pathophysiology. Among the most frequently 
tested candidate genes were genes in the dopaminergic and serotonergic systems, hormone 
receptors, and inflammatory pathways (for review see de Vries et al.72). These studies can 
produce valid results if carefully designed to overcome methodological issues regarding 
sample size, selection of cases and controls, selection of variants, correction for multiple 
testing, and replication of findings in independent populations, but this was rarely the 
case.  
Genome-Wide Association Studies in Common Migraine
Over the last few years, genome-wide association (GWA) studies have become the stan-
dard approach to identify disease susceptibility variants.  GWAs enable simultaneous 
testing of hundreds of thousands of common (that is with a frequency >5% in the general 
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population) DNA markers in several thousand cases and controls in a hypothesis-free 
manner Such large sample sizes are needed to correct for the large number of statistical 
tests performed. Since 2010, several migraine GWAS have been published that each 
investigated several thousand DNA samples from patients with a clinical diagnosis of 
migraine with aura66 and migraine without aura67 that came from established migraine 
clinics in the Netherlands (Leiden, LUMINA) but also other countries such as Germany 
and Finland. These studies, combined with a recent meta-analysis that studies in total 
23,285 cases and 95,425 controls from almost 30 cohorts worldwide, yielded 13 DNA 
variants that confer susceptibility to migraine. The individual migraine GWAs66,67,73 and 
subsequent meta-analysis68 revealed susceptibility genes involved in several pathways (for 
review see Eising et al.74). The polymorphisms in the MTDH,66 LRP167,73 and MEF2D67 
are involved in (glutamatergic) neurotransmission, a pathway that plays a central role in 
the pathophysiology of FHM. The MEF2D gene is also involved in development of 
neurons and synapses, just like four other susceptibility genes that were identified in these 
studies (ASTN2, PRDM16, PHACTR1 and TGFBR2). The latter two of these are also 
involved in brain vasculature function. Several variants in genes coding for metallopro-
teinases (AJAT1, 68, MMP16,68 and TSPAN268, involved in degradation of extracellular 
matrix proteins, were also found to increase disease risk. Lastly, two variants in the TRPM8 
gene67,73 involved in pain sensation and a variant in c7orf1068 involved in glutaric acid 
metabolism were found to be associated with migraine.
Each of these variants only slightly increased disease risk with an odds ratio not exceeding 
~1.2 and therefore explain only a few percent of the total genetic variance. This is in line 
with GWAS findings in other complex disorders. Due to their small effect sizes, but these 
variants have limited value from a clinical perspective. However, their identification may 
shed light on novel molecular disease pathways as the variants point to genes in pathways 
that have been implicated in migraine pathophysiology. 
Future genetic studies in migraine
Despite current efforts that are expected to yield higher numbers of migraine gene vari-
ants by further increasing sample size and/or by applying more advanced statistical meth-
odologies such as imputation strategies, it is expected that common variants in migraine 
at best will explain only a small portion of the genetic variance.69 There may be common 
variants with very small effect sizes that remain undetected as they would require extremely 
high numbers of cases and controls. Alternatively, there may be rarer variants that are 
not captured by commercial array chips. More recent technical developments known as 
next-generation sequencing allow the identification of such rarer variants with a medium 
effect size either by exome sequencing (i.e. sequencing all coding exons of an individual) 
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or—in the more distant future—whole genome sequencing.75 Other possibilities why 
current gene hunts capture only little of the variance in complex diseases may be that 
one has to take into account gene–gene interactions (epistasis) or even different genetic 
mechanisms such as epigenetic mechanisms, in which gene expression is modified by 
heritable changes in packaging of DNA.
 
Future genetic studies may also benefit from alternatives to current methods of diagnosing 
patients. In Chapter 8 we explored whether endophenotyping of patients can be performed 
by analyzing serum using proton nuclear magnetic resonance (1H-NMR) spectroscopy. 
This technique is used frequently to acquire metabolic profiles from large groups of 
patients because of the robustness and relatively low costs of this method.76 With 1H 
NMR it may be possible to identify (sets of ) low-molecular weight metabolites in serum 
that can distinguish migraine patients from controls. Using 1H-NMR profiles of sera 
from migraine patients and controls of the Erasmus Rucphen Family (ERF) population 
in combination with elastic net regression analysis, we identified a subset of 14 annotated 
metabolites that was associated with active migraine status, which should be regarded as 
hypothesis-generating and provides a subset of metabolites that may be involved in 
migraine pathophysiology. 
Recent findings from genetic studies in cluster headache
Cluster headache is considered a complex genetic disorder. Previous family studies using 
old data regarding cluster headache prevalence found up to 46-fold increased risks among 
first-degree relatives and up to eight-fold for second-degree relatives.77-79,79,80 Recalculated 
with a prevalence of 0.2%, first-degree family members have 5-18 fold increased risk and 
second-degree relatives have 1-3 fold increased risk of having cluster headache.81 Addi-
tional support for a genetic component in cluster headache comes from the observation 
of six monozygous twins both affected.82-87 However, the only systematic twin study 
showed both monozygous and dizygous twins to be discordant for cluster headache.88
Genetic research in cluster headache is scarce and its genetic background is almost entirely 
unknown. Several studies were inspired by the knowledge on migraine genetics. A mito-
chondrial mutation reported to cause MELAS was identified in a single cluster headache 
patient without a family history of this disorder,89 but this seems unrelated to the occur-
rence of cluster headache as additional studies failed to replicate involvement of mito-
chondrial mutations in cluster headache.90,91 Multiple small-scale studies were performed, 
including studies that tested the role of the FHM1 gene CACNA1A or rs1801133 poly-
morphism in the MTHFR gene, but these studies were negative or lack a replication 
sample rendering it plausible that they are all chance findings.92-94 Only one genetic factor 
148
Chapter 9
(i.e. a variant in the hypocretin type 2 receptor gene HCRTR2) was found to be associated 
with cluster headache in two of the three small studies and in a meta-analysis of these 
studies.4-7 In Chapter 6 the association of the previously found associated polymorphism 
(rs2653349) in HCRTR2 was tested in our LUCA population but no association with 
cluster headache was found. In contrast, when we performed a novel meta-analysis 
including the LUCA population we found a significant association of this variant with 
cluster headache susceptibility. There is growing concern, though, that many associations 
found in small-scale candidate gene studies are false-positive findings, even if they were 
replicated in another (equally small) population. Although our meta-analysis results 
remained positive after removal of the first study with an unusually large effect size, we 
concluded that such hypothesis-driven studies are likely to produce invalid results and 
therefore, are not going to help us to unravel the genetic basis of cluster headache. Other 
strategies using large discovery and replication cohorts are needed. With recruiting and 
validating our LUCA population we made one of the first steps in that direction.  
Mining the Erasmus Rucphen Family study for          
migraine research: studying comorbid vascular disease 
and serum profiling towards biomarker identification  
Some studies took advantage of the fact that certain disorders are comorbid with migraine. 
Although the observation can be spurious due to selection bias or reflect a unidirectional 
causal relationship (that is migraine causes [or is caused by] the comorbid disorder), it 
may also be that shared genetic and/or environmental factors underlie both migraine and 
the comorbid disorder.95 Taking advantage of comorbid disorders can be an attractive 
strategy for genetic migraine studies, as it might reduce genetic heterogeneity by selecting 
those migraine patients who also suffer from the comorbid disorder. Several examples 
that used this approach are discussed below.
Investigating Comorbid Depression in Migraine Genetics
Depression is one of the psychiatric disorders comorbid with migraine. A recent meta-anal-
ysis estimated the OR for depression in a migraine patient at 2.2. The risk appears highest 
for MA patients.96 Conversely, depression also increases the risk of migraine (OR = 
2.8–3.4), reflecting the well-established bidirectional relationship between both disorders 
that suggests involvement of shared pathophysiological mechanisms. Three recent studies 
investigated whether shared genetic factors for both disorders exist, although a direct 
comparison of the studies is complicated by methodological differences.97-99 Two of the 
studies investigated twins97, 98, of which one study included only male twin pairs 98 —
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whereas the third study was performed in a genetically isolated population.99 A decrease 
in heritability of migraine upon correction for the co-occurrence of depression was inter-
preted as evidence that part of the variance in migraine must be explained by genetic 
factors that play a role in both migraine and depression.97,99 Of these two studies, the one 
by Stam and co-workers found the largest prevalence of depression and the biggest drop 
in heritability in MA. The third study by Schur and co-workers98 concluded that the 
genetic architecture of migraine and depression is best described by a model that incor-
porated both genetic and environmental factors and estimated that shared genetic factors 
account for approximately 20% of the variance in migraine and depression. Preliminary 
data from a genome-wide linkage scan taking advantage of the comorbidity revealed some 
candidate chromosome regions with nominal evidence, but no susceptibility gene.100 
Investigating Comorbid Cardiovascular Disease in Migraine Genetics
The prevalence of cardiovascular disorders seems to be increased in migraine patients as 
well. A two-fold increased risk of ischemic stroke has been documented in observational, 
prospective and imaging studies.101-103 Several reports also indicate increased risk of 
peripheral arterial disease and coronary heart disease.101,104,105 This suggests that general-
ized vascular dysfunction is an important pathophysiological characteristic in migraine, 
but the underlying mechanism is unclear. Proposed mechanisms include a cortical spreading 
depression-mediated mechanism106,107, migraine-specific medication,108 patent foramen 
ovale (PFO),109,110 coagulation abnormalities,111 endothelial dysfunction 112,113 and/or 
shared underlying genetic 114 or environmental risk factors.115,116 Alternatively, an adverse 
cardiovascular risk profile and associated atherosclerosis could underlie the increased risk 
of cardiovascular disease in migraine patients. Some studies found an unfavorable cardio-
vascular risk profile, in particular for migraine with aura patients,104,117,118 while other 
studies did not find any119 or only a modest association.120 Framingham Risk Scores for 
coronary heart disease (FRS-CHD) were elevated in migraineurs in most,104,117,118,121 but 
not all studies.119,122 None of the studies reported on the Framingham Risk Score for 
ischemic stroke (FRS-Stroke) in migraine patients, probably because the electrocardio-
gram (ECG) data that are necessary to calculate this risk score were not available. 
In Chapter 7 we investigated the grade of prevalent atherosclerosis in migraine patients 
and controls from the ERF population. We used three complementary non-invasive 
preclinical functional and structural markers of vessel wall properties, including carotid 
intima-media thickness (IMT), pulse-wave velocity (PWV), and ankle brachial index 
(ABI). Although we found modest associations of three established cardiovascular risk 
factors with migraine status, this did not lead to higher Framingham risk scores for coro-
nary heart disease or stroke in migraineurs when compared to controls. This is in agree-
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ment with our main finding that atherosclerosis is no more prevalent in migraineurs than 
in controls. Overall, it seems unlikely that the higher risk of cerebro- and cardiovascular 
disease in migraineurs is mediated by atherosclerosis, although it might be possible that 
the process of atherosclerosis plays a role on a subclinical level with endothelial dysfunc-
tion as a presumed early marker.113 Larger, preferably prospective studies are necessary to 
further clarify the role of atherosclerosis in incident vascular events in migraineurs. It 
could be that enhanced susceptibility to ischemic depolarization akin to spreading depres-
sion predisposes migraineurs to infarction during mild ischemic events, thereby increasing 
the stroke risk. Recent findings from transgenic FHM1 mouse mutants provide further 
support that there seems a pathophysiological link between migraine and ischemic events. 
It was shown that the transgenic FHM1 mice have increased infarct size upon experi-
mental induction of stroke by transient middle meningeal artery occlusion and that they 
have more pronounced peri-infarct depolarizations mimicking spreading depression 
events.156 More translational studies are needed to provide insight in the comorbidity 
with cardiovascular disease and to develop prophylactic treatment strategies to prevent 
cerebro- and cardiovascular events in migraine patients.
Future perspectives
The research described in this thesis was directed at understanding the molecular mech-
anisms that underlie rare and common primary headache disorders. Although mutation 
analyses as performed in Chapters 2 and 3 and our genetic study on BFIC42 has provided 
some further insight in molecular mechanisms that have relevance to migraine, the search 
for migraine genes is far from over. The search for additional FHM genes is ongoing, as 
mutations in the three currently known FHM genes do not explain the occurrence of 
disease in all families. Over the last few years, exome sequencing has led to the identifica-
tion of many genes underlying monogenic disorders and one may expect that exome 
sequencing efforts will lead to the identification of additional genes for FHM as well. 
At the start of this thesis there were no well-established genetic risk factors for migraine 
despite some indications from candidate gene association studies and chromosomal loci, 
but no gene variants, from family-based linkage studies.  In recent years, through tech-
nical developments in genotyping methodology combined with rapidly decreasing costs 
for genotyping costs, large-scale GWAS have shown their capability to identify disease 
gene variants at an unprecedented scale. The real challenge with GWAS findings in the 
coming years is to elucidate the role of these novel susceptibility genes in the patho-
physiology of the disease. 
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One has to conclude that GWAS did not live up to the expectation with respect to being 
able to predict individual genetic risk to disease. In theory, one would expect that it is 
possible to identify individuals with multiple risk alleles that are at higher risk, but these 
calculations are not meaningful when only a fraction of the disease genes is known. At 
present a staggering ~80% of the disease heritability is still missing, as it is not within 
reach of current GWAS approaches. Future efforts should target the missing heritability 
in common disease and the identification of rarer gene variants with hopefully clinically 
relevant effect sizes that at least theoretically can be captured by next generation sequencing 
approaches seem nearest. In addition, some of the heritability in migraine may be explained 
by rare copy number variations as seems the case for neuropsychiatric disorders, such as 
autism spectrum disorder.123 Defining intermediate and/or functional phenotypes, such 
as an altered response to a migraine trigger like nitric oxide or defining endophenotypes 
using biomarker identification strategies like 1H-NMR spectroscopy should be tried as 
well. Finally, one has to take into account mechanisms such as epistasis, gene-environment 
interactions, and epigenetics. The potential of epistasis has not yet been investigated in 
migraine also because of substantially increased multiple-testing burden. Gene-environ-
ment interactions also have been understudied in GWAS, primarily due to lack of data 
on environmental exposures, which would require large prospective cohorts. Finally, 
epigenetic modifications, i.e. modifications to the genome other than changes in the 
DNA sequence, such as DNA methylation and histone modifications, may affect disease 
susceptibility by influencing gene expression, e.g. after exposure to environmental trig-
gers.
Clearly the genetics in cluster headache is less advanced than in migraine. Genetic research 
in cluster headache is hampered by the combination of low disease prevalence and the 
putative complex genetic nature of the disorder. Although our LUCA population is the 
current largest DNA collection of cluster headache patients worldwide, collaboration 
with other groups investigating this disease is needed to obtain valid results. It is unclear 
whether GWAS in CH are feasible given the difficulties to collect sufficiently large sample 
sets for the discovery and replication studies. Perhaps exome sequencing should be tried 
when one assumes that a limited number of rare variants with high individual effect size 
underlie susceptibility to cluster headache, which is unclear at this moment. 
One of the most challenging problems in genetic research of primary headaches, perhaps 
more so in migraine than in cluster headache, is the large clinical heterogeneity resulting 
from the ICHD-2 consensus criteria. More research efforts should go towards the iden-
tification of reliable disease biomarkers, which are currently lacking for all primary head-
aches. A first attempt to use 1H-NMR spectroscopy is this thesis revealed a metabolic 
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signature in serum, which suggests that a neurological disorder can lead to metabolic 
changes detectable in blood in our study that in its current state is, at best, hypothesis-
generating. A similar study performed using the ERF population as a validation study 
led to the identification of a metabolite score associated with coronary heart disease 
independent of traditional cardiovascular risk factors124 thereby illustrating that metabolic 
profiling can be a promising tool for identifying novel pathways involved in the patho-
physiology of diseases. Still, it would be interesting to perform biomarker discovery studies 
for brain diseases such as primary headaches in cerebrospinal fluid as this body fluid is 
more directly affected. As long as no biomarker for migraine exists, other strategies to 
reduce clinical heterogeneity remain an attractive strategy. In conclusion, genetic research 
has led to the discovery of the first genetic risks factors for migraine and more genes for 
primary headache disorders will be discovered in the coming years. Collaborative efforts 
of clinicians, geneticists, bio-informaticians and molecular biologists are needed to unravel 
novel pathophysiological mechanisms that may find new treatment options for these 
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MIGRAINE IS A HIGHLY PREVALENT, disabling brain disorder affecting approximately 15% of the population. Cluster headache is another primary head-
ache disorder with a lifetime prevalence of 0.12%. Despite the availability of prophylactic 
and acute therapies, treatment is not effective in many patients with these headache 
disorders. There is a clear need to develop better treatments but this is hampered by a 
lack of knowledge of the underlying molecular disease mechanisms. The research described 
in this thesis was aimed at elucidating some of the molecular genetic mechanisms of these 
two headache disorders by means of clinical and genetic studies in complex and/or mono-
genic forms of the disease and in related disorders.  Hopefully, knowledge that will come 
from studies like these can be used to the benefit of patients by improving clinical diag-
noses and/or by providing useful drug targets for future drug development strategies. 
Chapters 2 and 3 and an additional genetic study from our group describe four novel 
gene mutations in patients with pure familial hemiplegic migraine (FHM) (Chapter 2), 
a mixed phenotype of hemiplegic migraine and alternating hemiplegia of childhood 
(AHC) (Chapter 3), and benign familial infantile convulsions (additional study). In 
Chapter 2 the identification is described of p.Ile1498Met p.Phe1661Leu missense muta-
tions in the SCN1A gene in two Spanish families with FHM. These mutations, only the 
sixth and seventh FHM-causing mutations in this gene thus far, underline the importance 
of SCN1A testing in FHM families. Mutation carriers in these two families showed pure 
hemiplegic migraine with large variability in attack severity and frequency, which is in 
agreement with earlier findings in patients with other FHM mutations, be it in this gene 
or the other two hemiplegic migraine genes. Although no functional characterization of 
the mutation has been performed, the fact that the p.Ile1498Met mutation affects the 
important and evolutionary well-conversed so-called IFMT motif of the Na V1.1 channel, 
and thus likely affects the inactivation properties of the channel, seems to add to existing 
evidence from functional studies on other FHM-causing SCN1A mutations that decreased 
channel activity is the most likely cause of FHM3 patients. The majority of the mutations 
in SCN1A are however not associated with FHM, but instead lead to severe childhood 
epilepsy. How particular mutations in this gene lead to one of these two different allelic 
disorders remains to large extent a mystery. In Chapter 3 the involvement of two genes 
previously implicated in AHC in patients with hemiplegic migraine is investigated. No 
mutations were identified in the ATP1A3 gene, the gene previously was found to be the 
major genetic factor causing AHC, but an SLC2A1 mutation was found in a severely 
affected patient with hemiplegic migraine, intellectual disability, seizures and exercise-
induced dystonia. Mutations of the glucose transporter 1 that is encoded by SLC2A1 had 
been shown to lead to low glucose concentrations in the brain and leading to a wide 
spectrum of paroxysmal and permanent neurological symptoms. Our patient expands 
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the phenotypic spectrum with hemiplegic migraine attacks. In the additional genetic 
study we report a common heterozygous truncating mutation in the PRRT2 gene in three 
families with BFIC, an autosomal dominantly inherited epilepsy syndrome with onset 
between 3 and 12 months of age. Similar truncating mutations in the PRRT2 gene, which 
codes for proline-rich transmembrane protein 2, were first identified in patients with 
paroxysmal kinesigenic dyskinesia with or without infantile convulsions. With this study 
the phenotypic spectrum of PRRT2 mutations is extended to benign familial infantile 
convulsions without associated paroxysmal dyskinesia. Although the exact function of 
the protein is still unknown, it is speculated that PRRT2, through binding to synaptic 
protein SNAP25, may be involved in vesicle docking and calcium-triggered neuronal 
exocytosis. Mutant PRRT2 protein may result in abnormal neurotransmitter release and 
neuronal hyperexcitability. This functional phenotype resembles the hyperexcitability 
phenotype seen with FHM mutations, in particular in FHM1. One can speculate whether 
PRRT2 mutations are also found in FHM, which would provide an explanation why 
BFIC and FHM can co-occur in patients. Chapters 2 and 3 and the additional genetic 
study together show that there seems to be a spectrum of clinical phenotypes, related to 
(common) migraine, that are associated with mutations in the SLC2A1, ATP1A3, SCN1A 
and PRRT2 genes. 
Chapters 4 and 5 describe the validation of our recruitment strategy for patients with 
migraine and cluster headache that can be used, and has been used in the case of migraine, 
for large-scale genetic and clinical studies. In Chapter 4 we reported on the successful 
recruitment of some 2,400 self-reported migraine patients for our Leiden University 
Medical Centre Neuro-Analysis program (LUMINA) study. Good correlation was shown 
of our questionnaire-based migraine diagnoses with interview diagnoses. Virtually all 
patients meeting the screening criteria had a migraine diagnosis, but prediction of aura 
status by the ICHD-2 criteria-based algorithm was less accurate. To construct a predic-
tion rule for aura status, 33 items were selected from the LUMINA questionnaire and a 
stepwise forward logistic regression analysis was run. A seven-question subset provided 
higher sensitivity, slightly lower specificity, and similar positive predictive value in assessing 
aura when comparing with the ICHD-2-based algorithm. The migraine questionnaire 
has been successfully used already in recent genome-wide association studies (GWAS) in 
which LUMINA samples played an important role in the identification of migraine 
susceptibility gene variants. 
In Chapter 5 a similar project named the Leiden University Cluster headache Analysis 
(LUCA) program is presented, launched for recruitment of self-reported cluster headache 
patients for genetic and clinical studies. For this study, 437 self-reported cluster headache 
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patients meeting our screening criteria were recruited. Semi-structured telephone inter-
views revealed a high positive predictive value of an algorithm-based cluster headache 
diagnosis. Despite its high accuracy, the LUCA questionnaire is too long to be applied 
in large-scale population-based studies focusing on multiple disorders at the same time. 
Therefore, the shorter Quick Ascertainment of Cluster Headache (QATCH) question-
naire was developed by incorporating the items with highest positive predictive value and 
positive likelihood ratio in a stepwise forward logistic regression model. The QATCH 
questionnaire contains three questions and indicates that men with headache attacks of 
short duration and long headache-free intervals are very likely to have CH.
In Chapter 6 the LUCA study from Chapter 5 was used for the largest candidate-gene 
association study in cluster headache thus far. The association was re-evaluated of single 
nucleotide polymorphism (SNP) rs2653349 in the HCRTR2 gene that changes amino 
acid 1246 of the hypocretin receptor type 2 from a glycine residue into an alanine residue. 
Two small earlier studies had indicated that HCRTR2 may be a genetic risk factor for 
cluster headache, although a third study was negative. No support for HCRTR2 as a 
susceptibility gene in cluster headache was found by testing the SNP in our LUCA popu-
lation. Adding the LUCA study to existing data sets in a subsequent meta-analysis, which 
doubled in sample size, showed, however, suggestive association. A subsequent meta-
analysis including our LUCA study and without the initial study, that showed a very 
large protective effect (odds ratio of 0.27, which is equivalent to an odds ratio of 3.7 in 
case of a susceptibility-increasing variant), still showed a significance association, although 
the odds ratio was more modest (0.80 (equivalent to an odds ratio of 1.25 for a suscep-
tibility-increasing variant)). Although our study could not define whether HCRTR2 
should be disregarded as a promising susceptibility gene for cluster headache, one could 
argue that the outcome of combining small candidate gene association studies in a meta-
analysis, even if a significant result is obtained, should be treated with great caution. 
Chapter 7 describes a study in the genetically isolated population from the Erasmus 
Rucphen Family (ERF) study that consists of 3,465 living descendants of 22 couples who 
had at least six children baptized in the community church between 1850 and 1900 and 
from whom extensive clinical and genetic data is available. In this population 360 migraine 
patients and 1,291 subjects without severe headache were identified. The study aimed to 
investigate whether atherosclerosis explains the increased risk of ischemic stroke, myocar-
dial infarction and peripheral arterial disease that is frequently reported in epidemio-
logical and clinical studies on migraine. The degree of atherosclerosis was evaluated by 
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using three non-invasive measurements of atherosclerosis but no difference was found 
between patients and controls. It was therefore concluded that increased atherosclerosis 
is an unlikely explanation for the higher rates of cardiovascular disease in migraine patients.
 
In Chapter 8 the study in ERF was extended by focussing on metabolic profiling in 
serum using proton nuclear magnetic resonance (1H-NMR) spectroscopy. It was inves-
tigated whether a set of compounds could be identified that was associated with a migraine 
diagnosis. The study showed significant association for 14 metabolites: leucine, isoleucine, 
methionine, proline, serine, valine, dimethylglycine, glucose, 1,5-anhydrosorbitol, lipids 
(CH3) / cholesterol, lipids (CH2), lipids (CH2CO), creatinine and pyruvate. Notably, 
these metabolites were associated with an active migraine status, i.e. patients having 
migraine in the last year, not with migraine per se, and provide a good starting point for 
further research into metabolic changes in migraine patients. Although currently not 
suitable for application in clinical practice, it is a proof of concept showing that a metab-








MIGRAINE IS EEN ERNSTIGE HERSENAANDOENING die vaak voorkomt in de algemene bevolking met een prevalentie van circa 15%. Clusterhoofdpijn is 
ook een primair hoofdpijnsyndroom maar is veel zeldzamer dan migraine en treft slechts 
0.12% van de bevolking op enig moment. Behandeling van deze hoofdpijnvormen met 
de momenteel beschikbare acute medicatie en profylaxe is ineffectief gebleken bij veel 
patiënten.  Er is derhalve een duidelijke behoefte aan betere behandelmethoden, maar 
de ontwikkeling hiervan wordt gehinderd door het beperkte inzicht in de moleculaire 
mechanismen die aan deze ziekten ten grondslag liggen. Het onderzoek in dit proefschrift 
was gericht op het vergroten van het inzicht in de moleculair-genetische mechanismen 
die betrokken zijn bij het ontstaan van migraine en clusterhoofdpijn door middel van 
klinische en genetische studies in complexe en/of monogene vormen van beide ziekten 
en daaraan gerelateerde aandoeningen. Het uiteindelijke doel is dat kennis opgedaan uit 
dergelijke studies gebruikt kan worden voor het bevorderen van de zorg voor hoofdpijn-
patiënten door verbeterde klinische diagnostiek  en/of door het identificeren van nieuwe 
aangrijpingspunten voor toekomstige ontwikkeling van medicatie. 
Hoofdstukken 2 en 3 en een aanvullende genetische studie beschrijven vier nieuwe 
genetische mutaties in patiënten met pure familiaire hemiplegische migraine (FHM) 
(hoofdstuk 2), een gecombineerd fenotype van hemiplegische migraine en alternerende 
hemiplegie op de kinderleeftijd [alternating hemiplegia of childhood (AHC)] (hoofdstuk 
3) en benigne familiaire infantiele convulsies [(BFIC); aanvullende studie]. In hoofdstuk 
2 wordt de identificatie van de nieuwe SCN1A mutaties p.Ile1498Met en p.Phe1661Leu 
in twee Spaanse FHM-families beschreven. Deze mutaties zijn pas de zesde en zevende 
FHM-mutatie in dit gen en onderstrepen het belang van het onderzoek naar SCN1A-
mutaties in de DNA-diagnostiek voor FHM. Mutatiedragers in deze twee families hadden 
pure familiare hemiplegische migraine, maar de frequentie en ernst van de aanvallen 
wisselde sterk. Deze grote mate van variabiliteit komt overeen met bevindingen bij eerdere 
FHM-mutaties in zowel het SCN1A-gen als in de twee andere FHM-genen. Ondanks 
dat er geen functionele studies werden verricht lijkt mutatie p.Ile1498Met additioneel 
bewijs te leveren voor de gangbare hypothese dat verminderde activiteit van het NaV1.1-
kanaal het mechanisme is dat tot ziekte leidt in patiënten met SCN1A-mutaties, omdat 
deze mutatie het belangrijke, evolutionair sterk geconserveerde IFMT-motief van dit 
kanaal verandert en daarmee waarschijnlijk de inactivatie van het kanaal verstoort. Verreweg 
de meeste SCN1A-mutaties veroorzaken echter geen FHM, maar ernstige vormen van 
epilepsie vanaf de kinderleeftijd. Het is nog grotendeels onduidelijk waarom bepaalde 
mutaties in dit gen leiden tot FHM en andere tot ernstige epilepsiesyndromen. In 
hoofdstuk 3 wordt onderzocht of twee genen die eerder in verband zijn gebracht met 
AHC ook een rol spelen bij patiënten met hemiplegische migraine.  Er werden geen 
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mutaties aangetroffen in het ATP1A3-gen, het gemuteerde gen bij een ruime meerderheid 
van de AHC-patiënten, maar er werd wel een SLC2A1-mutatie gevonden in een ernstig 
aangedane patiënt met hemiplegische migraine, verstandelijke beperking, epilepsie en 
door inspanning geïnduceerde dystonie. Mutaties in de door SLC2A1 gecodeerde glucose 
transporter 1 leiden tot lage glucoseconcentraties in het brein en werden al eerder in 
verband gebracht met een breed spectrum van paroxysmale en permanente neurologische 
symptomen. Onze patiënt breidt dit spectrum verder uit met hemiplegische migraine en 
door inspanning geïnduceerde dystonie. De aanvullende genetische studie beschrijft een 
veel voorkomende truncerende mutatie in het PRRT2-gen in drie families met BFIC, 
een autosomaal dominant overervend epilepsiesyndroom waarvan de eerste symptomen 
optreden bij kinderen tussen de drie en twaalf maanden oud. Vergelijkbare truncerende 
mutaties in het PRRT2-gen, coderend voor het prolinerijk transmembraaneitwit 2, waren 
al eerder geïdentificeerd in patiënten met paroxysmale kinesigene dyskinesie met of zonder 
infantiele convulsies.  Met deze studie werd het fenotypische spectrum van PRRT2-
mutaties uitgebreid met benigne familiaire infantiele convulsies zonder geassocieerde 
paroxysmale dyskinesie. De exacte functie van PRRT2 is onbekend, maar de hypothese 
is dat het eiwit door binding aan het synaptische eiwit SNAP25 is betrokken bij 
aankoppeling van vesikels en calcium-geïnduceerde neuronale exocytose. Het mutante 
PRRT2-eiwit zou kunnen leiden tot aberrant gereguleerde afgifte van neurotransmitters 
en neuronale hyperexcitatie. Er kan worden gespeculeerd over het voorkomen van PRRT2-
mutaties bij FHM-patiënten, wat zou kunnen verklaren waarom BFIC en FHM gezamenlijk 
kunnen voorkomen in dezelfde patiënt. De hoofdstukken 2 en 3 en de aanvullende 
genetische studie illustreren gezamenlijk een spectrum van klinische fenotypes die zijn 
gerelateerd aan migraine en worden veroorzaakt door mutaties in de SLC2A1, ATP1A3, 
SCN1A en PRRT2-genen.  
De hoofdstukken 4 en 5 beschrijven de validatie van onze wervingsstrategie voor een 
grote groep van patiënten met migraine en clusterhoofdpijn die gebruikt kunnen worden 
(en voor migraine al gebruikt zijn) voor grootschalige genetische en klinische studies. In 
hoofdstuk 4 rapporteren we de werving van circa 2400 zelfverklaarde migrainepatiënten 
voor onze Leiden University Medical Centre Neuro-analysis (LUMINA) studie. Er bleek 
een goede correlatie te bestaan tussen de op de vragenlijst gebaseerde migrainediagnoses 
en de diagnoses gesteld tijdens telefonische interviews. Vrijwel alle patiënten die voldeden 
aan de screeningscriteria bleken ook inderdaad migraine te hebben, maar de voorspelling 
van aurastatus op basis van de ICHD2-criteria was minder accuraat.  Om een predictieregel 
voor aurastatus te ontwikkelen selecteerden we 33 vragen uit de LUMINA-vragenlijst 
voor een stapsgewijze logistische regressieanalyse. Dit resulteerde in een selectie van zeven 
vragen met hogere sensitiviteit, iets lagere specificiteit en vergelijkbare positief voorspellende 
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waarde voor aurastatus in vergelijking met het op de ICHD-2-criteria gebaseerde algoritme. 
De migrainevragenlijst is al met succes toegepast in recente genoomwijde associatiestudies 
waarin de DNA-monsters uit de LUMINA-studie een belangrijke rol hebben gespeeld 
bij de identificatie van meerdere genetische risicofactoren voor migraine.
In hoofdstuk 5 presenteren we een vergelijkbaar project getiteld de Leiden University 
Cluster headache Analysis (LUCA) studie. Dit project werd gestart voor het recruteren 
van zelfverklaarde patiënten met clusterhoofdpijn voor genetische en klinische studies. 
Voor de validatiestudie werden 437 patiënten geworven die voldeden aan de screenings-
criteria. De op de vragenlijst gebaseerde diagnose toonde een hoge positief voorspellende 
waarde voor de diagnose in een semigestructureerd telefonisch interview. Ondanks de 
accuratesse is de lengte van de LUCA-vragenlijst een probleem bij toepassing in grootschalige 
studies die zich richten op het gelijktijdig bestuderen van meerdere ziekten in dezelfde 
populatie. Daarom ontwikkelden we een korte vragenlijst door analyse van de vragen 
met de hoogste positief voorspellende waarden en hoogste positieve likelihood ratios in 
een stapsgewijze logistische regressieanalyse. Deze zogenaamde QATCH-vragenlijst bevat 
drie onderdelen en suggereert dat mannen met kortdurende hoofdpijn en langdurige 
pijnvrije intervallen een hoge kans hebben om clusterhoofdpijn te hebben.
In hoofdstuk 6 gebruiken we de populatie uit de LUCA-studie uit hoofdstuk 5 voor de 
grootste kandidaatgenstudie tot dusverre uitgevoerd in het onderzoek naar clusterhoofdpijn. 
We evalueerden de eerder gerapporteerde associatie van clusterhoofdpijn met het 
polymorfisme rs2653349 in het HCRTR2-gen. Dit polymorfisme verandert aminozuur 
1246 van de hypocretinereceptor type 2 van een glycine naar een alanine. Twee eerdere 
kleine studies suggereerden dat dit polymorfisme het risico op het krijgen van clusterhoofdpijn 
beïnvloedt, maar een derde studie was negatief. Toen we de associatie onderzochten in 
onze LUCA-populatie werd er geen associatie gevonden. Vervolgens verrichtten we een 
nieuwe meta-analyse waarin de LUCA-populatie werd toegevoegd aan de eerder 
gepubliceerde populaties, waardoor de studie in omvang verdubbelde. De meta-analyse 
suggereerde wel dat er associatie bestond tussen dit polymorfisme en clusterhoofdpijn. 
Vervolgens werd een meta-analyse verricht zonder de initiële studie, waarin een zeer groot 
effect (odds ratio (OR) 0.27, corresponderend met een OR van 3.7 in geval van een 
risicoverhogend effect) werd gevonden. De OR nam daarop af tot 0.80 (equivalent aan 
OR 1.25 in geval van een risicoverhogend effect) maar de associatie bleef significant. 
Hoewel door de discrepantie in resultaten niet kon worden uitgesloten dat dit polymorfisme 
in HCRTR2 het risico op clusterhoofdpijn beïnvloedt kan wel gesteld worden dat de 
resultaten van een meta-analyse op basis van kleine studies ook bij een significante associatie 
met grote voorzichtigheid moeten worden geïnterpreteerd.  
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Hoofdstuk 8 beschrijft een studie in de genetisch geïsoleerde  Erasmus Rucphen Familie 
(ERF) studie, welke bestaat uit 3465 levende nakomelingen van 22 koppels die tussen 
1850 en 1900 tenminste zes kinderen lieten dopen in de dorpskerk en van wie er uitge-
breide klinische en genetische data beschikbaar is. In deze populatie werden 360 
migrainepatiënten en 1291 controlepersonen zonder ernstige hoofdpijn geïdentificeerd. 
De in dit hoofdstuk beschreven studie was erop gericht om te onderzoeken of athero-
sclerose de verklaring vormt voor het frequent in de literatuur gerapporteerde verhoogde 
risico van migrainepatiënten op herseninfarcten, hartinfarcten en perifeer arterieel vaat-
lijden. De mate van atherosclerose werd beoordeeld door middel van drie niet-invasieve 
metingen, waarbij geen verschillen werden gevonden tussen de patiënten en controles. 
We concludeerden daarom dat atherosclerose een onwaarschijnlijke verklaring vormt 
voor het verhoogde risico op cardiovasculaire risico bij migrainepatiënten. 
In hoofdstuk 8 werd dezelfde ERF-populatie gebruikt voor een studie naar de metabo-
lieten in het serum van migrainepatiënten en controles door gebruik te maken van water-
stof kernspinresonantie spectroscopie (in het Engels proton nuclear magnetic resonance 
(1H-NMR) spectroscopy). Gebruikmakend van deze techniek werd gezocht naar een set 
van metabolieten geassocieerd met migraine status. De studie toonde significante asso-
ciatie voor 14 metabolieten: leucine, isoleucine, methionine, proline, serine, valine, 
dimethylglycine, glucose, 1,5-anhydrosorbitol, CH3-lipiden / cholesterol, CH2-lipiden, 
CH2CO-lipiden, creatinine en pyruvaat. Deze metabolieten waren geassocieerd met 
actieve migraine status, gedefinieerd als migraine optredend in het afgelopen jaar, en niet 
met een migraine diagnose op zich. Deze set metabolieten vormt een goed vertrekpunt 
voor verder onderzoek naar metabole veranderingen in migrainepatiënten. Hoewel deze 
metabolietenset niet geschikt is voor klinische toepassing toont de studie wel aan dat de 
methode geschikt kan zijn voor het zoeken naar een mogelijke metabole signatuur als 






1H-NMR proton nuclear magnetic resonance (spectroscopy)
ABI  ankle-brachial index
AHC  alternating hemiplegia of childhood
BFIC  benign familial infantile convulsions
CADASIL cerebral autosomal dominant arteriopathy with subcortical infarcts 
  and leukoencephalopathy
CD-CV  common disease – common variant (hypothesis)
CD-RV  common disease – rare variant (hypothesis)
CHD  coronary heart disease
CPMG  Carr-Purcell-Meiboom-Gill (spectrum)
CSD  cortical spreading depression
CSF  cerebrospinal fluid
DNA  deoxyribonucleic acid
EA2  episodic ataxia type 2
ERF  Erasmusm Rucphen Family (study)
FHM  familial hemiplegic migraine
FRS-CHD Framingham risk score for coronary heart disease
FRS-Stroke Framingham risk score for ischemic stroke
GEFS+  generalised epilepsy with febrile seizures+
GLUT1DS glucose transporter 1 deficiency (syndrome)
GWAs  genome-wide association studies
HMDB  Human Metabolome Database
ICHD-2 International Classification of Headache Disorders, 2nd edition
ICHD-3beta International Classification of Headache Disorders, 3nd edition, beta
IHS  International Headache Society
IMT  intima-media thickness
JRES  J-resolved spectrum
LUCA  Leiden University Cluster headache Analysis (program)
LUMINA Leiden University Migraine Neuro-Analysis (program)
MA  migraine with aura
MELAS  mitochondrial encephalopathy with lactic acidosis and stroke-like episodes
MO  migraine without aura
MRI  magnetic resonance imaging
NMR  nuclear magnetic resonance (spectroscopy)
OR  odds ratio
PCR  polymerase chain reaction
PWV  pulse-wave velocity
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List of abbreviations
QATCH quick ascertainment of cluster headache (questionnaire)
RVCL  retinal vasculopathy with cerebral leukodystrophy
SCA6  spinocerebellar ataxia type 6
SD  standard deviation
SHM  sporadic hemiplegic migraine
SMEI  severe myoclonic epilepsy of infancy
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